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ABSTRACT 
 
 
The purpose of this research was to describe calculated risk, risk perceptions of 
future breast cancer, and accuracy of risk perceptions of relatives (sisters or daughters) of 
women who have breast cancer and received genetic counseling regarding indeterminate 
negative BRCA1/2 test results. A secondary purpose was to evaluate breast cancer 
screening recommendations from relative’s primary care providers (PCPs) and recent 
screening participation. We assessed the type and amount of information about genetic 
counseling/testing that was shared among family members and with PCPs. Latent 
variable modeling was used to assess the influence of perceived amount of shared 
information on the accuracy of relative’s own risk perceptions about breast cancer. Using 
a cross-sectional design, surveys and telephone interviews were conducted with 85 
female relatives. Most estimated their risk to be higher than calculated estimates, yet 
calculated risk demonstrated that most were at average-risk (operationalized as < 20% 
lifetime risk by Claus and BRCAPRO risk calculators). A majority of average-risk 
relatives (87%) reported receiving recommendations for annual mammography from their 
PCP, and having a mammogram within the past 1-2 years. However, 10% of women 
were identified as being at elevated-risk (>20% lifetime risk by Claus or BRCAPRO), 
warranting annual breast magnetic resonance imaging (MRI) screening according to 
national guidelines; none of these women received recommendations for MRI screening. 
Regarding sharing of information, nearly 20% of relatives reported that nothing was 
iv 
 
shared with them about their family member’s genetic counseling; most (76.5%) did not 
discuss their family member’s genetic testing or test results with their PCP. Further, 
relatives were generally unaware of the existence of a genetic counseling summary letter 
provided as part of standardized genetic counseling. Those who perceived more 
information was shared with them about their relative’s genetic counseling had more 
accurate perceptions of their own risk for breast cancer (correlation = 0.748 (p=0.000) 
than women who perceived less information was shared (correlation = 0.346 (p=0.05). 
Our findings underscore the need for effective strategies that facilitate sharing of genetic 
counseling information with relatives and PCPs. 
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CHAPTER 1 
 
INTRODUCTION 
 Breast cancer is the second leading cause of cancer death in women (American 
Cancer Society, 2012).  Genetic influences play a crucial role in breast cancer 
development. Best practices for breast cancer screening and prevention vary based on an 
individual’s risk. Risk is influenced by genetic makeup as well as lifestyle and personal 
health history. Recently, annual magnetic resonance imaging (MRI) has been suggested 
as an adjunct to annual mammography for women ages 30 and above who are at 
elevated-risk for breast cancer with a lifetime risk of equal to or greater than 20% 
(American Cancer Society, 2014; Kuhl et al., 2010; National Comprehensive Cancer 
Network, 2013b; Saslow, 2007). Women at average-risk are encouraged to have 
mammography every 1-2 years beginning at age 40 or 50 depending on the guideline 
followed (see Table 1.1) (American Cancer Society, 2014; National Comprehensive 
Cancer Network, 2013b; U.S. Preventive Services Task Force, 2012). Despite advances 
in knowledge about screening and reducing risk for breast cancer in family groups with 
elevated-risk, many women with lifetime risk for breast cancer > 20% are not receiving 
mammography and MRI screenings based on these guidelines (Cohen, 2010; Guerra, 
Sherman, & Armstrong, 2009).   
Whether or not a woman receives a screening test depends on many factors, 
including availability of the test, recommendations by her primary care provider, and a 
2 
 
 
 
woman’s decision to be screened (Price et al., 2010; Rauscher, Hawley, & Earp, 2005). 
Women’s perceived risk for breast cancer plays a role in her decision to be screened 
(Katapodi, Lee, Facione, & Dodd, 2004; McCaul, Branstetter, Schroeder, & Glasgow, 
1996). Women with higher perceived risk are more likely to seek information about 
cancer screening either on their own or from their health care providers (Dillard, Couper, 
& Zikmund-Fisher, 2010). Many behavioral frameworks such as the health belief model 
(Rosenstock, Strecher, & Becker, 1988) and the Precaution Adoption Model (Weinstein, 
1988) include the concept of susceptibility to disease or perceived risk as antecedents to 
the uptake of healthy behaviors (Smerecnik, Mesters, Verweij, de Vries, & de Vries, 
2009).  Tilburt et al.  note, “perceived risk is an important subjective psychological 
phenomenon related to threat appraisal that is closely intertwined with judgments about 
susceptibility to disease as well as the probability of benefit from interventions” (2011, p. 
1). Thus, it is important to understand perceived risk as a component of women’s 
decisions to participate in breast cancer screenings. Ideally, a major component of 
perceived risk for breast cancer is a woman’s objective level of risk. Objective risk is 
influenced by family history of breast cancer, which is a manifestation of family genetics 
among other things. 
Familial cancer is a term used to represent a cluster of cancers that occur within a 
family due to a combination of genetic and environmental factors where a mutation in a 
single gene has not been identified or is not likely (Fisher Center for Familial Cancer 
Research, 2012). A family cluster may be identified in the absence of multiple cancers if 
one cancer is suspicious, for example a woman with just one sister who was diagnosed at 
45 years of age.  Hereditary cancer is a term used to describe cancer where a mutation in 
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a single gene is present and thought to contribute strongly to the cancer (Fisher Center for 
Familial Cancer Research, 2012). Occasionally, a woman who has had breast cancer that 
is suspected of being hereditary, because of family history, age of onset, or other factors, 
will seek genetic testing to determine if a DNA mutation is present. If testing is 
undertaken, the most common result is that no mutation is identified (van Dijk, 2005). 
The terms uninformative, inconclusive, and indeterminate negative have been used in the 
literature to describe such a negative test when there is a family history of breast and/or 
ovarian cancer and no currently known mutations in breast cancer predisposition genes 
(Cypowyj et al., 2009; Dorval et al., 2005; Mannis, Fehniger, Creasman, Jacoby, & 
Beattie, 2013; Patenaude et al., 2006; van Dijk, 2005). For the purposes of this 
dissertation, a nonpositive BRCA1/2 test result will be termed an indeterminate negative 
test result. Such a result simply means that the woman does not have a known mutation in 
any of the breast cancer predisposition genes. This result should not be interpreted to 
mean the family is not at increased risk for breast cancer based on genetic factors. Such a 
family may be described as having familial cancer rather than hereditary cancer. Women 
without breast cancer in the family should still obtain breast cancer screenings, based on 
the specific pedigree and other risk factors (see Table 1.1). If a woman’s lifetime risk for 
developing breast cancer is 20% or greater, screenings may include annual magnetic 
resonance imaging (MRI) exams in addition to annual mammography. Appropriate 
screening with MRI and mammography can lead to early detection and possibly more 
effective treatment in these women (Kriege et al., 2004; Kuhl et al., 2010; Lee et al., 
2010).  
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Genetic testing is often offered in the setting of genetic counseling. Counselors 
complete a risk assessment by compiling a family pedigree (diagram of family 
relationships with medical history) and asking the counselee about other personal risk 
factors. Counselors then provide personalized genomic information including information 
about risk of cancer (or risk of a second primary cancer). Cancer risk may be presented in 
terms of lifetime risk, 5-year risk, or qualitative descriptors of risk. Many risk assessment 
calculators exist to help health care providers attain these numbers. Two commonly used 
models include the BRCAPRO statistical model and the Claus model (Amir, Freedman, 
Seruga, & Evans, 2010; Gail & Mai, 2010). In addition to risk information, counselors 
also provide information about prevention and early detection methods. They may also 
provide general information about risk and prevention that may apply to the extended 
family.  
Goals of providing personalized genomic information include offering better 
health care for patients and allowing them to make informed decisions based on the most 
accurate and applicable information available (Weitzel, Blazer, Macdonald, Culver, & 
Offit, 2011). Families in which a member has undergone genetic counseling are a special 
population. The family pedigree has been evaluated by an expert in risk assessment. 
Counselors are knowledgeable about hereditary cancer syndromes, risk assessment 
instruments, and risk-specific screening recommendations. While these principles apply 
to many types of cancer, this research addresses breast cancer in particular. In a 
systematic review and meta-analysis about the psychological impact of genetic 
counseling for familial cancer, Braithwaite, Emery, Walter, Prevost, and Sutton (2006) 
note that one outcome of effective genetic counseling is accuracy of perceived risk.  In 
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cases of familial cancer, they assert, “…the goal is to communicate information regarding 
personal risk of cancer so that individuals can make informed choices regarding options 
for risk management, principally cancer surveillance and predictive genetic testing” (p. 
62). Tilburt et al. (2011) note, “misperception of risk has been shown to both increase and 
decrease use of preventive health services and therefore can have significant implications 
for the health of those at greater than average-risk of developing cancer” (p. 2).  
Genetic counseling sessions for breast cancer may involve a single family 
member or many family members; however, a family assessment is always included. If a 
DNA blood test is indicated within a family, it is best to test an affected family member 
first, especially a family member who had early onset cancer, bilateral breast cancer, or 
multiple primary cancers because that family member has the highest likelihood of 
having a positive test (National Comprehensive Cancer Network, 2013c, pp. MS-15).  
Regardless of the DNA test outcome, counselors often write a summary letter to the 
counselee providing information about the counseling session, testing that was done (if 
any), and also providing general information about the potential risk of other family 
members. The individual who receives the counseling (most often the individual who has 
had breast cancer) is encouraged to disseminate information to other family members and 
to encourage them to, in turn, share the information with their primary care providers. 
Genetic counselors typically do not contact family members who were not involved in 
the counseling session to share risk information, especially in the event of indeterminate 
negative DNA test results. This places the burden on the cancer survivor to disseminate 
this technical and sometimes complex information, which she herself often does not fully 
understand. Results from previous research suggest that this information is not 
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consistently and reliably communicated to family members (L. E. Forrest, Curnow, 
Delatycki, Skene, & Aitken, 2008; Seymour, Addington-Hall, Lucassen, & Foster, 2010; 
Vos, Jansen, et al., 2011; Vos, Menko, et al., 2011). As such, the genetic counseling 
summary letter can be a key piece of written information that is available for reference 
when sharing risk information with close family members. National guidelines identify 
the need to provide counselees with tools to inform and educate family members about 
genetic counseling information such as a letter, website, or referral to a genetic counselor 
(Riley et al., 2012).  
Purpose 
The purpose of the proposed cross-sectional descriptive study was to understand 
the impact of information shared about genetic counseling sessions by close relatives on 
the accuracy of risk perception for women potentially at increased familial risk of breast 
cancer. Participating women had biological first-degree relatives with a personal history 
of breast cancer who have received genetic counseling, received an indeterminate 
negative BRCA1/2 test result, and who have received genetic counseling summary letters 
suggesting that their close relatives may be at increased risk for breast cancer. This study 
intended to describe the contribution of a woman’s self-reported understanding of 
information shared about genetic counseling sessions by close relatives on her accuracy 
of risk perception about her own breast cancer risk (ultimately we replaced the variable of 
self-reported understanding of information with self-reported amount of information 
shared by close relatives about their genetic counseling sessions).  Further, in this study 
we calculated the lifetime breast cancer risk estimates for women, whose first-degree 
female relatives have undergone genetic counseling and testing with indeterminate 
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negative results, comparing the calculated objective risk with the woman’s self-described 
screening plan and self-report of breast cancer screenings to determine whether screening 
plans and screening participation are in alignment with risk-based guidelines of the 
American Cancer Society (ACS) and the National Comprehensive Cancer Network 
(NCCN).  
Conceptual Model 
This study drew upon Leventhal’s Common Sense Model of Self-regulation as a 
broad framework for exploring women’s responses to risk information (Leventhal, 
Brissette, & Leventhal, 2003). The Common Sense Model proposes that people will 
respond to situational stimuli such as an illness symptom or a health threat or stressor 
with the parallel processes of developing cognitive representations of the danger and 
developing representations of fear. As a result of cognitive and emotional responses, 
coping mechanisms are developed to control the danger and fear associated with the 
situational stimuli. Marteau and Weinman (2006) propose that Self-regulation theory can 
likewise be used to predict and understand behavioral response to genetic risk 
information (see Figure 1.1). Risk perceptions are part of the cognitive representation of a 
health threat that are influenced by both preexisting representations of the health threat as 
well as emotional responses to the health threat (Leventhal et al., 2003; Marteau & 
Weinman, 2006). 
Impact 
This study helped identify women who may be receiving inappropriate levels of 
screening or who may have inaccurate risk perceptions. Women make health and lifestyle 
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choices based on perceptions of personal risk. The data gleaned may inform future 
intervention research that will help health care professionals work with a population that 
would benefit from increased awareness about their individualized risk for breast cancer 
and personalized screening/ prevention strategies. More timely screening of women with 
familial risk for breast cancer may help identify cancer earlier. Conversely, avoiding 
unnecessary screening may save health care dollars and avoid false positive screens and 
downstream effects. Additionally, the knowledge gained about how women perceive their 
individual risk of developing breast cancer may provide insight as to how genetic health 
information is received, understood, and acted upon when delivered to extended family 
by their sisters and mothers who received genetic counseling. 
Specific Aims 
The specific aims for this study relate to women who have mothers or sisters who 
have received genetic counseling (counselees) and indeterminate negative BRCA1/2 test 
results. Upon completion of genetic counseling, counselees were provided with summary 
letters encouraging them to share genetic information with their close relatives. The 
women described in the following aims are those close relatives. 
Specific Aim 1 
Specific aim 1 was to calculate an estimate of women’s lifetime risk for breast 
cancer and compare this estimate to women’s perceived risk about developing future 
breast cancer. This aim included three research questions: 
1. What is the average calculated risk for breast cancer using the Claus model, 
the BRCAPRO model, and the Gail model for women (with sisters or mothers 
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who received genetic counseling and indeterminate negative BRCA1/2 
results)? 
2. What percent of women (with sisters or mothers who received genetic 
counseling and indeterminate negative BRCA1/2 results) qualify for annual 
MRI breast screenings based on NCCN guidelines (a lifetime risk for breast 
cancer > 20%) based on the Claus or the BRCAPRO risk calculators?  
3. What percent of women (with sisters, mothers, or daughters who have 
received genetic counseling and had indeterminate negative BRCA1/2 results) 
over-estimate vs. underestimate their risk as compared to their calculated risk 
for breast cancer?  
Specific Aim 2  
Specific aim 2 was to determine whether self-reported screening plans and self-
described screening practices are in alignment with risk-based guidelines in women 
whose first-degree female relatives have received genetic counseling and indeterminate 
negative BRCA1/2 test results.  This aim includes two research questions: 
1. What percent of women whose first-degree female relatives have received 
indeterminate negative test results report that they are screening for breast 
cancer according to risk-based guidelines, i.e., are women who have >20% 
lifetime risk of developing breast cancer, receiving both annual mammogram 
and MRI (as recommended by the National Comprehensive Cancer Network 
(NCCN) and the American Cancer Society (ACS))? 
2. What percent of women whose first-degree female relatives have received 
indeterminate negative test results report receiving recommendations for 
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breast cancer screening from their primary care physicians or from another 
source that are consistent with the National Comprehensive Cancer Network 
(NCCN) and American Cancer Society (ACS) guidelines based on the level of 
risk (i.e., annual mammography if < 20% lifetime risk and > 40 years of age; 
mammography with MRI if > 20% and > 30 years of age)? 
Specific Aim 3 
Specific aim 3 was to determine the contribution of a woman’s self-rated 
understanding of genetic health information, shared by her first-degree female relative 
about genetic counseling sessions, to her risk perception and to the accuracy of her 
perception of individual lifetime risk for breast cancer while controlling for confounding 
influences of factors known to contribute to risk perception, including age, education, 
health literacy, numeracy, knowledge about breast cancer genetics, and self-reported 
distress related to family history of breast cancer and perceived personal risk for breast 
cancer. This aim includes the following research questions: 
1. What is the magnitude of the relationship between calculated lifetime risk for 
breast cancer and perceived lifetime risk for breast cancer?  
2. Does a woman’s self-rated understanding of genetic health information shared 
by her first-degree relative moderate the accuracy of risk perception?  
3. Does a woman’s self-rated understanding of genetic health information shared 
by her first-degree relative predict risk perception?   
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Figure 1.1 
Leventhal's Common Sense Model of Self-regulation of Health and Illness to explain 
responses to health risk information.  Permission to print this adaptation of the Common 
Sense Model has been obtained by Linda Cameron and Howard Leventhal. 
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Table 1.1 Screening mammography and breast MRI guidelines for average- and high-risk 
women by organization 
 
Organization Risk Group Mammography  Breast MRI 
NCCN
a
 Average-risk Annual beginning at age 40 
– end age not given 
Not recommended 
 >20% lifetime 
risk by models 
largely 
dependent on 
family history 
Annual beginning at age 30 
– end age not given 
Consider annual 
beginning at age 30 – 
end age not given 
American 
Cancer 
Society
b
 
<15% lifetime 
risk (average-
risk) 
Annually beginning at age 
40, continue as long as in 
good health 
Not recommended 
 >20% lifetime 
risk 
Annually beginning at age 
30, continue as long as in 
good health 
Annually beginning at 
age 30, continue as long 
as in good health, 
consult with HCP 
 15%-20% 
lifetime risk 
Annually beginning at age 
30, continue as long as in 
good health 
Talk to doctor about 
limitation/ benefit 
screening MRI 
ACOG
d
 Average-risk Annually beginning at age 
40, end age not given – 
consider medical 
comorbidity and life 
expectancy for women 75 
years and older 
Not recommended 
 >20% lifetime 
risk 
Annually Annual – no begin or 
end age given  
USPSTF
c
 Average-risk Every 2 years 
begin at age 50, end at age 
74 
Not recommended 
 Elevated-risk No specific 
recommendations for 
mammography – women 
should be referred to genetic 
counseling 
No specific 
recommendations for 
MRI – women should 
be referred to genetic 
counseling 
a 
(National Comprehensive Cancer Network, 2013b) 
b
 (American Cancer Society, 2014) 
c 
(U.S. Preventive Services Task Force, 2012) 
d
 (American College of Obstetricians and Gynecologists, 2011)
  
 
CHAPTER 2  
 
BACKGROUND AND LITERATURE REVIEW 
Breast Cancer Etiology 
Breast cancer is the second leading cause of cancer death in women (American 
Cancer Society, 2012). All breast cancers are genetic; however, not all cancers are 
inherited (Daly et al., 2010). In other words, all cancers are the result of genetic and 
epigenetic alterations, for example, when the cell loses its ability to repair itself or when 
cell growth goes unchecked (Hanahan & Weinberg, 2000). These alterations, or 
mutations, may stem from a variety of factors, including age, environment, and lifestyle; 
they may also be inherited, that is, present in a person’s genetic make-up from 
conception.  Because the development of cancer requires a series of several mutations 
over years, having one or more mutations present at birth (inherited mutations) 
dramatically increases the chances of developing cancer and increases the likelihood of 
early onset cancer. However, less than 10% of breast cancers are due to a single, 
inherited, dominant gene mutation (Foulkes, 2008). 
Breast Cancer Risk Stratification and  
Screening Recommendations 
A variety of organizations have issued breast cancer screening guidelines and risk 
reduction measures that are based on a woman’s level of risk, including the American 
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Cancer Society (ACS) (American Cancer Society, 2014), the National Comprehensive 
Cancer Network (NCCN) (2013b), and  the National and the American College of 
Obstetricians and Gynecologists American College of Obstetricians and Gynecologists 
(2011). These organizations recommend annual MRI for women at certain levels of 
elevated-risk; see Table 1.1 for a summary of guidelines. Level of risk is therefore 
important and impacts decisions about screening and prevention. Level of risk is 
estimated in several ways. First, if an inherited germline gene mutation is identified, then 
risk is estimated based on the profile of the specific gene mutation (A. Antoniou et al., 
2003). The most common and well-known autosomal dominant gene mutations that can 
cause breast cancer are part of the syndrome called Hereditary Breast and Ovarian Cancer 
(HBOC). The genes that cause HBOC, the BRCA1 and BRCA2 genes confer a lifetime 
risk for breast cancer of between 31% and 78% by age 70 (A. Antoniou et al., 2003). 
Besides the BRCA1/2 genes, other autosomal dominant gene mutations that can cause 
breast cancer exist (see Table 2.1).  
In the absence of a known mutation, risks may be calculated through the use of 
risk calculators that take family history, age, and other elements of personal medical 
history into account (Afonso, 2009; Amir et al., 2010). The risk may be presented 
numerically or qualitatively with terms such as average, elevated, high, or very high. 
Numeric risk may be presented in terms of lifetime risk (percent chance that a woman 
will develop breast cancer in her lifetime), 5-year risk (percent chance that a woman will 
develop breast cancer in the next 5 years), or relative risk (the odds of developing breast 
cancer compared to the general population or to women their same age, race/ethnicity 
who do not have a family history); for example, a relative risk of 2.0 indicates that an 
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individual has twice the risk to develop breast cancer of the general population. A 
lifetime risk for breast cancer of 20% means that 20 out of 100 women with similar risk 
factors are predicted to be diagnosed with breast cancer at some point in their lifetime. 
Classifying Family Patterns of Breast Cancer 
 Because heredity plays a role in breast cancer risk, health professionals examine 
family pedigrees to determine if there is a pattern of breast and/or ovarian cancer in the 
family that could represent a hereditary syndrome. Cancers in a family might be 
classified as sporadic, familial, or hereditary.  This categorization can help in determining 
what type of screening and prevention measures might be undertaken, assist families in 
understanding their risk, and help health care professionals determine whether genetic 
testing might be warranted (Berliner & Fay, 2007).  Unfortunately, the classification is 
not always clear cut. In addition, as more family history becomes available or as more 
cancer cases present themselves, categories may shift over time.  
Sporadic Breast Cancer  
The majority of all breast cancers are sporadic. They arise from mutations that 
occur later in life and are not present at birth (National Human Genome Research 
Institute, 2012). Cancers in a family are termed sporadic if they occur at the typical age of 
onset (over 50) and demonstrate no particular pattern of inheritance (Berliner & Fay, 
2007). These cancers are likely due to nonhereditary causes and there is very little chance 
that genetic susceptibility testing would reveal a deleterious mutation in a dominant gene 
(Berliner & Fay, 2007). Lifestyle and environment factors are known to contribute to 
sporadic breast cancers. Women who belong to families with a sporadic breast cancer but 
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no other striking familial or personal risk factors for breast cancer are said to be at 
“population risk” or “average-risk.” In the general population, it is commonly reported 
that 12% of women, or 1 out of 8, will develop breast cancer at some time during their 
lives (National Cancer Institute, 2014a); however, Pharoah et al. (2002) note that if those 
with familial and hereditary cancer are removed from the “general population,” the 
remaining women have a significantly lower risk than 12% 
Sporadic breast cancers may be associated with multiple, common low-risk gene 
alleles that have been identified in genome-wide association studies (Foulkes, 2008); 
however, testing women for these low-risk alleles has not yet proven to be clinically 
useful (Winstead, 2010).  
Hereditary Breast Cancer 
Hereditary breast cancer refers to those cancers related to specific gene mutations 
that were inherited from a parent and thus, the mutations are found in all somatic cells 
and are present from birth. Inherited mutations are rare and account for approximately 5-
10% of all breast cancers (American Cancer Society, 2012) . Families who possess highly 
penetrant autosomal dominant genes generally have members with cancers occurring at 
younger ages, bilateral cancers, and/or a greater number of cancers in the family. Cancer 
in these families often demonstrate an autosomal dominant pattern of inheritance 
(National Comprehensive Cancer Network, 2013c). The most common genetic mutations 
associated with breast cancer are in the BRCA1 and BRCA2 genes. Other autosomal 
dominant genes exist that confer high risk (see Table 2.1).  Individuals carrying these 
types of high-risk gene mutations have a lifetime risk for breast cancer that is 
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approximately five times that of the general population (National Cancer Institute, 
2014a).  
Familial Breast Cancer 
The distinction between familial breast cancer and hereditary cancer can be 
difficult. Berliner and Fay (2007) note that individuals should be referred for cancer risk 
assessment when either personal or family history suggests familial or hereditary cancer. 
The NCCN describes familial cancers as follows: 
Familial cancers share some but not all features of hereditary cancers. For 
example, although familial breast cancers occur in a given family more frequently 
than in the general population, they generally do not exhibit the inheritance 
patterns or onset age consistent with hereditary cancers. Familial cancers may be 
associated with chance clustering of sporadic cancer cases within families, genetic 
variation in lower penetrance genes, a shared environment, or combinations of 
these factors. (National Comprehensive Cancer Network, 2013c, pp. MS-1) 
 
While other authors distinguish between hereditary and familial cancers in a 
similar fashion to NCCN (Berliner & Fay, 2007; Fisher Center for Familial Cancer 
Research, 2012), it should be noted that some have used the term “familial” to refer to 
cancers that may be or are known to be caused by inherited mutations (Foulkes, 2008). 
For example, a Cochrane Review describing cancer genetic risk assessment for those at 
risk of familial breast cancer includes studies about the care of BRCA1/2 carriers (Hilgart, 
Coles, & Iredale, 2012). Figure 2.1 presents an illustration of the amount of breast cancer 
attributed to sporadic, familial, and hereditary causes as well as common terms used to 
describe the risk level of each category and lifetime risk estimates for each category. 
For the purposes of the proposed study, the NCCN definition of familial cancer is 
utilized. The population of interest in this study includes women who have not had 
cancer, but have close family members who have had cancer and genetic testing with 
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indeterminate negative results. It is possible, therefore, that these women may have 
patterns of inheritance that appear to be familial or hereditary. Some of these women may 
be found to have levels of risk that are equal to or above 20% lifetime. Because these 
women have not received genetic counseling themselves, information that they have 
obtained about their risk for breast cancer and screening that should be done would likely 
have been obtained through self-study, through information from their primary care 
providers, or possibly through their relatives who have received genetic counseling.  
Breast Cancer Prediction Models 
Several computer-based statistical models have been developed to estimate 
lifetime and 5-year risks of breast cancer and/or the risk of carrying a BRCA1/BRCA2 
mutation in individuals and populations. These models vary in which risk factors are 
taken into account. They also differ in the epidemiological data which were used in their 
development. This in turn defines the population for that the specific model is 
appropriate. Each computer model has strengths and weaknesses. 
Evaluating Validity of Breast Cancer Prediction Models  
To evaluate the usefulness of a particular model, calibration and discrimination 
are commonly assessed indicators (S. W. Fletcher, 2013).  Calibration describes the 
ability of a model to accurately predict cancer occurrence at the population level. It is 
measured by comparing the number of women in a particular group that are estimated (E) 
to develop breast cancer with the number who are diagnosed with breast cancer, or the 
observed (O) number. If E/O is near 1.00, then a model is deemed to have good 
calibration (S. W. Fletcher, 2013). Well-calibrated models that accurately predict 
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population risk are important when developing policies or guidelines that are based on 
populations; health care policy makers can use these models when conducting 
cost/benefit analysis in a large group (Amir et al., 2010, p. 681).  
For the primary care clinician, a more useful model will accurately assess 
individual risk so that prevention and detection activities may be individualized (Amir et 
al., 2010).  Discrimination is a measurement of how well a model stratifies individual 
women into those who do and those who do not develop breast cancer in a given period; 
discrimination is a measure of how well models perform at an individual level (S. W. 
Fletcher, 2013).The concordance rate or the c-statistic is a method used to assess the 
discrimination of a model. The c-statistic is the proportion of randomly selected pairs in a 
group where one woman has a diagnosis of breast cancer and one does not in which the 
woman with cancer is given a higher calculated risk by the model than the woman 
without cancer. Values for the c-statistic can range from 0.50 (where the women with 
cancer were given higher risk 50% of the time– odds similar to a coin toss) to 1.00 
(where the model discriminates perfectly – always assigning higher risk to those with 
cancer) (S. W. Fletcher, 2013; Parmigiani et al., 2007). 
 Gail model. The Gail model is the most widely used tool for assessing breast 
cancer risk. It was developed at the National Cancer Institute by Dr. Mitchell Gail (Gail 
et al., 1989). This model calculates an individual woman’s risk of developing breast 
cancer over the next 5 years as well as lifetime risk to age 90, based on seven risk factors: 
current age, age at menarche, age at first live birth, number of first-degree relatives with 
breast cancer, number of previous breast biopsies, history of atypical hyperplasia, and 
race. Age at first live birth and the age at menarche are proxies for hormone exposure. 
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The Gail model has been modified since its original inception; the modified version is 
sometimes referred to as the NCI-Gail model (Amir et al., 2010) or as the Breast Cancer 
Risk Assessment Tool (BCRAT) (S. W. Fletcher, 2013). This instrument is easily 
accessible to health care providers and patients. It can be assessed online at 
www.cancer.gov/bcrisktool/.  
Fletcher (2013) presents an overview of studies using the Gail model. The Gail 
model demonstrates good calibration ranging from 0.94 to 1.03, indicating that it has 
good accuracy at a population level. However, it does not discriminate well for individual 
women with c-statistics calculated between 0.58 and 0.63 in different studies (S. W. 
Fletcher, 2013). These c-statistics indicate that in randomly selected pairs of women (one 
with and one without a breast cancer diagnosis), the woman with breast cancer had a 
higher Gail score in 58 to 63% of cases. These numbers are slightly better than a coin 
toss, but not a lot. In a study or 55,301 women, the sensitivity of the Gail model 
(proportion of all women who developed breast cancer over a 5-year follow-up who had 
an estimated 5-year risk >1.67%) was found to be 44% (Rockhill, Spiegelman, Byrne, 
Hunter, & Colditz, 2001). The specificity of the Gail model in that same sample 
(proportion of women who remained free of breast cancer over a 5-year follow-up with 
an estimated 5-year risk <1.67%) was 66% (Rockhill et al., 2001).   
In addition to the poor concordance rate (discrimination), another weakness of the 
Gail model is that it has performed poorly when used in higher-risk populations (Amir et 
al., 2010). The Gail model does not include family history beyond the first-degree 
relatives, and does not take into account age at diagnosis or types of cancer besides 
breast. Because it does not emphasize family history, it is not the type of model that the 
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ACS or the NCCN advocates for use when recommending more intensive breast cancer 
screenings. When following the NCCN guidelines or the ACS guidelines for screening 
and evaluating breast abnormalities, the Gail model should not be used to determine 
lifetime risk; NCCN guidelines rely on models that are largely dependent on family 
history (National Comprehensive Cancer Network, 2013b; Saslow, 2007). The Gail 
model is more easily accessible and easier to use than the models that take more family 
history into account, which may account for its more widespread use than other models.  
Health care providers may not be aware that it has limited ability to assess risk in families 
where there is a strong history of breast cancer.  
Breast Cancer Prediction Models Emphasizing Family History  
For patients with a family history that includes multiple cases of breast cancer, 
early onset breast cancer, or a family member with ovarian cancer, models that focus 
more on the extended pedigree are valuable for predicting breast cancer risk. Models that 
emphasize family history will provide risk estimates of developing breast cancer in a 
certain number of years and over a lifetime. This information is helpful in tailoring 
screening and prevention plans to individual women. These models also provide an 
estimate for risk of carrying a deleterious BRCA1 or BRCA2 gene mutation. These 
estimates are used to help decide whether or not to test a woman for gene mutations. 
Many models are available that emphasize family history include the Claus Model, the 
BRCAPRO Model, and the IBIS or Tyrer-Cuzick Model presented here. 
 Claus model. The Claus model estimates both 5-year and lifetime risks for 
developing breast cancer. It includes both maternal and paternal family history of breast 
cancer as well as ages of onset. The updated model includes family history of ovarian 
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cancer (Amir et al., 2010). The Claus model takes into account both first-degree and 
second-degree relatives. Amir et al. (2010) identify several limitations to the Claus 
model. First, the model does not include nonhereditary risk factors such as hormonal 
exposure. Second, the risk is calculated based on lifetime risk tables derived from North 
American women in the 1980s, which are lower than current North American risk or 
European risk. The Claus model is only for use with women who have at least one female 
first- or second-degree relative with breast cancer (Afonso, 2009). 
  BRCAPRO model. The BRCAPRO model provides both 5-year and lifetime 
risks for developing breast cancer. It also provides probabilities for carrying a BRCA1 
and BRCA2 mutation. It was developed at the University of Texas Southwestern Medical 
Center at Dallas and the BayesMendle Group at Johns Hopkins University. The 
CancerGene software that runs this model is publically available for downloading at 
www4.utsouthwestern.edu/breasthealth/cagene/. This model incorporates other predictive 
models for heritable breast cancer, including the Claus model, the Couch model, the 
Shattuck-Eidens model, the Frank model, and a Bayesian probability model added by the 
developers of the BRCAPRO model (S. W. Fletcher, 2013). The BRCAPRO model 
includes information about both affected and unaffected relatives; thus, two cases of 
breast cancer in a family where there are only two females in a single generation are more 
significant than two cases of breast cancer in a family where there are 30 females in a 
single generation. This model, like the Claus model, does not take into account non-
hereditary risk factors for breast cancer and is therefore likely to underestimate risk 
(Amir et al., 2010). 
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 Other models. More than a dozen models exist to estimate the likelihood of 
developing breast cancer and/or that a BRCA1/2 mutation is present (Parmigiani et al., 
2007). Models vary by the specific family and personal history data used for the 
calculations, and for the different source populations the resulting estimations of risk will 
differ. Other models include Breast and Ovarian Analysis of Disease Incidence and 
Carrier Estimation (BOADICEA), the family history assessment tool (FHAT), Finnish, 
Myriad, NCI, University of Pennsylvania (Penn), and Yale University (Yale) (A. C. 
Antoniou et al., 2008; Parmigiani et al., 2007).  The Tyrer-Cuzick model is also referred 
to as the IBIS model (Tyrer, Duffy, & Cuzick, 2004). The Tyrer-Cuzick model predicts 
10-year risk for cancer development. This model is unique in that it takes into account 
both personal risk factors (as the Gail model) as well as the family history of breast and 
ovarian cancer (as the Claus model). The personal risk factors included in this model are 
age at menarche, parity, age at first childbirth, age at menopause, atypical hyperplasia, 
lobular carcinoma in situ, height, and BMI (Tyrer et al., 2004). This model includes the 
most comprehensive set of personal and family variable models and unlike the other 
models, it allows for the possibility of multiple genes of differing penetrance (Amir et al., 
2010). The software for this model is available for download at www.ems-
trials.org/riskevaluator/ with a disclaimer that the instrument is for research purposes only 
(S. W. Fletcher, 2013)  
 With the exception of the Gail model, models that use computer programs to 
calculate risk are not likely to be used by a woman herself. Given that these computer 
models are not designed with the intention of being used solely by the lay public, it is 
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likely that women will turn to their primary care providers to help understand risk and 
make informed decisions about surveillance options for breast cancer.  
Breast Cancer Risk Assessment by Primary Care Providers  
Medical doctors (MDs), nurse practitioners (NPs), and physician assistants (PAs) 
who specialize in primary care are on the front line in health care. Most often, matters of 
primary prevention and promotion of cancer screening tests fall to primary care 
providers. Primary care providers have a great opportunity to identify patients at 
elevated-risk for breast cancer and refer them for a formal risk assessment and possible 
genetic counseling as well as recommend appropriate risk-based prevention and early 
detection interventions. For many women who are at increased risk for breast cancer, 
their primary care provider is the main source of information about their breast cancer 
risk and what screening methods are appropriate (Keogh, McClaren, Apicella, & Hopper, 
2011). Most primary care providers agree that assessing breast cancer risk is a primary 
care provider’s responsibility (Sabatino, McCarthy, Phillips, & Burns, 2007). However, 
not all primary care providers assess a woman’s risk for breast cancer or recommend risk-
appropriate screening tests.  
Primary care providers rarely use software to calculate breast cancer risk scores. 
In a cross-sectional survey of a nationally representative sample of 351 internists, family 
practitioners and obstetrician-gynecologists (OB-GYNs) Guerra, Sherman, and 
Armstrong (2009) found that although 88% of providers had discussed breast cancer risk 
at least once during the past 12 months, only 18% had used a software program to 
calculate the breast cancer risk. Physicians in the sample who were more likely to use 
software were OB-GYNs and those who had a family member with breast cancer, or who 
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had a greater knowledge of breast cancer risk. Similar findings are presented by Sabatino, 
McCarthy, Phillips, and Burns (2007), who found that 76% of primary care providers 
report they almost never calculate Gail scores; only 3% reported that they usually or 
always calculate risk by Gail score. It should be noted that of the software models 
presented, the Gail model is the most easily accessed and used. It does not require 
entering a pedigree or downloading specialty software. This study did not evaluate the 
use of models that rely heavily on family history such as the Claus model and the 
BRCAPRO model; therefore, it is unknown whether health care providers in this sample 
may have been calculating breast cancer risk using other models, but the likelihood of 
this is low. Models that rely heavily on family history are recommended for use in 
evaluating the need for more intensive screenings. These family history intensive models 
such as the Claus and the BRCAPRO are available to primary care providers; however, 
they are more difficult to use and require that software be downloaded. Literature in 
primary care journals explains the use of software for predicting risk such as the Gail 
model, the Claus model, and the BRCAPRO model (Afonso, 2009). Still, Berg et al. note 
in their discussion that physicians have less experience with these calculations (Berg et 
al., 2010). 
Primary care providers are more likely to collect family history and information 
about personal risk factors as a means of assessing breast cancer risk rather than use 
computer software to quantify risk. In a study by Sabatino, McCarthy, Phillips, and Burns 
(2007), 71% of primary care providers report that they usually or always ask about family 
history. Fewer report asking about nonhereditary risk factors, including parity (48%), 
history of biopsies (40%), or age at menarche (35%)(Sabatino et al., 2007).  Burke, 
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Culver, Pinsky, Hall, Reynolds, Yasui, and Press (2009) assessed primary care 
physicians’ skills in assessing family history for breast cancer risk using unannounced 
standardized patient visits. They found that physicians collected sufficient family history 
to assess breast cancer risk 48% of the time when encounters involved a scenario with an 
anxious standardized patient at moderate risk, 100% of the time when encounters 
involved a patient with a strong maternal history of breast cancer, and 45% of the time 
when the patient had a strong paternal history of breast cancer (Burke et al., 2009).  In 
other words, physicians frequently did not ask all of the family history questions they 
needed to ask in order to make an adequate risk assessment, and may not understand the 
dominant inheritance of breast cancer predisposing gene mutations (i.e., that paternal 
history is as important as maternal history). Furthermore, collecting sufficient data is not 
synonymous with interpreting it correctly and making correct recommendations.  
Once a primary care provider has collected risk assessment, information may be 
shared with the patient (risk education and counseling), used to form recommendations 
for prevention and screening, used as a basis for ordering a genetic test, or used as a basis 
to make a referral to an oncology specialist or genetic counselor who can provide 
education and recommendations.  In the study by Burke et al. (2009), 20% of primary 
care providers offered a numeric assessment of lifetime risk for breast cancer. Most often, 
however, primary care providers presented risk to their patients in words rather than 
numbers. Researchers found that physicians may convey the risk assessment in terms of 
“no increase,” “slight increase,” or “significant increase”; however, the most frequent 
way of describing risk was to state that it was “increased” without specifying the degree 
of increase. The authors note that the general statements about risk, “may reflect an 
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appropriately cautious approach to estimating risk-based on a single primary care visit; 
[i]t could also reflect a style of practice that is focused less on defining risk than on 
determining appropriate preventive strategies” (Burke et al., 2009, p. 355).  
A common response by primary care providers to a patient’s concern about breast 
cancer is to order a mammogram. In the study by Burke et al. (2009) where standardized 
patients presented for an unannounced visit, the physicians frequently recommended 
mammograms based on their interpretation of the patients’ risk level. It is noteworthy that 
in the two high-risk cases, with a family history possibly indicative of a heritable high-
risk mutation, physicians recommended mammography in 93% of patient encounters 
where the breast cancer was present in the maternal side of the family but only in 63% of 
the encounters where early onset breast and ovarian cancer was on the paternal side of the 
family (2009). The scenario with both breast and ovarian cancer on the paternal side of 
the family was a more concerning family history, yet mammography was not 
recommended 37% of the time. It should be noted that recommending magnetic 
resonance imaging (MRI) was not included as an outcome of the study because data 
collection was completed before MRI was added to guidelines for screening women at 
elevated-risk (Burke et al., 2009). 
Screening Mammography and
Resonance Imaging (MRI)  
Screening mammography is currently the most effective population-wide 
secondary prevention strategy to prevent morbidity and mortality related to breast cancer 
(Bleyer & Welch, 2012; Hellquist et al., 2011)  Screening mammograms are x-rays of the 
breast used to detect breast cancer in women who are asymptomatic as opposed to 
Magnetic
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diagnostic mammograms that are used to diagnose breast cancer when a woman has 
breast symptoms or when she has had an abnormal screening mammogram. 
Mammography may be recorded using images created on standard x-ray film or digital 
images. Both methods use x-rays to produce the images; the difference is in the way the 
images are recorded. Digital mammography yields better results for women who have 
dense breasts and are pre- or peri-menopausal (Pisano et al., 2005).  
Screening mammography is recommended for women as a method to discover 
breast cancer in earlier stages when treatment has a greater chance of success. Breast 
cancers found before they begin to cause physical symptoms are more likely to be smaller 
and less likely to have regional node involvement (American Cancer Society, 2014). In 
the U.S., recommendations vary about when average-risk women should begin screening 
and how often they should screen.  The U.S. Preventive Services Task Force Services 
recommends mammography screening every other year beginning at age 50 and 
continuing until age 74 (U.S. Preventive Services Task Force, 2009). Other organizations, 
including the ACS, NCCN, and the American College of Obstetricians and Gynecologists 
(ACOG), recommend average-risk women participate in mammography annually 
beginning at age 40 (see Table 1.1). For women with elevated-risk for breast cancer, 
typically defined as > 20% lifetime risk, many organizations recommend beginning 
mammography sooner and offering annual breast MRI as an adjunct to mammography 
(see Table 1.1).  
Images created through magnetic resonance imaging (MRI) are created using 
magnetic fields rather than x-rays. MRI breast screenings have been found to have 
significantly higher sensitivity than mammography (Saslow, 2007). The evidence for 
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MRI screening recommendations is still emerging. In one large study involving women at 
elevated-risk for breast cancer, many of whom had dense breast tissue, the supplemental 
yield of MRI in detecting breast cancer was 14.7 per 1000 women; 68 MRI screenings 
would be needed (after negative mammography and ultrasound results) to detect one 
cancer (Berg et al., 2012). One concern about MRI breast imaging is that while there is a 
higher rate of cancer detection, there is also a higher rate of false-positive findings (Berg 
et al., 2012). As would be expected based on higher prevalence rates in high-risk women, 
false-positive rates with MRI screening are lower for women who have had breast cancer 
or for those with a family history of breast cancer (Berg et al., 2012; M. E. Brennan et al., 
2009; S. Brennan, Liberman, Dershaw, & Morris, 2010). The current trend in guideline 
creating bodies has been to reserve MRI screening for women at elevated-risk.  
Whether a woman who is at elevated-risk for breast cancer obtains an MRI 
screening or not depends on whether MRI screening is ordered by a prescriber and 
whether the woman follows through to get the test. Even in high-risk populations, health 
care provider recommendations for MRI are low (Cohen, 2010). Similarly, uptake of 
MRI testing by women is low.  In a study of 1215 women at increased risk for breast 
cancer who were offered MRI screening free of charge as part of the study, 512 (42%) 
declined participation (Berg et al., 2010). Women in this study were more likely to 
participate if they had Gail or Claus lifetime risk estimates > 25%; the most frequent 
reasons they gave for not participating in MRI were claustrophobia (25.4%) and time 
constraints or other priorities (18.2%) (Berg et al., 2010). Participants were told that their 
insurance provider would be billed if their personal physician agreed to provide a referral 
and that the study would cover any costs for MRI screening not covered by insurance; 47 
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women (9.2%) did not participate because the physician either would not provide a 
referral or did not believe that MRI screening was indicated (Berg et al., 2010).  
Screening for breast cancer with MRI appears to be less tolerable to women than 
mammography. 
Communicating Information about Risk to At-risk Relatives  
 When a woman (counselee) receives genetic counseling and testing for potential 
hereditary breast and ovarian cancer syndrome (HBOC), a family pedigree is usually 
taken. A risk assessment is completed to determine if the woman would be a good 
candidate to have a blood test to look for a genetic mutation (Riley et al., 2012). After the 
blood test is completed, the counselor discusses with the woman her risk of developing 
cancer based on whether the test came back as positive, true negative, or indeterminate 
negative. Counselees are then encouraged to share that information with potentially at-
risk family members. The National Society of Genetic Counselors (NSGC) has published 
guidelines for cancer risk assessment and counseling (Riley et al., 2012). They declare 
that an essential element of disclosure is to “identify at-risk family members and provide 
[the] patient with tools to inform and educate family members” (p. 158). Examples of 
tools that can be used to inform and educate family members include a family contact 
letter, website information, or referrals to genetic professionals (Riley et al., 2012).   
While most genetic counselors consistently teach counselees about the 
implications of genetic health information for their close family members, most 
counselors do not contact family members directly. Generally, to preserve the autonomy 
and privacy of their patients, genetic counselors will leave it to the counselee to share 
information with family members. If family members refuse to share information with 
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relatives, then the genetic counselors should consider whether they have a duty to warn 
and consult with the ethics committee or HIPAA compliance officer at their institution 
(Riley et al., 2012, p. 158).  
Summary letters and letters written specifically for at-risk family members are 
tools that counselees can use when sharing information with their at-risk relatives. In a 
study of 626 genetic health professionals, it was found that 79% always send a summary 
letter to the counselee after a consultation and 90% consistently share information about 
the familial implications of the pedigree; however, 41% never write letters specifically 
for at-risk family members  (L. E. Forrest, Delatycki, Curnow, Skene, & Aitken, 2010).   
Women often report sharing test information with their close relatives. In a study 
of 1,103 women who were tested for BRCA mutations, 97.5% reported communicating 
the test result to at least one blood relative within 4 months of testing. Of women who 
were positive for BRCA mutations, 99.5 reported telling at least one family member, of 
women who were true negative, 99.0% reported sharing, and of those who were 
uninformative, 96.7% reported telling at least one family member (Cheung, Olson, Yu, 
Han, & Beattie, 2010). While this study seems to indicate a high degree of information 
sharing, self-report by the counselees was the main outcome of interest. Researchers did 
not verify the outcomes with the family members themselves. Further, this study only 
asked counselees if they told family members about their own risk. It did not ask whether 
they explicitly stated how that information may apply to the close relative. 
 Close family members may be told about test results by the counselee; however, 
the information may not be transmitted with much accuracy. In a study of families where 
a member was tested for BRCA 1/2 mutations, researchers followed the transmission of 
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information from the genetic counselor, to the counselee, and finally, to close family 
members. It was discovered that there is very little correlation between the information 
actually communicated and the recall and interpretation of that information by counselees 
and their family members (Vos, Menko, et al., 2011). Because counselees have a difficult 
time understanding risk information themselves, let alone interpreting it and teaching it to 
relatives, there have been calls for genetic counselors to guide counselees in the 
communication process or even inform relatives directly about test results and their risk if 
possible (Godard, Hurlimann, Letendre, & Egalite, 2006; Seymour et al., 2010; Stol, 
Menko, Westerman, & Janssens, 2010; Suthers, Armstrong, McCormack, & Trott, 2006; 
Vos, Jansen, et al., 2011). Further, there is some evidence that family members would 
prefer receiving risk information from a health care provider rather than from their family 
member (Tunin, Uziely, & Wolosik-Wruble, 2009). 
 Although in the future, different methods of delivering genetic risk information to 
at-risk family members may be employed, presently, the most common method of 
information dissemination within a family involves genetic counselors encouraging their 
counselees to spread the word within the family. The National Society of Genetic 
Counselors states that a counselor identifies disclosure as a key element in cancer risk 
assessment and counseling, noting that counselors should, “identify at-risk family 
members and provide [the] patient with tools to inform and educate family members (i.e. 
family contact letter, website information, referrals to genetic professionals)” (Riley et 
al., 2012). Family members who receive risk information from a close relative who has 
received genetic counseling then have the opportunity to respond to that information. The 
sharing of risk information within a family can influence risk perceptions. In the present 
33 
 
 
 
study, we evaluated the accuracy of risk perception in potentially at-risk family members 
when an extended member of the family has received genetic counseling.  
 Women who learn information from their close relatives about the relative’s 
genetic counseling session may or may not share that information with their primary care 
providers. Kinney et al. (2006) found that counselees with uninformative results were 
much less likely to discuss their BRCA test results with their primary-care providers than 
those with positive results. 
It is beyond the scope of the present study to assess actual knowledge transferred 
from counselees to sisters and daughters. This study focused on sisters’ and daughters’ 
self-rated understanding of genetic information that was shared. Ultimately, self-rated 
understanding of genetic information shared by a relative who received genetic 
counseling is a general sense that one has a working knowledge of the information, or 
that the information would be available for use. In this study, we aimed to determine 
whether self-rated understanding of genetic information contributes to accuracy of risk 
perception.  
Theoretical Foundations: Self-regulation Theory and 
Response to Risk Information 
 This study was broadly based on the Common Sense Model of Self-regulation  as 
presented by Leventhal et al. (2003) (see Figure 1.1). The constructs of the Common 
Sense Model were identified as the strongest among theoretical frameworks to help 
researchers understand “the process of developing and coping with perceptions of risk-
based on family history information” (Sivell et al., 2008, p. 53). According to the 
Common Sense Model of Self-regulation, when faced with health threats (termed 
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stimuli), people will take actions (termed coping procedures) that result from their 
cognitive representations of danger and their emotional representations of fear (Leventhal 
et al., 2003). These actions are taken with the intent of controlling danger and fear and 
are considered to be parallel actions – occurring simultaneously and interacting with one 
another. Coping actions are then evaluated for their success in reducing the negative 
emotions cause by the health treats (fear control) and in reducing the threats themselves 
(danger control) (Leventhal et al., 2003).  
Building on the Common Sense Model, Marteau and Weinman (2006) present an 
interpretation of the model that DNA risk information is a stimulus that can lead to 
coping actions that are dependent upon both cognitive and emotional representations. 
Marteau and Weinman use Self-regulation theory to “explain and predict the 
characteristics of risk information that are more and less likely to motivate behavior 
change” (2006, p. 1361). They propose that with DNA risk information as the stimulus, a 
main component of the cognitive representation of the health threat is perceived risk. The 
authors further propose that perceived risk is influenced by how well the risk information 
“fits” with people’s preexisting ideas about the threat to health. Thus, people are more 
likely to take actions including risk reducing behaviors for a health threat with a genetic 
component if they understand that health threat to be genetic in origin.  
In the proposed study, receiving DNA risk information was operationalized as the 
reported amount of information shared by her first-degree relative about the relative’s 
genetic counseling session. This is the stimulus that results in cognitive representations –
including risk perception and emotional representations of the health threat.  
35 
 
 
 
Other constructs known to influence risk perception were also taken into account. 
Tilburt et al. (2011) recently completed a systematic review of the literature related to 
risk perception in high-risk populations. The review included 53 studies, 64% of which 
focused on women at increased risk for breast cancer and most of which looked at 
women who had not personally been tested. This review has helped guide the selection of 
constructs that can influence risk perception and several were evaluated as covariates in 
the proposed study.  The Tilburt model illustrates important demographic, clinical, and 
psychosocial factors (cultural, affective, personality, motivational, and cognitive) that are 
associated with perceived risk for cancer in populations at elevated-risk for cancer (see 
Figure 2.2). In this study, measured cognitive factors included health literacy, numeracy, 
and knowledge about breast cancer genetics. The affective factor distress was measured 
as the fear representation of the health threat. Demographic factors taken into account 
included age and education as these have been shown to influence perceived risk. 
Perceived Risk and Accuracy of Risk Perception 
 Perception of risk plays a role in decisions people make about how to care for 
their health. Collins and Street (2009) define risk perception as, “a socially constructed 
perception about the likelihood of an adverse event built upon prior experiences and 
interactions” (p. 1507).  The concept of risk perception is multifaceted, influenced by 
scientific, psychological, social, economic, and cultural factors (Collins & Street, 2009, p. 
1506). Risk perceptions may be developed through both analytic reasoning and 
experiential reasoning, and while health care providers are more likely to rely on analytic 
reasoning, patients are more likely to rely on experiential reasoning (Collins & Street, 
2009). Lipkus (2007) notes, “a comprehensive understanding of risk requires knowledge 
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of precursors (e.g., risk factors), likelihoods (probabilities), consequences, and the pros 
and cons of preventive actions necessary to control/ avert the harm if possible” (p. 696). 
Lipkus further notes that, “most recent conceptualizations of risk view risk as a combined 
function, often multiplicative, of the probability of loss and consequence of loss (e.g., 
severity of loss in the physical, psychological, social and economic realms” (2007, p. 
697). This paper will focus primarily on the probability dimension of risk, especially 
comparative verbal and numeric risks and the accuracy of risk (see variable definitions 
and measures).  
 A primary goal of genetic counseling is to assist people to attain a more accurate 
perception of risk. It is believed that if people more accurately understand their risk, they 
are better prepared to take appropriate actions to reduce that risk (Haas et al., 2005). 
More studies have focused on risk perception than on accuracy of risk perception 
(Smerecnik et al., 2009; Tilburt et al., 2011).  
 Risk perceptions can be influenced either upwards or downwards when health 
care providers share information about likelihoods of disease. Information about risk can 
be shared using numeric, verbal, and visual formats (Lipkus, 2007).  Health care 
providers tend to view risk communication as the effective transmission of precise 
information that is completed effectively if the patient understands risk as the health care 
provider does (Collins & Street, 2009, p. 1507). Patients, on the other hand, may focus 
more on experiential reasoning to understand risk communications drawing upon 
personal life experience and emotion (Collins & Street, 2009). Indeed, many women have 
difficulty interpreting risk information, especially when it is presented in a numeric 
format (Leventhal, Kelly, & Leventhal, 1999; Schwartz, Woloshin, Black, & Welch, 
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1997). Women tend to underestimate risk when using verbal comparative scales but over-
estimate using numeric scales (Lipkus et al., 2000; Woloshin, Schwartz, Black, & Welch, 
1999). This study used measures of both comparative numeric and comparative 
qualitative risk estimates to evaluate risk perception (see variable definitions and 
measures in Chapter 3).  
 Younger women who are at increased risk for breast cancer are more likely than 
older women to have accurate risk perceptions compared to the Gail model (Haas et al., 
2005). An initial evaluation of the Gail model of 3,165 women found that women with 
the highest relative risk for breast cancer had the highest risk perceptions (Bondy, Vogel, 
Halabi, & Lustbader, 1992). These were the women with one or more first-degree 
relatives with breast cancer. Genetic counseling has been shown to increase accuracy of 
risk perception in counselees (Bjorvatn et al., 2007) and improvements may be 
maintained for at least 12 months (Watson et al., 1999). Women who received a written 
summary of genetic counseling results had greater accuracy of risk perceptions based on 
counselors’ categorizations risk (Lobb et al., 2004). 
 In the age of personalized medicine, people are increasingly seeking information 
about their risk for a variety of conditions. While genetic counseling is one way to obtain 
information about risk, a variety of risk calculators are readily available on the internet 
including a calculator for estimating risk for disease, including risk for heart disease from 
the Mayo Clinic: http://www.mayoclinic.com/health/heart-disease-risk/HB00047, a 
calculator to estimate colorectal cancer  risk from the National Cancer Institute: 
http://www.cancer.gov/colorectalcancerrisk/ , and a type II diabetes risk calculator from 
the American Diabetes Association: http://www.diabetes.org/diabetes-
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basics/prevention/diabetes-risk-test/ . The intent of providing risk information through 
these tools is to motivate users to act to reduce their risk (Cameron, Marteau, Brown, 
Klein, & Sherman, 2011). People are also willing to pay for their own DNA risk 
information. According to their web page, over 200,000 people have been genotyped 
using 23 and me: https://www.23andme.com/. 
Health Literacy 
Health literacy is defined as the “degree to which individuals have the capacity to 
obtain, process, and understand basic health information and services needed to make 
appropriate health decisions” (U.S. Department of Health and Human Services, 2000). 
Analysis from the 2003 National Assessment of Adult Literacy found that 36% of U.S. 
adults have limited health literacy. Nationally, higher levels of education are associated 
with higher levels of health literacy, and living below the poverty level is associated with 
lower levels of health literacy (Kutner, United States Dept. of Education., & National 
Center for Education Statistics., 2006). Low health literacy has been associated with poor 
health outcomes, including more hospitalizations, greater use of emergency care, and 
lower ability take medications as directed (Berkman, Sheridan, Donahue, Halpern, & 
Crotty, 2011). Differences in health literacy are consistently associated with lower use of 
mammography (Berkman et al., 2011). 
Adequate health literacy is necessary for women to understand their genetic risk 
and make decisions about which prevention and screening measures they would like to 
undertake (McBride, Koehly, Sanderson, & Kaphingst, 2010). Brewer, Tzeng, Lillie, 
Edwards, Peppercorn, and Rimer, (2009) studied posttreatment female breast cancer 
survivors (N=163) finding that women with lower levels of health literacy give higher 
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estimates for recurrence risk for a hypothetical scenario about women with early-stage 
breast cancer. Additionally, their estimates were more variable when provided in a 
numeric format (0% to 100%) but less variable when provided in a verbal format (“low” 
or “high”). Health literacy affects the variability in numbers chosen to interpret verbal 
descriptions of risk, even when controlling for age, income, race, and actual recurrence 
risk (Brewer et al., 2009).  
Numeracy 
 Health numeracy is considered by many to be an important subcomponent of 
health literacy (Squiers, Peinado, Berkman, Boudewyns, & McCormack, 2012). Health 
numeracy is defined as the “degree to which individuals have the capacity to access, 
process, interpret, communicate, and act on numerical, quantitative, graphical, 
biostatistical, and probabilistic health information needed to make effective health 
decisions” (Golbeck, Ahlers-Schmidt, Paschal, & Dismuke, 2005, p. 375). Increasingly, 
people are presented with numerical health information for the purpose of making health 
decisions that will reduce risk and improve health outcomes (Reyna, Nelson, Han, & 
Dieckmann, 2009).  
 Low health numeracy has been shown to distort risk perceptions and 
understanding of risks and benefit of screenings, reduce medication adherence, impede 
access to treatments, and hamper risk communication (Reyna et al., 2009). Innumeracy 
has been associated with overestimation of risk for breast cancer (Schapira, Davids, 
McAuliffe, & Nattinger, 2004). 
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Measurement of Numeracy  
Health numeracy has been measured in a variety of ways. Some scales ask 
participants to rate their own numeracy skills for a self-assessed numeracy measure 
(Fagerlin et al., 2007). However, other researchers have proposed that these types of 
scales may be measuring individual difference in confidence as opposed to the ability to 
understand and use numeric information (Weller et al., 2012). One of the original ability-
based measures of numeracy was developed by Schwartz, Woloshin, Black, and Welch 
(1997) and included three items that assessed individuals’ abilities to use the 
mathematical concepts of probability, proportions and percent. Lipkus, Samsa and Rimer, 
(2001) saw the need for an expanded instrument to assess health literacy because many 
people including highly educated individuals scored poorly on existing numeracy 
instruments. A longer instrument was needed to capture a broad range of abilities. Others 
have added questions and developed more instruments in an attempt to measure 
numeracy. In 2012, Weller et al. published the results of a psychometrically improved 
measure of numeracy developed through a Rausch analysis of 18 items pulled from 
existing numeracy scales. The resulting eight-item scale purports to assess a broader 
range of ability than previous skills while at the same time avoiding keeping subjective 
perceptions. The Rausch-based numeracy scale combines five questions from a numeracy 
instrument developed by Lipkus, Samsa, and Rimer (2001), expanded  one of the original 
measures of numeracy developed by Schwartz, Woloshin, Black, and Welch (1997),  and 
two questions from the cognitive reflection test (CRT) developed by Frederick. Less 
numerate individuals report higher risk perception (Dieckmann, Slovic, & Peters, 2009). 
Numeracy has been shown to correlate with a patient’s ability to interpret numerical 
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estimates of breast cancer treatment effectiveness (Lipkus, Peters, Kimmick, Liotcheva, 
& Marcom, 2010) 
Knowledge About Breast Cancer Genetics 
 Knowledge about the hereditary nature of cancer in the family has been positively 
associated with risk perception in families at risk for bowel cancer (Glanz, Grove, 
Lerman, Gotay, & Le Marchand, 1999). Tilburt et al. (2011) identify awareness of 
hereditary risk as a cognitive factor that influences perceived risk. Key outcomes of 
genetic counseling for breast cancer include improved knowledge about personal risk and 
knowledge about breast cancer heredity (Braithwaite, Emery, Walter, Prevost, & Sutton, 
2006). As noted above, although extended family members do not always attend genetic 
counseling sessions, a summary letter is sent with the person who received counseling 
and instructions that they should share information with extended family members, and 
encourage them to seek care from health care providers to help them understand their risk 
for breast cancer (Hayat Roshanai, Lampic, Rosenquist, & Nordin, 2010). 
Recommendations of the National Society of Genetic Counselors specify that an essential 
element of genetic cancer risk assessment counseling includes identifying at-risk family 
members, regardless of whether genetic test results came back as positive, negative, or 
indeterminate negative (Riley et al., 2012). In addition, genetic counselors are to provide 
their patient with the tools they need to inform and educate family members about breast 
cancer  and their personal risk; examples of tools include website information, a family 
contact letter, and referrals to genetic professionals (Riley et al., 2012, p. 158). Therefore, 
it can be expected that genetic counseling may have an impact on knowledge about breast 
cancer heredity and breast cancer risk among other family members at risk. Indeed, most 
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people who attend genetic counseling report that they do share information with their 
close relatives (Hayat Roshanai et al., 2010). In the present study, counselees who 
received genetic counseling through the REACH study were provided with pamphlets 
containing information about breast cancer genetics. These pamphlets could be used by 
counselees to educate themselves or family members about breast cancer genetics.  
 According to the Common Sense Model of Self-regulation of Health and Illness 
Behavior by Leventhal (2003), people respond to an internal or environmental stimuli 
with the parallel processes of cognitive and emotional responses in attempt to make sense 
of the health threat. In the present study, we are looking at the genetic counseling of a 
first-degree relative as a stimulus. When a family member who received genetic 
counseling shares the results of the counseling sessions and results of genetic tests with 
their close relatives, they are sharing personal genomic information that pertains to both 
themselves and their close family members. Close family members then will respond to 
that genetic risk information with both cognitive and emotional responses (Marteau & 
Weinman, 2006). In this study, knowledge about breast cancer heredity was assessed as a 
cognitive response to receiving DNA risk information. Further, awareness of hereditary 
risk is an important cognitive component of perceived risk (Tilburt et al., 2011). 
Cancer-related Distress 
 The construct of distress relates to responses including intrusive thoughts and 
avoidance reactions experienced as a result of a particular life event or particular life 
circumstances (Zakowski et al., 1997).  A variety of terms have been used to indicate 
distress about cancer, including cancer, worry, cancer anxiety, fear of cancer, cancer-
related distress, and cancer-specific distress (Hay, Buckley, & Ostroff, 2005). Some have 
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differentiated worry and fear by noting that worry pertains to feelings and thought 
processes whereas fear includes physiologic responses (Champion et al., 2004). The 
terms worry and distress are used fairly interchangeably; for example, researchers have 
measured distress with worry scales (Henderson et al., 2008) and worry with scales 
developed to measure distress (Patenaude et al., 2013). It is thought that worry and 
distress are highly interrelated because worry promotes intrusive thoughts (distress) 
therefore distress is a product of worry (McCaul & Goetz, 2008) 
Cancer-related distress and increased perception of risk for future breast cancer 
have been found to be associated with one another (Tilburt et al., 2011). Cancer-related 
distress has also been prospectively associated with increased uptake of screening 
mammography (Erblich, Bovbjerg, & Valdimarsdottir, 2000; Hay, McCaul, & Magnan, 
2006). In women with a family history of breast cancer, perceived risk has been 
positively correlated with anxiety and both the intrusion and avoidance subscales on the 
impact of events scale (Erblich et al., 2000). Breast cancer-specific distress in women 
who are at increased risk for hereditary breast cancer is significantly related to having at 
least one sister affected with breast cancer and to being involved with  a family member’s 
breast cancer diagnosis and treatment (van Dooren et al., 2005).  
Summary 
 A primary function of cancer genetics services is to provide patients with risk 
information. Accurate perceptions are a basis for informed decision making. Women who 
underestimate their risk for breast cancer may choose not to discuss their family history 
and risk with their primary care providers or may not take advantage of screenings that 
can catch breast cancer in earlier stages when it is more easily and successfully treated. 
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Alternatively, women who over-estimate their risk may experience higher levels of 
anxiety or push for inappropriate screenings.  
 When a woman receives genetic counseling for breast cancer, she is encouraged 
to share genetic information, including risk information, with her relatives. Counselees 
are instructed that close family members may be at increased risk for developing breast 
cancer and that they should discuss risks and screening plans with their primary care 
providers. This cross-sectional study explored how close relatives of counselees 
perceived their risk. Using a statistical analysis with latent variables, we assessed whether 
genetic information shared by the counselee contributed to accuracy of risk perception 
above and beyond other factors known to contribute to risk perception.  This study also 
examined self-reported screening behaviors and report of screening recommendations 
received from PCP by women who are close relatives of counselees. We calculated risk 
estimates using BRCAPRO and Claus models to determine how many women were at 
elevated-risk for breast cancer and of those, how many have received recommendations 
for breast screening with MRI. Additionally, historical data were collected to describe 
when, how, and what genetic information was shared within the family and with primary 
health care providers (see Appendix C).  
 Study results have advanced our knowledge about close family members of 
women who have received genetic counseling for breast cancer. This important 
population may carry higher than average-risk for breast cancer and may not have 
accurate understanding of recommended screenings based on their level of risk. Increased 
understanding about information needs in this population will inform future intervention 
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research aimed at providing family members with tools and information needed to make 
informed decisions based on personalized genetic information.  
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Figure 2.1  
Breast cancer genetic risk groups 
a
 (Hilgart et al., 2012) 
b
(National Cancer Institute, 2014b) 
c
(National Cancer Institute, 2012a) 
d
(Foulkes, 2008) 
 
Breast Cancer (BC) Genetic Risk Groups 
"High Risk" or Very High Risk"
Hereditary or Familial Cancers
Account for 5-10% of all BC
Lifetime Risk = 40-65%a
"Increased Risk"
"Moderate or High Risk"
Account for 15-20% of all BC
Lifetime Risk = 20-30%b,c
Relative Risk 1.5 to 2.0  c
"Low - Average Risk" or
"Population Risk"
Sporadic Cancers
Account for 70-80% of all BC
Lifetime Risk = 12%
Relative Risk 1.0
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Figure 2.2  
Tilburt’s model of risk perception in high risk populations (Tilburt et al., 2011, p. 11)  
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Table 2.1  
Genes associated with heritable breast cancer 
Syndrome  Name Germline 
Mutations in 
(gene): 
Breast Cancer 
Risk % by age  
Associated Cancers/ 
Disorders 
Hereditary Breast and 
Ovarian Cancer (HBOC) 
BRCA1 44-78%  by age 
70
a
 
Early-onset breast 
cancer 
Ovarian cancer 
Pancreatic cancer 
Male breast cancer 
Testicular cancer 
Early-onset prostate 
cancer 
Hereditary Breast and 
Ovarian Cancer (HBOC) 
BRCA2 31-56% by age 
70
a
 
Early-onset breast 
cancer 
Male breast cancer 
Ovarian cancer 
Prostate cancer 
Melanoma 
Pancreatic cancer 
Li-Fraumeni Syndrome P53 50% by age 50
 b
 Childhood sarcoma  
Brain tumors 
Leukemia 
Adrenocortical 
carcinoma 
b
 
Cowden Syndrome PTEN 25-50% 
Lifetime
 b
  
Multiple hartomas 
Breast cancer 
Gastrointestnal 
malignancies 
Endometrial cancer 
Thyroid disease 
Trichilemmomas 
Oral fibromas 
Papillomas 
Acral, palmar, plantar 
keratosis 
Peutz-Jeghers Syndrome STK11 32-54% by age 
60-70 
 
 
a
 (A. Antoniou et al., 2003) 
b
 (National Cancer Institute, 2012b) 
c
 (Foulkes, 2008) 
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Table 2.2  
NCCN criteria for referral to cancer genetics professional 
Affected individuals with one or more of the following: 
 A known mutation of breast cancer susceptibility gene in family 
 Early-age-onset breast cancer 
 Triple negative (ER-, PR-, HER2-) breast cancer 
 Two breast cancer primaries in a single individual 
 Breast cancer at any age, and 
o >1 close blood relative with breast cancer <50 y, or  
o >1 close blood relative with epithelial ovarian cancer at any age, or 
o >2 close blood relatives with breast cancer  and/or pancreatic cancer at any 
age 
o From a population at increased risk 
 >1 family member on same side of family with a combination of breast cancer 
and >1 of the following (especially if early onset): pancreatic cancer, aggressive 
prostate cancer (Gleason score >7); sarcoma, adrenocortical carcinoma, brain 
tumors, endometrial cancer, leukemia/lymphoma; thyroid cancer, dermatologic 
manifestations and/ or macrocephaly, hamartomatous polyps of GI tract; diffuse 
gastric cancer 
 Ovarian cancer 
 Male breast cancer.  
An unaffected individual with a family history of one or more of the following: 
 A known mutation in a breast cancer susceptibility gene within the family 
 >2 breast primaries in a single individual 
 >2 individuals with breast primaries on the same side of the family (maternal or 
paternal) 
 First- or second-degree relative with breast cancer <45 y 
 >1 family member on same side of family with a combination of breast cancer 
and >1 of the following (especially if early onset): pancreatic cancer, aggressive 
prostate cancer (Gleason score >7); sarcoma, adrenocortical carcinoma, brain 
tumors, endometrial cancer, leukemia/lymphoma; thyroid cancer, dermatologic 
manifestations and/ or macrocephaly, hamartomatous polyps of GI tract; diffuse 
gastric cancer 
 Male breast cancer 
(National Comprehensive Cancer Network, 2013c, pp. BR/OV-1)
  
 
CHAPTER 3 
 
RESEARCH DESIGN AND METHODS 
Sample 
 The sample was recruited from relatives of breast cancer patients enrolled in a 
pilot study who have agreed to be contacted for cancer-related research studies. The 
objective was to include 100 women ages 40 to 74, of all races and ethnicities, who are 
fluent in English and live in any state in the United States. Participants did not have a 
personal history of breast or other type of cancer besides nonmelanoma skin cancer, and 
did not have had a bilateral mastectomy.  Women who participated in this study had 
biological sisters or mothers who had previously been diagnosed with breast cancer, 
received genetic counseling, and had a BRCA1/2 genetic test with indeterminate negative 
results.  From here forward, the relatives who had breast cancer and received genetic 
counseling and testing will be referred to as the counselees. Counselees were not the 
participants in the proposed study; however, it is important to understand the background 
of the counselees because they are the women who received genetic counseling and may 
have shared that information with the proposed study participants. The counselees are 
also the ones who referred their relatives into the pilot study from which the proposed 
study will sample. The following paragraphs describe the counselees. 
The study recruited relatives from two groups of counselees.  The first group of 
counselees included women who participated in the Risk Education & Assessment for 
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Cancer Heredity (REACH) study (P.I. Anita Kinney, PhD, RN) and had BRCA1/2 testing 
with indeterminate negative results. REACH study participants were identified through 
the Utah Population Database (UPDB) and recruited through the Utah Cancer Registry. 
The REACH study provided standardized in-person or telephone genetic counseling to 
those who met the NCCN criteria for referral for genetic counseling for BRCA1/2 testing 
(National Comprehensive Cancer Network, 2013c). These women were offered genetic 
testing if appropriate. All women received an educational brochure about BRCA1/2-
related cancer risks, genetic testing, hereditary and familial risk, and recommended 
medical management (e.g., screening guidelines) for women who underwent testing. 
Posttest counseling was provided along with standardized summary letters alerting them 
to the possibility that close relatives may be at increased risk for breast cancer and may 
need more intensive breast cancer surveillance, (possibly including MRI) and 
encouraging counselees to share this information with their close relatives and to 
encourage the close relatives to, in turn, share that information with their primary care 
providers. 
The second group of counselees included patients who received genetic 
counseling and testing through the Family Cancer Assessment Clinic (FCAC) at 
Huntsman Cancer Institute. The High Risk Breast Cancer Clinic also follows the practice 
of sending genetic counseling summary letters. First-degree female relatives of 
counselees who attended genetic counseling through FCAC may be different from 
relatives of women contacted through women who received genetic counseling through 
the REACH study. Women attending FCAC have either self-referred for genetic 
counseling or have been referred by a concerned clinician. Women who self-refer for 
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genetic counseling may have a stronger concern about their family history of cancer and 
concern for how it may affect other family members and thus may be more likely to share 
information about risk than women enrolled through the REACH study. It was thought it 
would be helpful to have women in the study who have been referred by counselees from 
both settings because one group is likely to be representative of families who either are 
not aware of their family history, not as concerned, or do not have the resources to seek 
out specialized counseling, whereas the other group is likely to be more representative of 
women who were either concerned themselves, or had a primary care provider concerned 
enough, to refer them to the clinic, and had access to the resource. 
Counselees from both recruitment sources received their counseling between the 
fall 2010 and 2013.  Therefore, participants in the present study had family members who 
received counseling a few months prior to our contact with them to up to 2 1/2  years 
prior to our contact with them. Most of the participants received counseling at least a year 
or more prior to our contact with them. Data about the time of the family member’s 
counseling was to be collected as a part of this study and evaluated in terms of its effect 
on self-reported understanding about genetic information shared by the counselee as well 
as accuracy of risk perception.  We expected that most of the participants in the proposed 
study would have talked with their relatives about the relatives’ genetic counseling 
because they were referred into the study by their relatives. Participants in the present 
study (women with a family history of cancer) may not have gone immediately to their 
primary care providers to discuss their risk for breast cancer upon hearing about the 
counselee’s genetic counseling session. They may have waited until their next physical 
exam if they discussed the counseling at all. Many women have physical exams every 1 
53 
 
 
 
to 2 years. If a primary care provider makes a recommendation for screening 
mammography or screening breast MRI for a participating woman with a family history 
of breast cancer, she may not immediately obtain the test. The cross-sectional design of 
present study was intended to allow for analysis of the effect of time since relatives’ 
counseling on variables such as accuracy of risk perception, self-report of discussing 
genetic information with primary care provider, and self-report of screening plans and 
screening actions. Information gathered about the effect of time on these variables was 
intended to future studies designed to assess the impact of receiving personalized genetic 
information.  
Counselees from both groups described above were asked by REACH 
investigators to provide contact information for their sisters and daughters. Those sisters 
and daughters were then asked to participate in a survey that aimed to collect preliminary 
data for a planned breast cancer prevention study involving genomic risk information 
targeting at-risk women who have relatives with a personal history of breast cancer who 
received indeterminate negative BRCA1/2 results. Unaffected women with a family 
history of breast cancer who agreed to participate completed a single questionnaire. 
Participants were asked if they would be willing to be contacted in the future for cancer-
related research. Only women who indicated they would be willing to have future contact 
were invited to participate in the proposed study. 
Inclusion and Exclusion criteria 
Included participants were of any race, aged 40-74 years, fluent in English, had a 
mother or sister who received genetic counseling during 2010-2013 for possible 
hereditary breast cancer, and had indicated that they would be willing to be contacted for 
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future research. The counselee’s mother or sister(s) were tested for BRCA1/2 mutations, 
received indeterminate negative results, and received a genetic counseling summary 
letter. Potential participants were excluded if they had a personal history of any type of 
cancer (except nonmelanoma skin cancer), had received genetic counseling or testing 
themselves, had bilateral mastectomy, lived outside the USA, or were incarcerated.   
Human Subjects Protections  
Institutional Review Board (IRB) approval for the REACH Project and the pilot 
study (P.I. Anita Kinney) was granted through the University of Utah. Additionally, both 
studies (from which participants for the present study were recruited) were approved by 
the University of Utah Clinical Cancer Investigations Committee (CCIC), Utah Cancer 
Registry (UCR), and Resource for Genetic and Epidemiologic Research (RGE).  
For the present study, IRB approval was obtained from the University of Utah and 
was considered primary. Additionally IRB deferral was obtained from Brigham Young 
University because of Deborah O. Himes’ employment. Two research assistants were 
hired to assist with data collection and data entry. All study personnel completed 
appropriate Collaborative Institutional Training Initiative (CITI) and HIPAA training. All 
data collected from participants are stored in a locked office and on encrypted key drives 
stored in locked file cabinets. Only approved research personnel have access to this data. 
Procedures 
  After IRB approval, REACH staff provided Deborah O. Himes P.I. with a list of 
REACH-pilot participants who have indicated they would be willing to participate in 
future research.  Names and contact information were sent via the encrypted email system 
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approved for transferring personal health information. Data were collected from two 
sources: a mailed packet and a telephone interview. The following sections describe the 
procedures in more detail. The initially conceived timeline is illustrated in Figure 3.1: 
Initial Project Timeline.  
Recruitment 
Once contact information for potential participants was obtained, an introduction 
and consent cover letter was sent to potential participants (see Appendix A). The letter 
introduced the study and alerted the women to expect a telephone call within about a 
week. During the telephone call, verbal consent to participate was obtained. Those 
declining to participate were asked to provide the primary reason that they declined 
participation and to provide their age, education, and self-described race/ethnicity so that 
differences between participants and nonparticipants can be evaluated. Women who 
completed the study were thanked for their time with a $25.00 visa gift card once all data 
were collected.  
Data Collection 
 Data were collected from two sources: a paper and pencil packet that will be 
mailed and a telephone interview (see Appendix B for the survey packet and Appendix C 
for the telephone interview). Women who agreed to participate were instructed that a 
survey packet would be sent in the mail. The packet included written survey questions 
that took approximately 15 minutes to complete based on testing with two women in ages 
50 and 60.  A stamped and addressed return envelope was included for women to mail 
the survey back. Participants were asked to fill it out and mail it back quickly after 
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receiving it. If women agreed to participate during the recruiting telephone call, an 
appointment for the telephone interview was for 2 to 3 weeks in the future at a mutually 
agreed upon day and time. Two to 3 weeks was selected to allow enough time for the 
woman to receive the packet in the mail, fill out the forms, and mail them back. A 
reminder telephone call was placed if the survey has not been received back by 7 days 
ahead of the scheduled interview. If the packet was received back prior to the telephone 
interview, it was be reviewed for accuracy so that unanswered questions could be 
clarified during the telephone interview, if possible, to minimize missing data. The packet 
included questions about demographics, perceived risk, distress, health literacy, 
numeracy, and knowledge about breast cancer genetics. Additionally, the packet included 
a family history form that women were asked to mail back. This form helped facilitate 
obtaining pedigree information during the telephone interview (see Appendix B).  
During the telephone interview, answers to any unanswered survey questions 
were obtained if possible and answers to questions were clarified if needed. Data were 
collected about women’s understanding of information shared by their sisters or mothers 
about their genetic counseling sessions, breast cancer screening plan and 
recommendations, and the pedigree and health history information necessary to complete 
the Gail, Claus, and BRCAPRO instruments (see Appendix C). The reason for collecting 
pedigree and screening information on the phone was to ensure accuracy and 
completeness of the data. The telephone interviews took approximately 40 minutes to 
complete. The initial plan was to audio tape the telephone if participants agreed and that 
participants would not be excluded if they refused audio taping. At the conclusion of the 
telephone interview, women were instructed that estimates of lifetime risk for breast 
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cancer would be calculated based on the pedigree information they provided. Women 
were asked if they would like to have information about personal risk for breast cancer 
once the calculations were completed. If women wanted the information, a letter was be 
sent with the lifetime risk calculations along with the thank you letter (see Appendix D). 
Participants who received risk information were encouraged to share that information 
with their primary care providers. After all data were collected from both the survey and 
the telephone interview, a $25.00 visa gift card and thank you letter was sent as a thank 
you. The thank you letters included a web address published by the National Society of 
Genetic Counselors that can be used to find a genetic counselor by zip code as well as 
contact information for the Family Cancer Assessment Clinic in case participants wanted 
more information.  
Variable Definitions and Measures 
 Guided by the Common Sense Model of Self-regulation (see Figure 1.1), a 
structural equation model (see Figure 3.2) was developed to determine the contribution of 
understanding of information shared about genetic counseling sessions to the accuracy of 
a woman’s perception of individual risk for breast cancer controlling for the confounding 
influences of demographic, cognitive, and emotional factors known to contribute to risk 
perception. Variables were selected for the model based on important constructs 
identified in Tilburt’s Model of Risk Perception in High Risk Populations (see Figure 
2.1). The following sections describe variables and measures that will be used in the 
proposed study. 
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Perceived Risk  
The latent variable, perceived lifetime risk for breast cancer, was measured using 
two instruments that evaluate comparative quantitative and qualitative estimates of 
lifetime risk for breast cancer. The reliability of these instruments as a measure for the 
overall construct of perceived risk was to be deemed good if the measurement error is 
small. If the coefficients of the relationships between the measured variables and the 
constructs are high, then these instruments would be deemed valid measures of the 
construct. The qualitative item was asked first based on work by Taylor et al. (2002), 
which found that asking for qualitative comparative rating of risk before asking for other 
estimates of risk resulted in more accurate risk perceptions. In that study, the other 
questions about risk included numeric estimates for quantitative population risk and 
quantitative personal risk without anchors. Using an anchor of population risk has been 
shown to increase accuracy of risk estimates (Apicella et al., 2009; Dillard, McCaul, 
Kelso, & Klein, 2006). 
Qualitative risk perception. To evaluate qualitative risk perception, we asked, “In 
your opinion, compared to other women your age, what are your chances of getting breast 
cancer?” with five Likert type options ranging from “much lower” to “much higher.” A 
“don’t know” option was also be included. This is the same question format used in the 
REACH study when women were asked about their risk of getting breast cancer or 
having it recur. This will allow for potential future secondary analysis of concordance of 
risk perception between first-degree relatives.  
Comparative quantitative risk perception. To measure comparative quantitative 
perceived risk, women were presented with a graphic of 100 women (see Appendix B). 
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Twelve women were shaded. The question read, “On average, 12 women out of 100 will 
get breast cancer in their lifetime. This is a picture with 12 women shaded dark.” This 
statement offers women a basis for comparison or an “anchor” for what is normal or 
average. The question went on to state, “Picture yourself in a room with 100 women 
exactly like you. How many of you will get breast cancer in your lifetime? Please pick a 
number between 0 and 100. ” This latter half of this statement used wording by Schapira 
et al. (2004, p. 666). A frequency format with a graphic has been shown to have a lower 
risk estimation error when compared to the percentage scales when estimating lifetime 
risk for breast cancer (Schapira et al., 2004, p. 668). This format has been used in recent 
work; Cameron et al. (2011) purport that “individuals may comprehend risk estimates 
better when they are presented graphically” (para. 11). Providing women with the graphic 
with 12 of 100 women shaded and providing them with the information that “on average 
12 women out of 100 will get breast cancer in their lifetime” provides an anchor or a 
context within which women can make their estimates. This method was used by 
Cameron et al. (2011) in a study of communication strategies related to genetic risk .  
Calculated Risk 
Calculated risk was assessed using three models: Claus, BRCAPRO, and Gail. 
Questions related to risk calculations were asked over the telephone as these are more 
difficult questions with some foreign terminology that may need to be explained.  Only 
the Claus and BRCAPRO models were be used as indicators of the latent variable 
calculated risk because participants had family histories for breast or ovarian cancer 
significant enough to warrant genetic counseling and testing in the family. A discussion 
of these risk calculators can be found in Chapter 2. 
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Accuracy of Perceived Risk 
Studies operationalize accuracy of perceived risk in many ways. In the present 
study, the accuracy of perceived risk were be assessed as the coefficient of the path 
between the latent variable “calculated lifetime risk for breast cancer” measured by the 
three breast cancer risk models and the latent variable “perceived lifetime risk for breast 
cancer” as measured by the comparative quantitative estimate and the comparative verbal 
estimate of risk. A beta weight of 1.0 would be perfect accuracy (see Figure 3.2).  
Demographics 
Demographics included age, marital status, highest education level attained, 
race/ethnicity, income, health insurance coverage, type of primary health care provider (if 
any), and historical questions about how information related to the genetic counseling 
session and summary letter was shared between the relatives. Demographics to be 
included in the initial path analysis include age and education because they have been 
shown to be associated with perceived risk (Tilburt et al., 2011).   
Health Literacy  
Self-assessed health literacy was measured using the Set of Brief Questions 
developed by Chew, Bradley, and Boyko (2004). This instrument was selected because it 
offers a practical way to identify patients with low health literacy. Being only three 
questions, it will not add a great deal to participant burden. Questions ask individuals to 
rate their difficulty understanding written and verbal information in the health care setting 
on a five-point Likert scale. The questions about how often help is needed to read 
hospital materials and how often one has problems learning about a medical condition 
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range from “never” to “always.” The question about confidence in filling out medical 
forms ranges from “not at all” to “extremely” (see Appendix B).  
Content validity for this instrument is supported because investigators based 
questions on domains of health literacy described in qualitative research (Baker et al., 
1996; Chew et al., 2004). Both reliability and criterion-related validity has been 
supported using areas under the curve receiver operating characteristic (AUROC) when 
compared to the two most commonly used measures of health literacy, the Rapid 
Estimate of Adult Literacy in Medicine (REALM) and the Short Test of Functional 
Health Literacy in Adults (STOFHLA) (Baker, 2006; Davis et al., 1993; Parker, Baker, 
Williams, & Nurss, 1995). The instrument was compared to the STOHFLA in a 
population of 332 Veterans’ Administration clinic. The three questions, (1) “How often 
do you have someone help you read hospital materials?”,  (2) “How confident are you 
filling out medical forms by yourself?”, (3) “How often do have problems learning about 
your medical condition because of difficulty understanding written information?”, had 
areas under the receiver operating characteristic curves (AUROC) of 0.87 (95%CI=0.78-
0.96), 0.80 (95% CI= 0.67-0.93), and 0.76 (95%CI=0.62-0.90), respectively (Chew et al., 
2004). When compared to the REALM in 305 English-speaking adults in a university-
based primary care clinic, the single question “How confident are you in filling out 
medical forms by yourself?” had an AUROC of 0.82% (95% CI=0.77to 0.86) in 
detecting limited or marginal health literacy. Adding one or both of the other screening 
questions did not significantly increase the AUROC for limited or marginal health 
literacy (Wallace, Rogers, Roskos, Holiday, & Weiss, 2006).  
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Numeracy  
Numeracy was measured using the Rausch-based numeracy scale recently 
developed by Weller, Dieckmann, Tusler, Mertz, Burns, and Peters  (2012). This 
instrument includes eight items that assess the users’ ability to understand, manipulate, 
and use numerical information including probabilities (see Appendix B). Questions 
reauired participants to answer mathematical questions and analyze information from a 
table.   
Reliability for the Rausch-based numeracy scale is supported by a Cronbach’s 
alpha of .71 in three separate samples recruited to reflect ranges of education levels (total 
n=1970). Because this Rausch-based numeracy scale is newly developed, there are not 
further studies with Cronbach’s alpha to report. However, this newly created instrument 
is a compilation of questions from previously developed instruments for measuring 
numeracy. This instrument with eight items had higher alpha values than any of the 
earlier instruments when administered to the same sample (Weller et al., 2012). Internal 
consistency is further supported with a mean interitem correlation of r=.24
 
(Weller et al., 
2012). This level of interitem correlation is near optimal when measuring a broad, higher-
order construct (Clark & Watson, 1995, p. 316). 
Predictive validity is supported because the Rausch-based numeracy scale was 
able to predict performance on tasks that involved understanding and application of 
mathematical principles (Weller et al., 2012). An advantage of this scale over previously 
developed instruments is that it approached normal distribution in the two large samples 
in which it has been tested, allowing numeracy to be treated as a continuous rather than a 
dichotomous variable. 
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This new scale represents a composite of four previously developed scales 
(Frederick, 2005; Lipkus et al., 2001; Peters, Dieckmann, Dixon, Hibbard, & Mertz, 
2007; Schwartz et al., 1997). The scale was developed to address limitations of the 
previous instruments. Previous instruments were skewed and less successful at predicting 
various levels of numeracy with some being more difficult and some being too easy. For 
example, when the cognitive reflection test was administered to a group of highly 
numerate students from highly respected universities, over 60% of students scored either 
zero or one on the three-item test (Frederick, 2005).  With the Lipkus et al. (2001) 
instrument on the other hand, nearly a third of participants were able to answer all eight 
items correctly, indicating an inability of the Lipkus instrument to discriminate at the 
upper levels of the latent trait.   This Rausch-based numeracy scale is able to discriminate 
among a broader range of numeracy, and yields a more normal distribution of results 
(Weller et al., 2012). This instrument is an objective measure of numeracy as opposed to 
instruments that ask participants to describe their comfort/ ability to use numbers in a 
subjective way. The Rausch-based numeracy scale assesses a range of numeracy abilities 
with minimal subject burden. 
Knowledge About Breast Cancer Genetics  
In this study, breast cancer genetic knowledge was be measured using the 27-item 
Breast Cancer Genetic Counseling Knowledge Questionnaire (BGKQ) (Erblich et al., 
2005). Twenty-three items may be answered as either “true,” “false,” or “don’t know,” 
four items are multiple choice items with five to six options (see Appendix B). This 
instrument was developed to assess knowledge of information that is typically included 
during genetic counseling for breast cancer. This questionnaire has been chosen because 
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it has been shown to distinguish between women who have received genetic counseling 
information from those who have not. Although the participants in the present study had 
not received genetic counseling at the time of their participation, the expectation was that 
their first-degree relatives who have received genetic counseling will have had the 
opportunity share knowledge gained counseling sessions with them. 
 Items for the Breast Cancer Genetic Counseling Knowledge Questionnaire 
(BGKQ) were developed following a detailed content analysis of genetic counseling 
pretest sessions that followed guidelines. Potential questions were developed from these 
sessions then assessed by four genetic counselors for appropriateness. Three of the four 
genetic counselors needed to agree (interrater agreement of 0.75) that the questions were 
appropriate for them to be included. Items were reevaluated; some were dropped and 
some were modified until a 45-item version of the questionnaire was formed with an IR 
of 0.93, indicating high levels of content validity (Erblich et al., 2005). Once initial items 
were developed, a second phase of development involved administering the questionnaire 
to 75 people, including nurses with and without oncology certification, and healthy 
women with and without family histories of breast cancer, as well as people who had 
attended genetic counseling. These groups with supposed differing levels of knowledge 
of information presented in genetic counseling were given the 45-item version of the 
BGKQ along with the Breast Cancer and Heredity Knowledge Questionnaire (BCHK), an 
11-item instrument previously validated for use in lower risk women. Based on this work, 
items were dropped if they were too simple or too difficult. The remaining 37 items were 
then evaluated by confirmatory factor analysis, which indicated that 27 items loaded onto 
a single factor. An ANOVA was conducted to compare scores of the five groups 
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controlling for demographics; a main effect of group was observed (P < 0.0001), 
indicating support for good criterion-related validity within this sample. With the 27-item 
GBKQ, women who had received counseling scored higher than all other groups, 
indicating that the instrument measures knowledge obtained through genetic counseling.  
The GBKQ has been used to detect genetic counseling knowledge obtained in part 
through the family member who received the counseling as reported in the study by 
Patenaude et al. (2013). In this study, daughters of mothers with BRCA 1/2 mutations 
were administered the GBKQ an average of 3.1 years following the mother’s BRCA1/2 
test result and genetic counseling. Daughters scored an average of 61.9% correct on this 
questionnaire (Patenaude et al., 2013). In the study by Erblich et al. (2005), women who 
had received genetic counseling themselves scored an average of 76.6% on the 
questionnaire and women who had not had breast cancer nor received genetic counseling 
scored an average of 35% and 41% for those who had a positive family history of breast 
cancer and those who did not, respectively.  
Reliability for this instrument has been demonstrated by a Cronbach’s alpha of 
0.92 in a study of 75 women (Erblich et al., 2005). This instrument was also used in a 
study of 40 daughters of mothers with BRCA 1/2 mutations to assess knowledge of the 
daughters who had not attended genetic counseling (Patenaude et al., 2013); however, 
internal consistency was not assessed in this study (A.F. Patenaude, personal 
communication, March 10, 2013).  
Distress 
The concept of  distress related to a family history of breast cancer and personal 
risk for breast cancer was measured using the 15-item Impact of Event Scale (IES), 
66 
 
 
 
which was designed to measure current subjective distress during the prior week in 
reaction to a defined stressor (Horowitz, Wilner, & Alvarez, 1979). This instrument was 
adapted for the REACH study (P.I. Anita Kinney) so that the potentially stress-inducing 
event is the state of having a certain risk for breast cancer related to family history (see 
Appendix B). Because the same adapted instrument was used in REACH as well as the 
proposed study, future comparisons in secondary analysis will be able to be made 
between counselees and their unaffected first-degree female relatives.  This self-report 
instrument is intended to measure “the current degree of subjective impact experienced as 
a result of a specific event.” (Horowitz et al., 1979, p. 209). Participants rate the 
frequency of certain psychological, physiological, and behavioral responses to the event 
on a four-point scale. Weights are applied to the responses as follows: not at all = 0, 
rarely = 1, sometimes = 3, often = 5. The full Impact of Events Scale is 15 items 
including one subscale related to intrusion and one subscale related to avoidance. 
Intrusive phenomena include experiences like thinking about a stressful event, or having 
dreams about it. Avoidance phenomena include actions like trying to stay away from 
reminders or trying not to talk about the event. A total score can be calculated for the 
complete IES or for the subscales. The range for the full scale is 0-75. Based on multiple 
examples from the literature, a score of > 40 on the full scale is indicative of a significant 
stress response.  
 The intrusion subscale of the IES has demonstrated satisfactory internal 
consistency in samples of relatives of women with breast cancer with a Cronbach’s 
alphas for the total scale of 0.91 (Thewes, Meiser, & Hickie, 2001), for the avoidance 
subscale of .84 - .87 (Kim, Duhamel, Valdimarsdottir, & Bovbjerg, 2005; Thewes et al., 
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2001) and for the intrusion subscale of .81 to .83 (K. E. Fletcher et al., 2006; Kim et al., 
2005; Thewes et al., 2001). Test-retest reliability for the intrusion subscale of the IES was 
found to be r=0.75, suggesting a moderate agreement between scores from one 
administration to another (Thewes et al., 2001). 
To assess face validity for women at increased risk for breast cancer, a small 
group was asked to describe what they believed the IES measured and to assess the 
clarity of the instructions and the items. Women felt that the items were about anxiety, 
worry, or emotional well-being. For the most part, they thought the instructions and items 
were clear and easy to understand. Perhaps most importantly, they felt that the items were 
pertinent for women with a family history of breast cancer (Thewes et al., 2001).  
The IES was assessed for construct validity in a sample of women at risk for 
familial breast cancer; a component factor analysis yielded a two-factor solution, 
consistent with the two subscales in the instrument (Thewes et al., 2001). The IES was 
assessed for convergent validity in the same sample by calculating point-biserial 
correlation coefficients between scores on the IES and two other measures of generalized 
distress: the Beck Depression Inventory (BDI) and the state component of the State-Trait 
Anxiety Inventory (STAI-State), the General Health Questionnaire (GHQ-28), as well as 
breast-cancer related attitudes and events. Breast cancer-related events and attitudes 
included contemplation of prophylactic mastectomy, a breast-cancer related live event 
within the past year, and the total number of first- and second-degree relatives who have 
either been diagnosed with or died from breast cancer (Thewes et al., 2001).  Scores on 
the total IES were significantly related with breast cancer-related attitudes and events 
supporting the idea that the IES is a useful measure of breast cancer-related distress in 
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women at increased risk for breast cancer due to family history (Thewes et al., 2001, p. 
465).  
Reported Amount of Information Shared About Genetic  
Counseling Session  
A question was asked about how much women felt was shared with them by their 
sister or mother who attended genetic counseling. The variable “amount of information 
shared” was assessed by asking the question, “Would you please rate on a scale of 0-5 
how much information your sister or mother shared with you about what she learned in 
her genetic counseling session. With zero being she shared nothing about the session to 
five being she shared a great deal” (see Appendix C).  
Self-rated Understanding of Genetic Health Information 
Historical questions about how information was shared from the genetic 
counseling session were asked during the telephone interview (see Appendix C). 
Questions were tailored based on the relative who received genetic counseling. The 
variable, “understanding of genetic counseling information” was assessed by asking the 
question, “To what degree do you understand the information she shared with you about 
her genetic counseling session? Please rate how well you understand the information she 
shared on a scale of 0-5 with zero being you don’t understand it at all to five being you 
understand a great deal.” This is an ordinal level question that was intended to be used in 
the path analysis to assess whether self-rated understanding of genetic counseling 
information provided to a close relative mediates accuracy of risk perception (see Figure 
3.2). 
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Screening Recommendations/ Screening History  
To obtain information about what types of breast screenings have been done 
(mammography and/or MRI) and what screenings have been recommended, we used an 
adaptation of questions developed by Vernon et al. (2004) and the questions developed 
for the Behavioral Risk Factor Surveillance System (BRFSS) by a working group of the 
CDC and BRFSS state coordinators, which can be accessed at 
http://www.cdc.gov/brfss/questionnaires/english.htm .  
The BRFSS is a state-based health survey that “collects information on health risk 
behaviors, preventive practices, and health care access primarily related to chronic 
disease and injury” (Office of Surveillance Epidemiology and Laboratory Services, 
2013). This questionnaire is administered annually and collects data on mammography 
but not on breast MRI.  The questions related to mammography on the BRFSS include: 
1. A mammogram is an x-ray of each breast to look for breast cancer. Have 
you ever had a mammogram? 
 
a. Yes 
b. No 
c. Don’t know/ not sure 
d. Refused 
 
2. How long has it been since you last had a mammogram? 
a. Within the past year (anytime less than 12 months ago) 
b. Within the past 2 years (1 year but less than 2 years ago) 
c. Within the past 3 years (2 years but less than 3 years ago) 
d. Within the past 5 years (3 years but less than 5 years ago) 
e. More than 5 years ago 
(Office of Surveillance Epidemiology and Laboratory Services, 2013) 
 
The instrument presented by Vernon et al. (2004) was developed by members of 
the Division of Cancer Control and Population sciences sponsored by the National 
Cancer Institute (NCI). Researchers in the field of colorectal screening had identified a 
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problem with data collection: patients often did not know the difference between 
colonoscopy and sigmoidoscopy. Therefore, this group worked over several years to 
develop a core set of colorectal screening measures and standardized descriptions of the 
tests. The instruments measure whether patients are aware of, or have participated in, 
various screenings for colon cancer. The questions also focus on whether the tests are for 
screening or diagnostic purposes. Cognitive testing was performed on the questions to 
assess whether people could comprehend and interpret the questions and to assess the 
strategies people used to recall the information (Vernon et al., 2004). Performing 
cognitive testing helps improve “reliability and validity of self-reports of retrospective 
information by identifying and reducing sources of response error that may go unnoticed 
in field tests of survey instruments” (Vernon et al., 2004, p. 900). 
The advent of MRI screening recommendations for women at elevated-risk of 
breast cancer is relatively new (Saslow, 2007). Because MRI breast screening may be 
less familiar to women, it was thought that a description of the screening should 
accompany the questions about the screenings to yield more accurate results when asking 
about screening participation. Therefore, the Vernon instrument was adapted and used to 
measure screenings related to breast cancer. The introduction to the questions vided a 
brief description explaining mammography and breast MRI exams are. The description 
for mammography was modeled after the BRFSS questionnaire. The description for 
breast MRI was adapted from patient information posted on the website 
RadiologyInfo.org, which was developed by the Radiological Society of North America 
and the American College of Radiology. After explaining each type of screening, the 
questions asked whether or not the woman had “ever heard of” the test, “ever had” the 
71 
 
 
 
test, and if so, what was the date of the “most recent?” These questions were used 
initially by Vernon (2004) in a face-to-face interviewer-administered mode, but they were 
written with the intent that they could be adapted to use in telephone interviews or in self-
administered questionnaires. Additional questions added for the purpose of this study 
asked related to mammography and breast MRI tests included whether or not “anyone 
ever recommended it?” if so, “how often was it recommended that you receive it?” and 
“do you plan to get” the screening and if so, “how often do you plan to get” the 
screening? These additional questions were used to help determine if the woman had a 
screening plan that is in agreement with the NCCN guidelines based on her risk level. 
Analysis 
Sample  
The sample was described using percentages for categorical measures. 
Additionally, measures of central tendency were used to assess the distribution 
continuous variables including. Risk was calculated and reported based on the Claus, 
BRCAPRO, and Gail models. Accuracy of lifetime risk perception was reported for each 
model; women will be considered accurate if their estimate falls within +/- 3% of a given 
scale. Kurtosis and skewness were assessed. An absolute value less than two was 
considered to not be overly skewed or kurtotic. Psychometric performance of instruments 
was assessed. Internal consistency was calculated using Cronbach’s alpha where 
appropriate. Internal consistency is not appropriate for measures that are not based on a 
redundancy (internal consistency model). Numeracy, for example, might not be 
appropriate for internal consistency evaluation. For such scales, we will use communality 
estimates as lower bounds of reliability from exploratory factory analyses. 
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Analysis of Specific Aim 1 
Specific aim 1 was to calculate an estimate of women’s lifetime risk for breast 
cancer and compare this estimate to women’s perceived risk about developing future 
breast cancer. This aim included three research questions: 
4. What is the average calculated risk for breast cancer using the Claus model, 
the BRCAPRO model, and the Gail model for women (with sisters or mothers 
who received genetic counseling and indeterminate negative BRCA1/2 
results)? 
5. What percent of women (with sisters or mothers who received genetic 
counseling and indeterminate negative BRCA1/2 results) qualify for annual 
MRI breast screenings based on NCCN guidelines (a lifetime risk for breast 
cancer > 20%) based on the Claus or the BRCAPRO risk calculators?  
6. What percent of women (with sisters, mothers, or daughters who have 
received genetic counseling and had indeterminate negative BRCA1/2 results) 
over-estimate vs. underestimate their risk as compared to their calculated risk 
for breast cancer?  
Risk scores were calculated for the Claus and BRCAPRO models using Cancer 
Gene software and for the Gail models using the NIH website. Because the Gail model is 
the most commonly used risk calculator by primary care providers, for purposes of 
comparison, a Gail estimate of risk was calculated along with Claus and BRCAPRO.  
Average calculated risk was reported using percentages and frequencies. We did not 
categorize women as qualifying for MRI breast screening based on Gail scores. 
Frequencies and percentages were reported about the number of women above and below 
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the 20% lifetime risk threshold for each model. Over- and under-estimation will be 
reported for each risk calculator. Over- and under-estimation was defined as a woman’s 
perceived risk estimate that is (+/-) 3% from the score produced by the risk calculator. 
Three percent was chosen as the cut off for over- or under-estimation because average-
risk is 12% and the ACS  uses 15% (a difference of 3%) as a starting point for suggesting 
discussions about MRI screenings with primary health care providers. Therefore a 
difference of 3% can have clinical significance.  Because the risk calculators provide 
different lifetime risk estimates for breast cancer, it was possible for a woman’s estimate 
to be categorized as an over-estimate for one calculator and an underestimate for another. 
Over- and under-estimates were provided for risk perceptions vs. both the Claus, 
BRCAPRO, and Gail models. 
Analysis of Specific Aim 2 
Specific aim 2 was to determine whether self-reported screening plans and self-
described screening practices are in alignment with risk-based guidelines in women 
whose first-degree female relatives have received genetic counseling and indeterminate 
negative BRCA1/2 test results.  This aim includes two research questions: 
1. What percent of women whose first-degree female relatives have received 
indeterminate negative test results report that they are screening for breast 
cancer according to risk-based guidelines, i.e., are women who have >20% 
lifetime risk of developing breast cancer, receiving both annual mammogram 
and MRI (as recommended by the National Comprehensive Cancer Network 
(NCCN) and the American Cancer Society (ACS))? 
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2. What percent of women whose first-degree female relatives have received 
indeterminate negative test results report receiving recommendations for 
breast cancer screening from their primary care physicians or from another 
source that are consistent with the National Comprehensive Cancer Network 
(NCCN) and American Cancer Society (ACS) guidelines based on the level of 
risk (i.e., annual mammography if < 20% lifetime risk and > 40 years of age; 
mammography with MRI if > 20% and > 30 years of age)? 
To answer these questions, two dichotomous variables were computed, one for 
whether or not women self-report screening according to NCCN and ACS guidelines and 
one for whether or not women report being recommended to screen according to NCCN 
and ACS guidelines. Women were considered as screening according to NCCN and ACS 
guidelines if they had a risk less than 20% and received their most recent screening 
mammogram within the past year. If women  have a risk of 20% or greater, they were 
considered to be screening according to NCCN and ACS guidelines if they received both 
a screening mammogram and screening breast MRI within the past year. Likewise, they 
average-risk women were considered to have received recommendations for screenings in 
accordance with guidelines if they reported recommendations to screen annually with 
mammography. Women at elevated-risk were considered to have received screening 
recommendations according to guidelines if they were instructed to receive annual 
screening mammograms and breast MRI. Questions about self-reported screening 
practices and self-reported screening recommendations by primary care providers ask 
women about the most recent mammogram and MRI as well as the one(s) before the 
most recent one(s). We intended to count women as screening annually if both intervals 
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were 1 year or less and procedures were done for screening and not diagnostic purposes. 
The exception was intended to be women of average-risk who are exactly 40 years of age 
since 40 is the age to begin mammogram screenings. These women would not be 
expected to have received two mammograms to be screening according to guidelines. 
After the telephone interview was completed, a lifetime risk estimate for breast 
cancer was calculated using the pedigree information obtained. If lifetime risk in either 
Claus or BRCAPRO was found to be > 20%, then a woman was be considered to be up-
to-date with the screening guidelines if she had received a screening mammogram and a 
screening breast MRI within the past 1 year. For women whose lifetime risk for breast 
cancer did not exceed 20% in the Claus and BRCAPRO models, women were counted as 
“screening according to guidelines” if they had received a screening mammogram within 
the past year. A similar assessment was made of the women’s reports of 
recommendations by their providers. Additionally, we intended to report on whether 
women were over-screening. The items assessing MRI and mammography screening 
asked whether each test was for diagnostic or screening purposes. Diagnostic tests were 
excluded when assessing for over- or under-screening.   
Note that the following is the initial conception of specific aim 3. We altered the 
aim slightly as the study progressed. 
Analysis of Specific Aim 3  
Specific aim 3 was to determine the contribution of a woman’s self-rated 
understanding of genetic health information, shared by her first-degree female relative 
about genetic counseling sessions, to her risk perception and to the accuracy of her 
perception of individual lifetime risk for breast cancer while controlling for confounding 
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influences of factors known to contribute to risk perception, including age, education, 
health literacy, numeracy, knowledge about breast cancer genetics, and self-reported 
distress related to family history of breast cancer and perceived personal risk for breast 
cancer. This aim includes the following research questions: 
1. What is the magnitude of the relationship between calculated lifetime risk for 
breast cancer and perceived lifetime risk for breast cancer?  
2. Does a woman’s self-rated understanding of genetic health information shared 
by her first-degree relative moderate the accuracy of risk perception?  
3. Does a woman’s self-rated understanding of genetic health information shared 
by her first-degree relative predict risk perception?   
These questions were to be answered using structural equation modeling (SEM) 
to look at the strengths of associations among latent and measured variables. A 
provisional recursive SEM model was used to estimate these relationships (Figure 3.2).  
In this initial model, predictor variables, which are exogenous (unexplained), included 
age, education, health literacy, numeracy, knowledge of breast cancer genetics, distress, 
and understanding of information shared about the relative’s genetic counseling session. 
All of these exogenous variables except self-reported understanding of genetic health 
information from a close relative’s genetic counseling session are known to influence risk 
perception and were treated as covariates in the predictive relationships (that is, all 
regression relationships were conditioned statistically on the exogenous variables). The 
correlation between the latent constructs “Calculated Risk” and “Risk Perception” related 
to lifetime risk for breast cancer is, in essence, accuracy of risk perception – it could be 
viewed as the validity of the perceptions. The latent variable “Calculated Risk” was 
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estimated using the Claus and the BRCAPRO models. The latent variable “Risk 
Perception” was estimated using comparative quantitative and qualitative risk 
perceptions. It was intended that if understanding about genetic health information shared 
by the counselee was found to increase the regression coefficient of the path between 
calculated and perceived risk, then we would have been able to state that self-reported 
understanding about the genetic health information shared by the counselee had a positive 
moderating effect on the accuracy of risk perception. It was intended that if the direct 
effect of self-reported understanding of genetic health information improved prediction of 
a woman’s perceived risk above and beyond the other covariates in the model, then the 
understanding about the genetic health information shared by the counselee could have 
been said to contribute to a woman’s risk perception. 
Power 
Unlike simple planned comparisons between groups, power computations for 
multivariate structural equation models are complex, with different power for every 
parameter and relationship and requiring assumed specific values for every unique model 
parameter. Therefore, generic approaches have been developed in terms of global fit 
statistics (e.g., Root Mean Squared Error of Approximation or RMSEA) that are 
appropriate for more realistic scenarios where this degree of theoretical specific 
knowledge is lacking. For the Figure 3.2 structural equation model, a sample size of 100 
would give a power of .88 to reject the null hypothesis that the population RMSEA is <= 
.06 when the true RMSEA is .10 (df=90) and alpha = .05 (MacCallum, Browne, & 
Sugawara, 1996). 
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Software 
IBM SPSS version 21 was be used to run statistical analysis on specific aims 1 
and 2. Mplus software by Muthen and Muthen was used to run the structural equation 
model for specific aim 3. 
Missing Data  
Missing data were expected to be minimal. Most packets were received back by 
mail before the telephone portion of data collection and they were reviewed for 
completeness. Incomplete information was collected over the telephone when possible. In 
some instances, the telephone interview took place before a completed packet was 
received. The proportion of missing data was reported. The analysis under maximum 
likelihood estimation is valid under the usual assumptions of ignorable missingness 
(missingness not dependent on the unobserved value of the censored observation). 
Missing data bias was intended to be reviewed by computing a dummy variable reflecting 
the presence or absence of missing data for each variable in the model and then the 
dummy variable will be correlated with all other variables in the model as well as 
selected demographic and historical variables. 
Linearity and normality assumptions were assessed for all variables using all of 
the usual diagnostics. We also tested for conditional independence in the measurement 
relationships, which states that measures of the same construct will be correlated only 
because of the underlying true construct.  
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Non-normality  
In structural equation modeling, non-normal data increases the likelihood of 
rejecting models that may not be false and well as committing a type I error. Multivariate 
normality was intended to be tested using Mardia’s test for multivariate normality. 
Univariate indicies of skewness and kurtosis were examined to determine if the absolute 
value is greater than 2.0. If non-normality is pronounced, then bootstrapping was 
intended to be undertaken to derive standard errors and confidence intervals. With 
bootstrapping, the data are treated as the population; a sample is taken with replacement. 
Each sample with replacement produces a different set from the samples. The number of 
bootstrap replicates will be 2000. Bootstrap standard errors do not require the assumption 
of normality. 
Indices of Fit 
Although historically structural equation models have been evaluated according to 
several global fit indices (Bollen & Long, 1993), modern practice strongly favors the 
Root Mean Squared Error of Approximation (RMSEA) as the primary criterion. It 
subsumes the common chi-square test of model lack of fit in the special case where the 
null RMSEA = 0. The Root Mean Square Error of Approximation (RMSEA) should be 
less than 0.08 for satisfactory fit for the model as a whole), the p value for the test of 
close fit (should be statistically nonsignificant). If the model does not fit satisfactorily 
(i.e., RMSEA >.08), then modification indices for omitted relationships can suggest 
additional relationships that will necessarily improve the model fit by the stated amount; 
these were planned to be added only if consonant with theory and substantive knowledge. 
Significance of each path was computed via likelihood ratio test of the difference in chi 
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square between two tested models, one with and one without the path in question, 
evaluated at one degree of freedom. The coefficient having the largest p-value greater 
than .05 by this test was deleted. The significance of the remaining paths was 
recalculated. This process was followed until all remaining paths are significant by the 
likelihood ratio test.  
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Steps 
 Recruitment & Data 
collection 
Follow Up & 
Thank You 
Completion 
 
Start 
+1 
Week 
+10 
days  
+2-3 
Weeks 
 
All 
Data 
In 
  
 
Mail introductory letter 
to potential participants X  
 
      
Call potential 
participants one week 
after introductory letter 
mailed (recruitment/ 
set interview time) 
 X 
 
      
Mail survey – same 
day as recruitment 
phone call 
 X 
 
      
Reminder phone call 
10 days after survey 
mailed if survey not 
received back 
  X       
Conduct participant 
interviews at pre-
arranged time  (2-3 
weeks after initial call) 
  
 
X      
Calculate Risk (Gail 
Claus BRCA Pro) 
  
 
 X     
Send risk summary 
letter to those who 
requested it 
  
 
 X     
Mail participant 
incentive (after packet 
received) 
  
 
  X    
Data cleaning and data 
entry  
  
 
   X   
Data Analyses        X  
Complete dissertation 
chapters and articles 
  
 
     X 
 
 
Figure 3.1  
Initial project timeline 
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Figure 3.2  
Initial latent variable model
  
 
CHAPTER 4 
 
RESULTS MANUSCRIPT 1: RISK FOR BREAST CANCER AND SCREENING  
BEHAVIORS IN WOMEN WHOSE FIRST-DEGREE RELATIVES HAVE 
RECEIVED INDETERMINATE BRCA1/2 GENETIC TEST RESULTS 
 Two manuscripts have been prepared for publication based on the results of the 
present study and are presented in Chapters 4 and 5 for the purposes of the Results and 
Discussion sections of the dissertation and comprise Chapters 4 and 5. Figures and tables 
in each manuscript are specific to the research questions outlined in each manuscript and 
correspond to the dissertation research aims and are presented at the end of each 
chapter/manuscript. References for each manuscript are included in the references at the 
end of the dissertation as a whole. Further results that were beyond the scope of these 
manuscripts are presented in Chapter 7. 
 The first results manuscript presented here in Chapter 4 has been prepared for a 
primary care provider audience and addresses the results pertaining to specific aims 1 and 
2. The second manuscript, presented in Chapter 5, has been prepared for an audience of 
genetic counselors and presents the findings related to specific aim 3.  
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Abstract  
Purpose  
The purpose of this study was to describe calculated risk, risk perceptions, recent 
screening recommendations, and practices for women whose first-degree female relative 
was diagnosed with breast cancer and received genetic counseling and BRCA1/2 testing 
with indeterminate results. We also assessed whether women shared their family 
members’ indeterminate test results with their primary care providers.   
Methods  
This cross-sectional study utilized survey and interview techniques to assess 
comparative verbal and quantitative risk perceptions among women with a first-degree 
relative with breast cancer who received an indeterminate BRCA1/2 test result. Five-year 
and lifetime risks were calculated using the Gail, Claus, and BRCAPRO models; 
differences between the calculations and women’s own estimates of lifetime risk are 
presented. Breast cancer screening behavior was assessed using questions from the 
Behavioral Risk Factor Surveillance System questionnaire. Women were asked what 
information they shared with their primary care providers (PCP). 
Results 
Eighty-five women participated. Most women estimated their risk to be higher 
than estimates calculated by the Gail (42.9%), Claus (73.8%), and BRCAPRO (78.6%) 
models.  Most (86.8%) women at average-risk (operationalized as < 20% lifetime risk by 
Claus and BRCAPRO) reported receiving recommendations for annual mammography 
from their primary care provider and had received a mammogram within the past 1-2 
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years. Approximately 10% of women were identified as being at elevated-risk for breast 
cancer based on their family pedigree, warranting annual breast MRI screening according 
to national guidelines, yet none of these women had received recommendations for 
enhanced screening. Most women (76.5%) did not discuss their family member’s genetic 
testing with their PCP.  
Conclusions 
Women tended to over-estimate their risk for breast cancer and women at 
elevated-risk did not receive recommendations for annual breast MRI. Primary care 
providers are encouraged to calculate pedigree-based individualized risk for breast 
cancer, refer to genetics specialists as needed, and follow risk-based screening guidelines. 
Introduction 
For most women, including those at increased risk for breast cancer, primary care 
providers (PCPs) are a main source of information about breast cancer risk and 
appropriate screening methods (Keogh et al., 2011). Guidelines for screening and risk 
reduction are based on estimated level of risk for a woman and vary by organization (see 
Table 4.1) (American Cancer Society, 2014; Mainiero et al., 2013; National 
Comprehensive Cancer Network, 2013a, 2013b, 2013c; The American College of 
Obstetricians and Gynecologists, 2011). Women with first-degree relatives with breast 
cancer may fall into the category of average-risk, or elevated/high risk. Assessing risk for 
breast cancer is a complex process requiring the evaluation of a family pedigree and 
personal risk characteristics (Berliner & Fay; National Comprehensive Cancer Network, 
2013b).  Several organizations stratify breast cancer screening guidelines based on a 
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woman’s percent chance of developing breast cancer over her lifetime; women with 
higher levels of risk should be offered annual screening breast MRI in addition to 
mammography (see Table 4.1). To calculate lifetime risk estimates for breast cancer, a 
risk prediction model must be used. 
Risk Prediction Models 
Many risk prediction models exist. Some models are better in certain populations 
and for certain purposes. Complicating matters, different models provide different 
calculations for the same woman. The Gail model (Gail et al., 1989) (more recently 
updated and referred to as the NCI-Gail model or the Breast Cancer Risk Assessment 
Tool (BCRAT) (S. W. Fletcher, 2013) is the most commonly used risk prediction model; 
however, the Gail model takes into account limited family history and is not appropriate 
for determining need for annual MRI (American Cancer Society, 2014). The Gail model 
may estimate risk higher than other models based on personal risk factors (Ward & 
Smith, 2010). It tends to perform poorly in higher-risk populations (Amir et al., 2010). 
The Gail model is, however, used to determine the appropriateness of chemoprevention 
for women >35 years of age based on 5-year risk calculations (Freedman et al., 2011; 
U.S. Preventive Services Task Force, 2013).   
The Claus, BRCAPRO, and Tyrer-Cuzick (also called IBIS) models assess an 
extended family cancer history and are appropriate to use in determining the need for 
annual screening breast MRI. Both the ACS and NCCN suggest that women should 
consider annual screening breast MRI if lifetime risk for breast cancer exceeds 20%. The 
ACS has suggested that there is not enough evidence to recommend for or against MRI 
between 15 and 19% but recommend against MRI below 15%. The Claus and 
87 
 
 
 
BRCAPRO models have been widely used in research as well as genetic counseling 
practice (Amir et al., 2010; National Cancer Institute, 2014b) and can be helpful for 
women without a known cancer-associated gene mutation with one or two first- or 
second-degree relatives with breast cancer (Claus, Risch, & Thompson, 1994). The 
BRCAPRO model estimates the chance of carrying BRCA1/2 mutation and a women’s 
individualized lifetime risk for breast cancer (National Comprehensive Cancer Network, 
2013a, 2013b; Parmigiani et al., 2007).  
Genetic Testing 
When the family history of cancer looks as if a potentially harmful mutation in 
breast cancer susceptibility genes could be present, a risk assessment should be 
performed by a trained health professional, including trained PCP or genetic counselor, to 
determine whether genetic testing is warranted (Moyer, 2013).  Genetic testing can be 
done to identify mutations that predispose a person to cancer. Published guidelines list 
criteria to be considered for BRCA1/2 testing, including but not limited to a cancer 
diagnosis at age 45 or younger, or a diagnosis at age 50 with 1 or more close relatives 
with cancer at any age, diagnosed at any age with one or more close relative with breast 
cancer diagnosed younger than age 50, having a close male relative with breast cancer at 
any age, having two primary breast cancers including bilateral disease or two separate 
cancers with one diagnosed prior to age 50 (National Comprehensive Cancer Network, 
2013c). Ideally the first testing in a family is performed in an individual with breast 
cancer because lack of a positive result in an unaffected individual is difficult to interpret. 
If a positive result is found, then other family members should be tested to determine if 
they carry the mutation. Family members who carry the mutation are considered to be at 
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high risk; those who do not have the mutation are considered to be at average-risk. A test 
result can only be considered a true negative if there is a known familial mutation and the 
tested individual does not carry this exact mutation.  
Indeterminate Test Results   
The most common outcome of genetic testing in a family without a known 
BRCA1/2 mutation is an indeterminate test result.  In the absence of a known familial 
mutation, failure to find a deleterious mutation is referred to as an “indeterminate” test 
result (National Comprehensive Cancer Network, 2013c). This type of language is used 
because (1) there is the possibility that a mutation not yet identified in the BRCA1/2 
genes is present, (2) there could be a mutation in a gene not tested (e.g., PTEN-Cowden’s 
Syndrome or P53-LiFraumeni’s Syndrome), and (3) we do not want to give the 
impression that the family cancer history does not include hereditary causes. Other terms 
used in the literature to describe a negative BRCA test in the absence of a known family 
mutation include “indeterminate negative”(Patenaude et al., 2006), “inconclusive” 
(Cypowyj et al., 2009; Dorval et al., 2005), “uninformative”(Mannis et al., 2013; 
National Comprehensive Cancer Network, 2013c; van Dijk, 2005; Vos, Menko, et al., 
2011), or “uninformative negative”(Riley et al., 2012). The terms “inconclusive” and 
“uninformative” have also been used to describe variants of unknown significance that 
are mutations that have not at this time been shown to affect breast cancer risk, but could 
be labeled as deleterious in the future as more research is made available (National 
Comprehensive Cancer Network, 2013c; Vadaparampil, Malo, de la Cruz, & Christie, 
2012). 
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Purpose 
The purpose of this cross-sectional, study was to determine whether sisters and 
daughters of women who received indeterminate BRCA1/2 test results were at elevated-
risk for breast cancer and whether they had received screening recommendations from 
their PCP and breast cancer screening congruent with their level of risk. Additionally, we 
evaluated women’s risk perceptions and compared them to individual calculated risks. 
Finally, we asked women about the extent to which they shared their family history of 
breast cancer and the fact that they had a sister or mother who received genetic testing 
and counseling with their PCPs. This population of women is important to study because 
their family pedigree has already been evaluated by a genetic counselor and found 
suspicious enough to warrant a BRCA1/2 test in a family member affected by cancer and 
may have a greater proportion of women at elevated-risk for breast cancer than the 
general population.  
Methods 
We had two sources of probands, (1) REACH participants who were identified 
through the Utah Population Database (UPDB) and recruited through the Utah Cancer 
Registry, and (2) patients who received genetic counseling and testing through the Family 
Cancer Assessment Clinic (FCAC) at Huntsman Cancer Institute. These probands 
(women who had previously received genetic counseling and testing following their own 
breast cancer) referred their female family members without cancer to the Risk Education 
and Assessment for Cancer Heredity (REACH)-Pilot Study. Women who completed the 
REACH-Pilot Study and agreed to be contacted for future cancer-related research were 
contacted for the present study. Information sent to us by REACH-pilot included only 
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name, contact information, and family grouping variable. We do not know whether our 
participants’ family member was counseled through REACH or through FCAC. 
Following IRB approval, introductory letters were mailed to 135 women. The 
final sample consisted of 85 women who met inclusion criteria: age 40–74 years, fluent 
in English, and had a mother or sister with a personal history of breast and/or ovarian 
cancer who received BRCA1/2 genetic counseling and testing between 2010 and 2013 
who had an indeterminate negative BRCA1/2 result. Women were excluded if they had a 
personal history of any type of cancer (except nonmelanoma skin cancer), ever received 
BRCA1/2-related genetic counseling or testing, have had a prophylactic bilateral 
mastectomy or oopherectomy, lived outside the United States, and/or were incarcerated. 
Women of Ashkenazi Jewish descent were not included because of very a small number 
of women in this category and because their relatives may have had testing based on 
descent only as no additional family history is required to perform genetic testing for 
founder mutations in this subgroup (National Comprehensive Cancer Network, 2013c) . 
Participating women were mailed a survey packet with a consent cover letter and a future 
date and time was set for a telephone interview. Interviews were conducted from October 
to December 2013. A more detailed description of the study protocol can be found in 
Himes et al. (in process).   
Measures  
Women provided written, three-generation family cancer histories. We created 
pedigrees from these histories and reviewed them with participants during the telephone 
interview if any clarification was needed (e.g., if they had not written an age of death for 
a family we asked them to provide an estimate). Pedigrees with family cancer histories 
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were entered into CancerGene software to obtain BRCAPRO and Claus model estimates 
of 5-year and lifetime risk for breast cancer. Gail risk estimates were calculated using the 
Breast Cancer Risk Assessment Tool on the NIH website.  
Women were asked in the survey to rate their risk of developing breast cancer 
using verbal descriptors (such as lower, higher), and to estimate a percent lifetime risk in 
comparison to other women of the same age. Information about screening behaviors and 
screening recommendations was obtained during the telephone interview using questions 
from the Behavioral Risk Factor Surveillance System (BRFSS) questionnaire developed 
by state coordinators and the CDC (Office of Surveillance Epidemiology and Laboratory 
Services).  
Additional questions were asked in the interview about what information women 
shared with their PCP, including (1) their family history of cancer, (2) having a sister or 
mother that received genetic counseling, and (3) BRCA1/2 test result of their sister or 
mother. All data were analyzed using IBM SPSS version 21.  
Results 
Study Population 
Of the 122 women who were contacted, 98 were eligible and 85 completed the 
study. Participants were mostly married, non-Hispanic White, and highly educated with a 
mean age of 52.2(SD 8.9) (see Table 4.2).  
Risk Calculations  
Calculated risks are presented in Table 4.3. Of importance, 10.6% of the 
participants (n = 9 of 85) had a lifetime risk as calculated by the Claus model that was 
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20% or higher; 16.7% had a risk that was 15% or higher. We operationalized being at 
elevated-risk as having a lifetime risk for breast cancer of 20% or greater by either the 
Claus or BRCAPRO models because these models take a larger amount of family history 
into account and are the type of model used to determine appropriateness of annual 
screening breast MRI based on ACS and NCCN guidelines. None of the women had a 
lifetime risk equal to or greater than 20% using the BRCAPRO model; therefore, when 
we refer to women at elevated-risk in our study, we are referring to those with an lifetime 
risk estimate >20%  based on the Claus model. The ACS adds a third risk group called 
“moderate risk” for women with a lifetime risk between 15% and 20%, noting that there 
is not enough evidence to advise for or against screening MRI at this risk level.  
Notably, 78.8% of participants had Gail 5-year risk higher than 1.67%, the risk 
generally considered sufficient to justify chemoprevention. We did not collect data about 
chemoprevention. 
Risk Perception  
Most women rated their chances of developing breast cancer in their lifetime as 
“higher” or “much higher” than other women their own age (see Table 4.4). Women 
provided quantitative estimates for their personal lifetime risk for breast cancer ranging 
from 1% to 95% (mean 20%, SD = 20). Most women described their risk as being 
between 5 and 30%; however, a few selected very high numbers.  One woman described 
her lifetime risk as being 95% (Claus estimate = 12.1%), and 2 women thought their risk 
was 90% while their Claus model estimates were 16.9% and 13.1%, respectively. More 
women perceived their numeric risk as 12% than any other number (n=15 of 84), 
mirroring information they were provided in the stem of the question: “On average 12 
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women out of 100 will get breast cancer in their lifetime.” The 9 women with risk 
calculations 20% or greater had estimated their risk as being 12-70% with verbal scores 
ranging from “higher” to “much higher.” 
Congruence Between Risk Calculations and Women’s Estimates  
Differences between women’s quantitative risk perceptions and their calculated 
scores were obtained for each of the three risk models. We considered women’s self-
reported estimates as congruent with a particular model if their estimate was within +/- 
3% of the model’s calculated estimate. As can be seen in Table 4.5, the percent of women 
who estimated their risk to be higher or lower than a particular model varied. A 
difference of 3% was selected because average-risk is often reported to be 12% and 
according to the ACS, women with 15% lifetime risk may be offered annual screening 
breast MRI, thus 3% can make a clinical difference. 
Screening Recommendations - Mammography 
All women at elevated-risk (>20% lifetime), and 86.8% of women at average-risk 
(<20% lifetime) reported receiving screening recommendations for annual 
mammography from their PCP. One woman in her 40s with a lifetime risk <20% by the 
Claus model indicated that she received a recommendation to have screening 
mammography every 2 years. Table 4.6 delineates women’s reports of mammography 
recommendations from their PCPs according to risk strata and age. According to NCCN 
and ACS, all women over 40 years of age should receive annual mammograms. The 
shaded cell in Table 4.6 indicates that 86.8% of women report they have received 
recommendations for annual mammography in accordance with NCCN/ACS guidelines. 
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According to the USPSTF (2012), women should discuss with their health care providers 
the pros and cons of breast cancer screening based on personal risk factors and values, 
but in general should begin biennial mammography screening at age 50. The boxed cells 
in Table 4.6 indicate that no women reported receiving a provider recommendation for 
minimum USPSTF population-based guidelines, most received recommendations to 
screen more frequently than USPSTF minimum recommendations.  
Screening Recommendations – Breast MRI  
The USPSTF does not have published screening guidelines for women at 
elevated-risk. NCCN and ACS recommend that women at > 20% lifetime risk by models 
that take extended family history into account receive annual MRI in addition to annual 
mammography. None of the elevated-risk women, defined by having a Claus calculation 
>20%, reported receiving a PCP recommendation for annual MRI; therefore, none of the 
elevated-risk women are considered to have received screening recommendations from 
their PCP in accordance with risk-based guidelines. Two women reported receiving 
recommendations for annual screening breast MRI; however, these women did not fall 
into an elevated-risk category by the Claus model. They had lifetime risks of 7.7% and 
12.3%. 
Recent Screening Practices – Mammography 
Most women (80.0%) at all levels of risk reported receiving a screening 
mammogram within the past 1-2 years. Table 4.7 illustrates the most recent screening 
mammogram for women based on age and risk categories. Seven of the 76 average-risk 
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women (9.2%) received their most recent mammogram for diagnostic reasons and 
therefore were not included in this table.  
Recent Screening Practices - MRI  
None of the women at elevated-risk had received breast MRI screening according 
to risk-based guidelines.  Only 7 (8.2%) women reported receiving a breast MRI at any 
time. Five of these were diagnostic tests and 2 were done for screening purposes. The 2 
women who had breast MRI for screening purposes were not considered to be at high risk 
according to the Claus and BRCAPRO models.  
Information Shared with PCP 
A large number of women (89.4%) reported that they shared information about 
their family history of cancer with their PCP. Far fewer shared information about their 
sister or mother’s genetic counseling (24.7%) or their sister or mother’s test results 
(22.4%).  
Discussion 
Calculation and interpretation of breast cancer risk is a complex task. When a 
BRCA1/2 mutation has not been previously identified in a family, the most common 
outcome of BRCA1/2 testing in a cancer patient is an indeterminate result. If a family 
member tests positive for a BRCA1/2 mutation, other family, members can be tested to 
determine risk level. In contrast, in families where there is an indeterminate result, other 
members’ risk must be quantified based on the patient’s family history for appropriate 
medical management. PCPs are challenged to assess cancer risk, help patients understand 
their risk, and recommend appropriate risk-based screenings for these patients. 
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Recommendation of appropriate screening is made even more challenging by the 
differing guidelines, including the ACS (American Cancer Society, 2014), NCCN 
(National Comprehensive Cancer Network, 2013b), and USPSTF (2012) and by the fact 
that various risk calculators provide different estimates of risk for the same woman.  
Women in our study comprised a unique group because (1) these women had 
mothers or sisters that met consensus-approved guidelines BRCA1/2 testing and received 
indeterminate test results; (2) at the conclusion of the genetic risk notification counseling 
session, our participants sisters/mothers received a standardized summary letter 
informing them that their female relatives could be at elevated-risk and may meet the 
requirements for breast MRI screening or chemoprevention; and (3) these women are 
typically followed by primary care providers rather than genetics professionals because 
they have not had cancer themselves and are not in a family with an identified high risk 
gene.  
We suspected that this group might have a greater proportion of women at 
elevated-risk than the population at large. Indeed, 10.6% of our sample was found to be at 
>20% lifetime risk by the Claus model and would meet guidelines for annual screening 
breast MRI. In contrast, approximately 1% of the U.S. female population is at > 20% 
lifetime risk for breast cancer (Graubard, Freedman, & Gail, 2010). ACS guidelines 
indicate that there is insufficient evidence to recommend against MRI in the 15-20% 
lifetime risk range; 16.5% of our sample would qualify for annual MRI based on a risk of 
>15% lifetime risk.  The Gail model is not for use in determining need for annual 
screening breast MRI. As can be seen in Table 4.3, if PCPs were to rely on the Gail 
model to identify women for MRI, many more women would qualify. As mentioned, 2 
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women in our study received recommendation for annual screening MRI from their PCP. 
Although their risk was not elevated by Claus, we do not have enough information to 
infer that these screening recommendations indicate over-screening. There could be other 
reasons their PCP recommended annual MRI including increased breast density. 
The Gail model is important in assessing the need for chemoprevention. The FDA 
has approved Tamoxifen and Raloxifene for women with 5-year risk >1.67% according 
to the Gail model, although it has recently been suggested that higher cut-offs should be 
used for women over 50 (Freedman et al., 2011). We did not ask women whether they 
had received recommendations for chemoprevention; however, nearly 80% of our study 
population with an average age of 52.2 years had 5-year risk for breast cancer >1.67% by 
the Gail model. Thus, our sample had a much higher proportion of women who meet the 
criteria for chemoprevention than women in the general population where elevated 5-year 
Gail estimations range between 4-36% depending on age (Graubard et al., 2010).  
Women who receive genetic counseling and testing receive personalized genetic 
information, which has implications for close biological relatives. Practice guidelines for 
cancer genetic risk assessment encourage genetic counselors to share familial 
implications of the assessment with their patients so that their patients may share that 
information with family members (Riley et al., 2012). Ninety percent of genetic 
counselors report that they consistently do so (L. E. Forrest et al., 2010). Women who 
have received counseling are encouraged to share risk information with their families and 
encourage family members to share that information with their PCPs. Our findings 
suggest that women are not consistently sharing information with PCPs about their 
sister’s and mother’s genetic counseling and test results. It could be that the women in 
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our study were evaluated too close to the time of their family member’s test and had not 
yet had the opportunity to share this information with their PCPs. We did not have the 
test dates for relatives of our participants. It could also be that they did not understand the 
information or perceive it as pertinent to their care.  
To enhance care delivery, it is important that genetic specialists communicate 
with counselee’s PCPs (Nelson et al., 2014). Many PCPs have expressed a lack of 
confidence in basic knowledge of cancer genetics (Cox et al., 2012). Research has shown 
that women at elevated-risk may not be receiving appropriate mammography and MRI 
recommendations (Cohen, 2010). Close relatives of women in our sample had extensive 
pedigrees created and analyzed by professionals in cancer risk assessment, yet they may 
have never known it, because they had not received information about the genetic 
counseling and testing from their relatives. Previous research indicates that women who 
have received counseling may have difficulty understanding the implications of an 
indeterminate test result (Cypowyj et al., 2009). Additionally, information is often lost as 
messages go from genetic counselor to patient and from patient to other family members 
(Vos, Menko, et al., 2011). If those who have received counseling do not understand the 
implications of an indeterminate result, they cannot explain it adequately to their family 
members, and the family members may not explain it well to their care providers. Based 
on our results, PCPs should not assume that women will volunteer information about 
their family’s genetic counseling and testing. Similarly, if a patient reports that her close 
relative had a BRCA1/2 test showing her family member’s cancer was “not genetic,” her 
risk should not be assumed to be low or average. PCPs should also not assume that if a 
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woman is at elevated-risk she, would have been told by her family member who received 
an expert risk assessment.  
Most of our study participants were considered to be at average-risk and had 
received mammography screening recommendations from their PCP in line with national 
guidelines.  It is concerning, however, that more than 10% of the women were found to 
be at increased risk for breast cancer, yet none had received a recommendation for annual 
MRI in accordance with ACS and NCCN guidelines. Our findings are consistent with 
national patterns, indicating that breast MRI screening is under-utilized among elevated-
risk women (Miller et al., 2013).  
Many PCPs do not use risk calculating software. When they do, it is more likely 
to be the Gail model than more complex software based models that can be used to 
determine risk level for and the need for MRI screening (Afonso, 2009; Berg et al., 2010; 
Edwards, Maradiegue, Seibert, Saunders-Goldson, & Humphreys, 2009; Guerra et al., 
2009; Sabatino et al., 2007). In a busy primary care practice, it can be challenging to find 
the time to perform a comprehensive breast cancer risk assessment (Wood, Flynn, & 
Stockdale, 2013). However, there is an opportunity for interdisciplinary collaboration. 
Registered nurses and other supportive staff working in primary care often assume the 
roles of collecting, organizing, and assessing patient history, including family history. 
These health care staff members often coordinate referrals and could be effectively 
trained in cancer risk assessment to identify women at increased risk and help coordinate 
risk-appropriate care.  
The USPSTF recently issued new guidelines encouraging PCPs to identify 
women with family histories that may be associated with mutations in breast cancer 
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susceptibility genes with simple screening tools. It is recommended that high-risk women 
receive genetic counseling and be offered BRCA1/2  testing if warranted, from a health 
care provider trained in breast cancer risk assessment, including genetic counselors or 
trained primary care professionals (Moyer, 2013). The USPSTF has classified the 
screening and referral of women to genetic services for counseling and testing if 
appropriate as a level B recommendation. The Affordable Care Act deems that preventive 
measures rated level A or B are to be covered without copayment by the patient(Centers 
for Medicare & Medicaid Services, (ND)).  
We suggest PCPs use two levels of screening for breast cancer risk assessment. 
First, women who need in-depth risk assessment need to be identified. The USPSTF has 
identified several screening tools that could serve this purpose (Moyer, 2013); studies 
have also looked at using self-administered online screening tools that can be 
incorporated into the electronic health record to help PCPs collect this type of data (S. M. 
O'Neill et al., 2009; Ruffin et al., 2011). Second, for women who screen positive  - 
indicating the need for an in-depth risk assessment, PCPs should assess risk using risk 
estimating models that take extensive family history into account or refer patients to 
health care providers including genetic counselors who are trained in breast cancer risk 
assessment to make these calculations. Armed with evidence-based lifetime risk 
estimates, PCPs will be able to recommend guideline concordant breast cancer screening, 
including MRI for women at elevated-risk. 
Primary care providers (including physicians, nurse practitioners, physician 
assistants, and the nurses in their practices) as well as our colleagues in genetic 
counseling apply judgment, skill, and compassion when assessing and explaining risk to 
101 
 
 
 
women. A multidisciplinary approach is helpful when caring for women whose families 
have a suspicious but indeterminate genetically based risk for breast cancer.   
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Table 4.1 
Risk-based cancer screening guidelines for women without breast cancer  
    
Organization 
Risk Categories 
& Definition 
Mammography  Screening 
Recommendations   
  Breast MRI Screening 
Recommendations 
American 
Cancer 
Societya 
Average-risk 
 (<15% lifetime risk) 
Annual beginning at age 40 and continuing 
as long as in good health 
Not Recommended 
 
Moderately increased risk 
(15 - 20% lifetime risk) 
Annual beginning at age 40 and continuing 
as long as in good health 
Not enough evidence to recommend 
against or for annual MRI 
  
High Risk 
(about 20-25% or greater 
lifetime risk
b
) 
Annual beginning at age 40 and continuing 
as long as in good health 
Annual MRI Recommended - no 
starting age suggested 
U.S. Preventive 
Services Task 
Forcec 
Average-risk 
(no known genetic mutation 
or history of chest radiation) 
Aged 40-49 - Individualize decision about 
screening based on circumstances and 
values. 
Aged 50-74 every 2 years 
Aged >75  no recommendation 
Insufficient Evidence 
National 
Comprehensiv
e Cancer 
Network 
(NCCN)d 
Average-risk 
 (as defined by qualitative 
and quantitative assessment) 
Annual beginning at age 40  
  
Increased Risk 
(> 20% lifetime risk
e
) 
Annual beginning at age 30 Consider annual MRI beginning at age 
30 
Note: Risk categories are presented using labels and definitions as defined by each organization. 
aACS Guidelines 2014 
b"according to risk assessment tools that are based mainly on family history such as the Claus model" 
cUSPSTF Guidelines 2009  
dNCCN Guidelines 2013 
e"as defined by models that are largely dependent on family history (e.g., Claus, BRCAPRO, Tyrer-Cuzick)" 
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Table 4.2 
Characteristics of study population  
(n=85)  
                 
Variable   n (%) M (SD) 
Age, years 
   
52.2 (8.9) 
Race/ ethnicity 
  
 
Non-Hispanic White 84 (98.8) 
  
 
Asian 
 
1 (1.2) 
  Education 
  
 
High school/ GED 13 (15.3) 
  
 
Some college 15 (17.6) 
  
 
Vocational 8 (9.4) 
  
 
2 year college 9 (10.6) 
  
 
4  year college 28 (32.9) 
  
 
Master's degree 11 (12.9) 
  
 
Professional degree 1 (1.2) 
  Marital status 
  
 
Married 
 
67 (78.8) 
  
 
Member unmarried couple 1 (1.2) 
  
 
Separated 3 (3.5) 
  
 
Divorced 
 
10 (11.8) 
  
 
Widowed 2 (2.4) 
  
 
Never married 2 (2.4) 
  Religion 
  
 
Protestant Christian 5 (5.9) 
  
 
Roman Catholic 3 (3.5) 
  
 
Latter-day Saint  61 (71.8) 
  
 
None 
 
13 (15.3) 
  
 
Other
b
 
 
3 (3.5) 
  Insurance     
  
 
Insured 
 
78 (91.8) 
  
 
Not Insured 7 (8.2) 
  Primary Care Provider     
  
 
Physician 69 (81.2) 
  
 
Nurse Practitioner 5 (5.9) 
  
 
Physician Assistant 4 (4.7) 
    None   7 (8.2)     
b
 Open responses for "other" religion included "atheist, nondenominational, Spiritual." 
 
  
    
 
 
1
0
4
 
Table 4.3 
Calculated risk 
  
                    
                            
            Lifetime   Lifetime   5-year 
            >15%risk   >20%  risk >1.67% risk 
Model   [Range %] M (SD)   n (%)   n (%)   n (%) 
Gail                            
  5-year [0.6-12.0] 3.14 (2.3)               67 (78.8) 
  Lifetime [8.3-38.8] 20.07 (6.6)   72 (84.5)   29 (34.1)       
Claus                            
  5-year [0.2-5.7] 2.15 (1.2)                   
  Lifetime [2.0-38.3] 11.84 (6.7)   14 (16.5)   9 (10.6)       
BRCAPRO                            
  5-year [0.8-2.2] 1.24 (0.5)                   
  Lifetime [4.0-14.7] 9.53 (2.0)   0 (0.0)   0 (0.0)       
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Table 4.4 
Self-reported perceived relative 
risk (n=85) 
 
Response n (%) 
Much lower 2 (2.4) 
Lower 
 
9 (10.8) 
The same 
 
27 (32.5) 
Higher 
 
40 (47.1) 
Much higher 5 (5.9) 
Don't know/ No 
Answer 2 (2.4) 
Compared to women of similar age 
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Table 4.5 
Congruence between risk calculator and women's estimates 
          
Model n (%)   
Gail        
 
 
Women estimated higher risk 36 (42.9) 
 
 
Women congruent with risk 
calculation  15 (17.8) 
 
 
Women estimated lower risk 33 (39.3) 
 Claus        
 
 
Women estimated higher risk 62 (73.8) 
 
 
Women congruent with risk 
calculation  13 (15.5) 
 
 
Women estimated lower risk 9 (10.7) 
 BRCAPRO        
 
 
Women estimated higher risk 66 (78.6) 
 
 
Women congruent with risk 
calculation  13 (15.5) 
   Women estimated lower risk 5 (6.0)   
Note: Percent calculations are based on women who gave estimates of their lifetime risk for 
breast cancer (n=84). One woman did not provide a numeric estimate. Women were 
considered to provide estimates congruent with each risk calculator if their estimate came 
within 3% (+/-) of the risk calculator result. 
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Table 4.6 
Mammography recommendations from PCP for average and elevated-risk women by age 
                               
   
Average-risk (n=76) 
 
Elevated-risk (n=9) 
   
age 40-49 
 
age >50 
 
All Ages 
 
All Ages 
    n (%)   n (%)   n (%)   n (%)   
Every year (annually)   26 (86.7)   40 (87.0)   66 (86.8)   9 (100.0) 
 Every two years   1 (3.3)   0 (0.0)   1 (1.3)   0 (0.0) 
 Just one time   1 (3.3)   0 (0.0)   1 (1.3)   0 (0.0) 
 Never recommended   0 (0.0)   1 (2.2)   1 (1.3)   0 (0.0) 
 Don't Know   0 (0.0)   1 (2.2)   1 (1.3)   0 (0.0) 
 Other     2 (6.6)   4 (8.7)   6 (8.0)   0 (0.0) 
 Total     30 (99.9)   46 (100.1)   76 (100.0)   9 (100.0) 
 Boxed cells represent minimum mammography screening recommendations by USPSTF. Shaded cell represents minimum mammography 
screening recommendations by ACS and NCCN. Primary care providers may recommend screenings earlier than guidelines based on other risk 
factors.  
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Table 4.7 
Most recent screening mammogram for women by risk category and age  
                                 
   
Average-risk Women 
 
Elevated-risk 
Women 
   
 Ages 40-49 
 
Ages 50-74 
 
All Ages 
 
All Ages 
   n (%)   n (%) 
 
n (%)   n (%) 
A year ago or less 
 
20 (69.0) 
 
27 (67.5) 
 
47 (68.1) 
 
6 (0.75) 
More than 1 but not more than 2 years ago 6 (20.7) 
 
7 (17.5) 
 
13 (18.8) 
 
2 (0.25) 
More than 2 but not more than 3 years ago 0 (0.0) 
 
1 (2.5) 
 
1 (1.5) 
 
0 (0.0) 
More than 3 but not more than 5 years ago 0 (0.0) 
 
3 (7.5) 
 
3 (4.3) 
 
0 (0.0) 
More than 5 years ago 2 (6.9) 
 
2 (5.0) 
 
4 (5.8) 
 
0 (0.0) 
Has never had a mammogram 1 (3.4) 
 
0 (0.0) 
 
1 (1.5) 
 
0 (0.0) 
Total:     29 (100.0)   40 
(100.0
)   69 
(100.0
)   8 (100.0) 
Note: women whose most recent mammograms were performed because of a symptom or as a follow-up from a previously abnormal test are not included in this table. The boxed data represent the 
35 women who are considered to have received their most recent screening mammogram in accordance with USPSTF guidelines. The shaded box represents the 47 women who received their most 
recent screening mammogram in accordance with ACS and NCCN guidelines. Note that women screening outside USPSTF guidelines are mostly receiving screenings earlier than suggested. 
Women screening outside of ACS and NCCN guidelines are mostly receiving screenings less frequently than suggested. No women in the elevated-risk category are considered to be screening by 
guidelines because none have received screening breast MRI. 
  
CHAPTER 5 
 
RESULTS MANUSCRIPT 2: BREAST CANCER RISK PERCEPTIONS AMONG 
RELATIVES OF WOMEN WITH INDETERMINATE NEGATIVE  
BRCA1/2 TEST RESULTS: THE MODERATING EFFECT  
OF AMOUNT OF SHARED INFORMATION 
Abstract 
The most common result of BRCA1/2 mutation testing when performed in a 
family without a previously identified mutation is an indeterminate negative test result. 
Women in these families may have an increased risk for breast cancer because of 
mutations in non-BRCA breast cancer predisposition genes, moderate- or low-risk genes, 
or shared environmental factors. Risk estimates, therefore, must be based on family 
history and other risk factors. We evaluated 85 sisters and daughters of women who 
received an indeterminate negative BRCA1/2 results and found that most of them reported 
receiving very little information from their family member about her counseling session. 
When participants perceived that more information was shared about their relative’s 
genetic counseling session, they had more accurate perceptions (correlation = 0.748 
(p=0.000) of their own risks for breast cancer than those who perceived that less 
information was shared (correlation = 0.346 (p=0.05), where perfect accuracy is 
operationalized as a correlation of 1.00 between calculated and perceived lifetime risk).  
Overall, very little information was shared between close relatives who received genetic 
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counseling and our study participants; nearly 20% reported that nothing was shared with 
them about their mother or sister’s genetic counseling. Family members were generally 
not aware of the existence of a genetic counseling summary letter that their relatives 
received following the session.  Our findings underscore the need for effective strategies 
that facilitate counselee’s to share information about their genetic counseling sessions 
with their relatives.  Such communication may help their relatives better understand their 
cancer risks and enhance risk appropriate cancer prevention.  
Introduction 
 Breast cancer risk assessment has implications for both patients and their family 
members. A cancer risk assessment includes evaluating the patient’s family history and 
other risk factors, as well as providing individualized interpretation of genetic test results. 
Genetic counselors can help their patients understand what test results mean to them as 
well as their family members in terms of risk for future cancer and appropriate medical 
management. Counselors typically encourage their patients to share information and 
genetic test results with family members and to encourage family members, in turn, to 
share information with their primary care providers (Riley et al., 2012). The purpose of 
this study was to determine whether the accuracy of sisters’ and daughters’ perceptions of 
their own risk for future breast cancer are improved when more information is shared by 
their family members who received BRCA1/2 genetic counseling and received 
indeterminate negative results. We hypothesized that the level of family communication 
influences the accuracy of breast risk perceptions among counselee’s at-risk relatives.  
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Background 
 Genetic counselors play a key role in identifying at-risk family members and 
helping their patients communicate risk information to family members. The National 
Society of Genetic Counselors (NSGC) recommends that an essential element of 
disclosure is to “identify at-risk family members and provide [the] patient with tools to 
inform and educate family members” (Riley et al., 2012, p. 158). Because of concerns 
about patient privacy, the most common method counselors use to disseminate risk 
information within the family is to suggest that patients share the information with 
relatives (L. E. Forrest et al., 2010). Although patients are often willing to share 
information, research has shown that information is often not disseminated to all family 
members who may benefit from receiving it and the information that is shared is often 
inaccurate (K. Forrest et al., 2003; Hayat Roshanai et al., 2010; MacDonald et al., 2007; 
Vos, Menko, et al., 2011). Thus, many at-risk relatives lack critical information that 
could help them better understand their cancer risks and be aware of appropriate 
preventive and screening measures (Ersig, Williams, Hadley, & Koehly, 2009; Vos, 
Jansen, et al., 2011).  
 Much of the research on communication and risk perception among families at 
risk for breast cancer has focused on families with a known BRCA1/2 mutation. Yet the 
most common outcome of BRCA1/2 testing is an indeterminate negative result, meaning 
a negative result in the absence of a known family mutation. Members of these families 
may still be at increased familial cancer risk. In the absence of an identified mutation, it is 
recommended that familial risk be estimated based on a family history evaluation 
including the types and ages of onset of cancer in a family (National Comprehensive 
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Cancer Network, 2013c). Some families have more cases of cancer than would be 
expected due to chance. Women in these so-called family clusters may have an increased 
risk for breast cancer because of inheritance of another high- or moderate-risk gene 
mutation, shared environmental factors, or a combination of the two (Berliner & Fay, 
2007). While these families may not carry the same level of risk as BRCA1/2 positive 
families, risk may still be high enough earlier onset of screening, screening breast MRI, 
and/or chemoprevention (Freedman et al., 2011; National Comprehensive Cancer 
Network, 2013b). Thus, risk assessment and individualized communication about genetic 
test results by the counselor are important to family members beyond the counselor’s 
immediate patient, even in the presence of an indeterminate negative BRCA1/2 test result.  
 A primary goal of genetic counseling is to help people accurately understand risk 
and make informed decisions based on personal risk (Hilgart et al., 2012; Riley et al., 
2012; Smerecnik et al., 2009). It is believed that if people more accurately understand 
their risk, they are better prepared to take appropriate actions to reduce and manage this 
risk (Haas et al., 2005). Research assessing accuracy of risk perception related to breast 
cancer in families at elevated-risk has primarily focused on women who received genetic 
counseling rather than their family members (Hilgart et al., 2012; Tilburt et al., 2011). In 
the presence of an indeterminate negative test result within the family, family members 
do not often seek genetic counseling. If they receive information about their family 
member’s test results, they must generally rely on second-hand information shared by the 
counselee. Women with indeterminate negative test results are less likely to share 
information obtained during genetic counseling sessions than those who tested positive 
for mutations (Patenaude et al., 2006). 
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Risk perceptions can be measured using verbal or numeric estimates. Health care 
providers tend to view successful risk communication as the transmission of precise 
information, expecting that patients should understand their risk as the health care 
provider does (Collins & Street, 2009, p. 1507). Patients, on the other hand, may focus 
more on experiential reasoning to understand risk communications, drawing upon 
personal life experiences and emotions (Collins & Street, 2009). Indeed, many women 
have difficulty interpreting risk information, especially when it is presented in a numeric 
format (Leventhal et al., 1999; Schwartz et al., 1997). Often women’s verbal and 
numerical risk estimates are not congruent (Smerecnik et al., 2009). Women tend to 
underestimate risk when using verbal comparative scales but over-estimate their numeric 
risk (Lipkus et al., 2000; Woloshin et al., 1999). The terms “over-estimate” and 
“underestimate” suggest that there is an accurate estimation, but varying risk models may 
give quite different risk estimates.  
To assess accuracy of risk perception, an objective or “gold standard” measure of risk 
is needed against to compare subjective risk perceptions. Researchers typically set 
arbitrary breaks between categories of accuracy vs. overestimation or underestimation of 
risk using either numeric or verbal categories (Smerecnik et al., 2009).  For example, 
some have required women’s perception to fall within two categories of counseled risk 
on a six-point scale to be counted as accurate (Bjorvatn et al., 2007), or to fall within one 
category of counseled risk estimate (Lobb et al., 2004). Haas et al. (2005) categorized 
women as “high-risk” if they had a Gail score of more than 1.67%, all other women were 
determined to be “average-risk,” and women’s risk perceptions were deemed inaccurate 
if they did not choose the verbal category (high or average) that corresponded with their 
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Gail scores and the numeric cut-points selected by the authors. Metcalfe et al. (2013) 
calculated lifetime risk of breast cancer in sisters of breast cancer patients using the 
Tyrer-Cuzick model and  categorized women as overestimating or underestimating if 
they did not select the exact same percent of lifetime risk for breast cancer that the model 
generated; they reported the average degree of overestimation.  Thus, definitions of 
accuracy in the literature are not consistent. A woman may have an accurate estimation of 
her personal risk in relation to one objective measure of risk but have an inaccurate 
estimation of her risk when compared to another measure. Even when using the same 
objective measure of risk (e.g., the Gail model or the Claus model), researchers have 
categorized overestimation, underestimation and accurate estimation in different ways 
(Bjorvatn et al., 2007; Domanska, Nilbert, Soller, Silfverberg, & Carlsson, 2007; Haas et 
al., 2005; Lobb et al., 2004; Rimes, Salkovskis, Jones, & Lucassen, 2006)  
Methods 
Study Population 
Participants included biological sisters and daughters of women who had a 
personal history of breast cancer and received indeterminate negative BRCA1/2 test 
results from a board certified genetic counselor. Participants were between the ages of 
40-74. Women were excluded if they ever received breast cancer-related genetic testing, 
had received a prophylactic bilateral mastectomy or oopherectomy, had a personal history 
of any type of cancer other than nonmelanoma skin cancer, and/or if they were of 
Ashkenazi Jewish descent as the associated high-risk status with this ancestry 
necessitates special consideration in evaluating risk. 
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Participants were referred to the study by their sisters or mothers with breast 
cancer who had received genetic counseling either as part of the Risk Education & 
Assessment for Cancer Heredity (REACH) study, a population-based randomized 
equivalency/noninferiority cluster randomized trial of remote in-person vs. telephone 
BRCA1/2 counseling and testing or through the clinical genetic counseling service at 
Huntsman Cancer Institute. It is unknown which of the current study participants were 
referred by counselees from the two sources. All counselees who referred participants to 
our study had received pre- and posttest genetic counseling along with standardized 
summary letters alerting them to the possibility that close relatives may be at increased 
risk for breast cancer and may need more intensive breast cancer surveillance, possibly 
including breast MRI. Counselees were encouraged to share this information with their 
close relatives (our potential participants) and encourage their relatives to share that 
information with their primary care providers.  
Procedures  
All procedures were approved by the University of Utah Institutional Review 
Board. Potential participants were mailed introductory letters followed by telephone calls 
to assess for eligibility and invite them to participate. Eligible women who agreed to 
participate were sent a packet in the mail with a survey and a family history collection 
tool. They also completed a telephone interview to review their family history data and 
ask additional questions. Prior to the telephone interview, a pedigree was drawn from the 
self-reported family history. Women were asked if they wanted to receive their 5-year 
and lifetime risk estimates by the three models used. Women who completed the study 
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were thanked with a mailed $25.00 prepaid gift card and for those who desired, their 
breast cancer risk estimates.   
Measures  
Risk perception. The mailed survey included two questions about perceived risk 
for breast cancer. The initial question asked women to rate their perceived risk verbally 
stating, “In your opinion, compared to other women your age, what are your chances of 
getting breast cancer?” Women could respond on a five-point scale ranging from “much 
lower” to “much higher.” The second question first presented women with a graphic 
showing 12 of 100 women shaded dark and stating, “On average 12 women out of 100 
will get breast cancer in their lifetime.” Then the question instructed, “Picture yourself in 
a room with 100 women exactly like you (same risk-factors). How many of you will get 
breast cancer in your lifetime?” This question was accompanied by a picture of 100 
women with none shaded and the statement, “You can pick any number between 0 and 
100.” A frequency format with graphic has been shown to have a lower risk estimation 
error when compared to the percentage scales when estimating lifetime risk for breast 
cancer (Cameron et al., 2011; Schapira et al., 2004). Asking the qualitative question first 
and providing an anchor population has been shown to increase accuracy of risk 
perception (Apicella et al., 2009; Dillard et al., 2006; Taylor et al., 2002). 
Calculated risk. Five-year and lifetime risks were calculated using the Claus, 
BRCAPRO, and Gail models. Claus and BRCAPRO lifetime risk estimates were used as 
indicators for the latent variable calculated risk.  
 Accuracy of risk perception. Some refer to the agreement between perceived risk 
and calculated risk as accuracy. Inherent in this terminology is the assumption that the 
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calculations are correct and women are “accurate” if their perceptions are close to the 
estimates.  However, every model calculates risk-based on different factors and estimates 
may vary widely between models. Therefore, we use the term “accuracy” recognizing 
that it is a common term in the literature, but the term “agreement” may hold less bias. 
We operationalized the concept of accuracy of risk perception as the level of agreement, 
or in statistical terms, the path coefficient, between the latent variable “calculated lifetime 
risk” for breast cancer and “perceived lifetime risk” (see Figure 5.1). We chose not to 
include the Gail calculations in the model because it does not take extensive family 
history into account and is therefore not an appropriate model to use for lifetime risk 
calculation when determining medical management (American Cancer Society, 2014). 
The Gail model considers risk factors beyond the family history and is the most 
frequently used model. 
 Information shared. Women were asked to rate how much information their 
sister or mother with breast cancer shared about her genetic counseling session on a scale 
of 0-5 with 0 indicating that the family member shared no information and 5 indicating a 
great deal of information shared. Similarly women were asked to rate how well they 
understood the information shared on a 0-5 scale with 0 indicating that she understood 
none of the information and 5 indicating that she understood a great deal. We also asked 
whether women were aware of the posttest counseling summary letter, or the 
informational pamphlet that was provided to their sisters/mothers following their 
relative’s posttest genetic counseling session.  
Numeracy, knowledge, and health literacy. We assessed three cognitive variables 
known to influence risk perception including numeracy, knowledge, and health literacy  
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(Tilburt et al., 2011). Numeracy was measured using the eight-item Rausch-based 
numeracy scale that assesses the users’ ability to understand, manipulate, and use 
numerical information including probabilities. Possible scores range from 0-8 with higher 
scores indicating higher levels of numeracy (Weller et al., 2012). The 27-item Breast 
Cancer Genetic Counseling Knowledge Questionnaire (BGKQ) was used to assess 
knowledge about breast cancer genetics. Scores could range from 0-8 with higher scores 
indicating higher levels of knowledge (Erblich et al., 2005). We assessed health literacy 
using the Set of Brief Questions developed by Chew, Bradley, and Boyko (2004). Each 
of the three questions has five response options that were scored from 0-4. Questions 
included, “How often do you have someone help you read hospital materials?” (“never” 
to” always”), “How confident are you filling out medical forms by yourself? (“not at all” 
to “extremely”), and “How often do you have problems learning about your medical 
condition because of difficulty understanding written information?” (“never” to 
“always”).  Total scores could range between 0-12 with higher levels indicating higher 
levels of health literacy. 
 Cancer-related distress. Cancer-related distress was measured to assess the 
emotional response to being at risk for breast cancer. We used the 15-item Impact of 
Event Scale (Horowitz et al., 1979), which asks about how frequently certain statements 
were true for the participant during the past 7 days ranging from “not at all” to “often.” 
Instructions to women were, “thinking about your family history of cancer, how often 
would you say…” followed by a list of comments made by people after stressful life 
events that are thought to be indicators of distress. 
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Statistical Analyses 
Descriptive statistics (percents and frequencies) were calculated using IBM SPSS 
software version 21. Latent variable modeling was completed using Mplus software; 
version 7 was employed to test the hypothesis that the amount of information shared by 
women’s sisters or mothers who received genetic counseling would increase the accuracy 
of perceptions about their personal breast cancer risk.  
Latent variable models are built on theory and clinical experience (Borsboom, 
Mellenbergh, & van Heerden, 2003; Byrne, 2012). Our study/ model was based broadly 
on the Common Sense Model of Self-regulation (CSM) by Leventhal et al. (2003). The 
CSM proposes that people respond to health threats with both cognitive and emotional 
reactions. Cognitive and emotional responses simultaneously influence one another and 
are key drivers of actions that people take to control the threat and control fear. It has 
been proposed that the CSM provides a strong framework for studying risk perception 
based on family history information (Marteau & Weinman, 2006; Sivell et al., 2008). We 
view risk perception as a cognitive response to the health threat of breast cancer (having a 
close family member with breast cancer who has received genetic counseling and 
testing). This cognitive response can be simultaneously influenced by other cognitive 
factors (numeracy, knowledge, health literacy) as well as emotional factors (cancer 
related distress). Our primary aim was to evaluate perceived risk while controlling for 
cognitive and emotional factors known to influence risk perception (Tilburt et al., 2011) 
We selected a novel approach to measuring accuracy of risk perception that does 
not require the calculation of a difference score or an arbitrary break in categories. Using 
latent variable modeling we were able to consider both calculated risk and perceived risk 
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as latent variables. Latent variables are constructs that are measured by other indicators. 
The individual measurement items can be modeled as manifestations of the underlying 
latent construct and error terms for each measurement item can be estimated (Kline, 
2010). Accuracy of risk perception was defined as the level of agreement (i.e., as a 
continuous variable) between risk perception and calculated risk. In our study, the 
construct of perceived lifetime risk for breast cancer was operationalized with both a 
verbal and numeric estimate provided by the participant (see Figure 5.1). Using a 
combination of both numeric and verbal measures allowed a more comprehensive view 
of a woman’s risk perception. The concept of calculated risk was measured by the 
lifetime risk calculations produced by Claus and BRCAPRO models. Although we 
calculated Gail scores, we did not include those as indicators of calculated lifetime risk 
because medical management for familial cancer risk is primarily based on selected 
features of a patient’s family history (National Comprehensive Cancer Network, 2013a, 
2013b). This approach allowed us to examine the impact of amount of information shared 
on accuracy of risk perception, simultaneously accounting for verbal and quantitative risk 
perceptions and multiple measures of calculated lifetime risk.  
Given that risk perception is a complex concept, our goal was to control for 
significant covariates that could complicate interpretation of our results. Selection of 
initial covariates was informed in part by  Tilburt et al. (2011). Only significant 
covariates were included in the final model. Covariates that were evaluated but ultimately 
not included in the final model included age, education, and health literacy. Significant (p 
< 0.5 by Wald test) covariates that were retained include numeracy, knowledge about 
breast cancer genetics, and distress (see Figure 5.1).  
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Results 
Demographics 
Of the 135 women who were mailed introductory letters, 98 were ultimately 
eligible and 85 completed both the survey and the telephone interview (see Figure 5.2). 
Participant ages ranged from 40-71 with a mean of 52.2 (SD = 8.9). Nearly all women 
(98.8%) reported their race and ethnicity as non-Hispanic White with 1 woman reporting 
her race as Asian. Age, race/ethnicity, and educational level were similar between 
nonparticipants who shared demographic information (n = 11) and study participants (see 
Table 5.1).  
Risk Perceptions 
More women perceived their lifetime risk for breast cancer as being “higher” or 
“much higher” (53%) than other women their age as opposed to “the same” (32.5%), or 
“lower” or “much lower” (13.2%) using verbal measures. On average women estimated 
their quantitative lifetime risk to be 25.62% (SD=19.94) with a range of 1-95%.    
Calculated Risk 
Calculated 5-year and lifetime risk estimates by risk prediction model are 
presented in Table 5.2. Additionally, the percentage of women with lifetime risks equal to 
or greater than 15% and 20% are delineated. These cut-points are significant because 
both the NCCN and the ACS suggest that women screen with annual screening breast 
MRI in addition to mammography when lifetime risk is estimated to be greater than 20% 
using models that take extended family history into account. The ACS has suggested that 
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there is not enough evidence to determine whether to recommend for or against annual 
screening breat MRI in women with risk estimates between 15% and 20%. 
Summary Letter and Informational Pamphlet 
Women were asked whether they were aware that their sister or mother received a 
summary letter about their genetic counseling session. Only 12 women (14.3%) reported 
that they were aware of such a letter. Of those who were aware of a letter, 7 women saw 
the letter and 2 were given a copy to keep. Only 3 women reported that they shared 
information about the letter with their primary care provider. Two women reported that 
they provided their primary care provider with a copy of the letter. Women were asked to 
rate on a 0 to 5 scale whether some of the information in the letter applied to them with 
zero indicating that none of the information applied to them, and 5 indicating that some 
of the information applied strongly to them. Of the 12 women who were aware of the 
letter, 58% rated the letter’s applicability to them as a 4 or 5 on the 0-5 scale. Four 
women reported that they were aware of an informational pamphlet that their sister or 
mother received as a part of the genetic counseling session. Two women reported that 
they saw the pamphlet and 1 reports that she read it. 
Covariates of Perceived Risk  
Family pedigree, distress, knowledge, health literacy, numeracy, age and 
education were all considered as variables that could influence perceived risk. As shown 
in Table 5.3, overall, women had low levels of cancer-related distress, high levels of 
health literacy, and average levels of numeracy and knowledge about breast cancer 
genetics. Health literacy, age, and education were not significantly associated with risk 
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perception and therefore were not included in the final latent variable model. The 
relationships between retained covariates and perceived risk are illustrated in Figure 5.1 
as the standardized path coefficients. Numeracy and distress were associated with higher 
risk perception, but knowledge was inversely associated with risk perception. 
Standardized path coefficients less than 0.10 indicate weak relationships, values around 
0.30 represent a moderate association, and values of 0.50 or more represent a strong 
relationship between constructs (Kline, 2010).   
Amount of Information Shared and Understanding 
Overall, women rated the amount of information shared by their sisters and mothers 
about their genetic counseling sessions as low (see Table 5.4). Only 18.8% of women 
reported that their sisters or mothers did not share information; these women were not 
asked how well they understood information shared. Women generally reported high 
levels of understanding the small amounts of information shared. As 1 woman stated, “all 
she told me was ‘I’m negative, but you should still get your mammograms’ – so that’s 
not hard to understand.”  The families from which we recruited were not identified as 
having any BRCA1/2 mutations; therefore, none of the sisters or mothers were likely to 
have a true negative test result. All of their relatives’ test results were indeterminate 
negatives.  
Moderating Effect of Information Shared on  
Accuracy of Risk Perception 
To evaluate the moderating effect of information shared between relatives on 
associations between perceived and calculated lifetime risk for breast cancer, we 
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compared two models: one with moderation (allowing different slopes and intercepts for 
the regression of perceived risk on calculated risk) and one with no moderation (with 
slopes and intercepts equal across levels of information shared). We hypothesized that the 
amount of information shared by sisters and mothers about genetic counseling would 
moderate the relationship between a woman’s perception of her risk and objectively 
calculated risk (accuracy of risk perception).  
The variable “amount of information shared” was stratified into high and low groups 
based on the amount of information women reported their family member had shared 
with them about the genetic counseling session. The “low shared information” group 
(n=68) included women who responded between 0 and 3 and the “high information 
shared” group (n=17) included women who responded 4-5 on the Information Shared 
scale. Stratifying on the basis of all six options (0-5) was not feasible due to the small 
sample size.  
 A chi square test was conducted to assess significance of the difference of 
deviance between the models. A difference in chi-square between the model with 
moderation and the model where the groups were constrained to be equal was 4.79 (df=1) 
(p = 0.287). This indicates significant improvement in model fit when the high and low 
amount of information shared groups is not constrained to be equal. Fit indices for the 
alternative model assessing moderation effect of amount of information shared were Chi-
Square Test of Model Fit 22.550 (df=28, p=.7552), RMSEA = 0.0000, 90% CI [0.000-
0.086].  A nonsignificant chi-square indicates that the model–implied covariance matrix 
is consistent with the population covariance matrix and supports the model; in other 
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words, the model and the data are not significantly different (Kline, 2010). RMSEA is 
below 0.05, indicating good model fit.  
In summary, the amount of information shared by sisters and mothers about their 
genetic counseling sessions had a significant moderating effect on the accuracy of risk 
perception in their sisters and daughters who did not attend genetic counseling (see 
Figure 5.1). Perfect correlation between perceived and calculated risk (perfect accuracy) 
would yield a path coefficient of 1.0 between the two latent variables. In our sample, 
women who rated the amount of information shared as high had nearly twice the 
accuracy (standardized path =0.707, p=0.000) as those who rated the amount of 
information as low (standardized path = 0.326, p = 0.003) while controlling for distress, 
numeracy, and knowledge about breast cancer genetics. Thus, having a high amount of 
information shared more than doubled women’s accuracy of risk perception.  
Discussion 
 A familial cancer risk assessment by its very nature produces information that is 
valuable to the entire family. Our study is among the first to demonstrate that the 
accuracy of risk perceptions is better among counselee’s relatives when they share more 
information about their genetic counseling session with them. In fact, with high amounts 
of information sharing, accuracy of risk perception in family members more than 
doubled. The salience of this finding is underscored given that genetic counselors often 
encourage their patients to share information with family members. Our study provides 
evidence that sharing makes a difference. It is noteworthy that the majority of our study’s 
participants reported that limited information was shared with them. Nearly 20% reported 
that nothing at all was shared about their family member’s genetic counseling session and 
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over 80% were considered in the low amount of information shared group. Thus, our 
findings suggest that communication could be improved in families where an 
indeterminate negative BRCA1/2 test has been found. These findings are consistent with 
other literature, indicating that women with indeterminate negative BRCA1/2 results are 
less likely to share their test results with family (Cheung et al., 2010; Patenaude et al., 
2013). Our study is unique in that it elicited information about perceptions of the amount 
of information shared and did not focus specifically on test results. 
The low amount of shared information does not necessarily mean that families do 
not communicate. Indeed, our participants were referred to the study by their sisters and 
mothers, indicating that they had some contact with or knowledge about their family 
members.  It is possible that the low amount of information shared about genetic 
counseling could indicate that the information provided during genetic counseling was 
not something counselees deemed worth sharing with their close biological relatives 
because the genetic test result might have been perceived as “negative.” Some women 
reported that their sisters or mothers told them the cancer was “not hereditary.” The 
observed low level of information sharing in our study may be because the information 
was perceived as too complex to share in depth, or much of the information was shared 
but our participants had limited recall.  
The sisters and mothers of our participants received genetic counseling according 
to a standardized protocol. A summary letter and an informational pamphlet were 
provided as part of test disclosure. Previous clinic patients had expressed the desire for an 
informational pamphlet specifically to help them explain cancer genetics to their family 
members. We initially thought that family members who were aware of or read the 
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summary letter and the informational pamphlet might have more accurate risk 
perceptions. However, few women were aware of the letter (14.1%) or pamphlet (3.5%), 
and even fewer reported reading them; therefore, we did not include these variables in 
our structural equation model. Although very few women were aware of a summary letter 
per se, we cannot rule out that the summary letter may have helped women convey 
information to their family members. Genetic counseling summary letters are not 
necessarily intended to be shared with family members; they are typically written for the 
woman herself, perhaps with a section that applies to the extended family.  
It has been suggested that misperception of risk can increase or decrease use of 
screening and preventive services (Tilburt et al., 2011). Higher risk perceptions are 
generally associated with higher levels of screening (Katapodi et al., 2004). However, the 
ultimate goal is not to undiscerningly increase screening, but to achieve screening 
congruent with risk-based guidelines. The ACS and the NCCN recommend that women 
with lifetime risk for breast cancer of greater than 20% be screened annually with breast 
magnetic resonance imaging (MRI) in addition to mammography when risk is calculated 
with models that depend largely on family history. The ACS further suggests that breast 
MRI may be considered when a woman’s estimated lifetime risk levels exceed 15%. 
Over 10% of our participants were considered to be >20% lifetime risk according to the 
Claus model, yet none of them had been offered or received screening breast MRI 
(Himes et al., in preparation). Thus, whether they had high or low levels of accuracy or 
high or low amounts of information shared, the highest risk women in our study had not 
been offered risk-appropriate breast cancer screening.   
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Practice Implications 
It is important that genetic counselors consider disclosure methods that balance 
confidentiality with obligation to identify and inform family members that may be higher 
risk (Godard et al., 2006). The duty to warn would suggest that at least for close 
biological relatives in whom high levels of risk are suspected, the genetic counselor 
should act (Offit, Groeger, Turner, Wadsworth, & Weiser, 2004; Stol et al., 2010; Suthers 
et al., 2006). Practice recommendations for genetic cancer risk assessment, counseling, 
and testing published by the National Society of Genetic Counselors suggest that, “If a 
patient refuses to share information with relatives, the genetic counselor should evaluate 
his/her potential legal and/or ethical duty to warn. This evaluation should include a 
consultation with their institution’s HIPAA compliance officer and/or ethics committee” 
(Riley et al., 2012, p. 58).  Our findings suggest that encouraging patients to share 
information with family members and providing a summary letter is not enough. Women 
with an elevated lifetime risk for breast cancer been shown to benefit from more intensive 
screening including annual MRI (Berg et al., 2012; Kriege et al., 2004). Yet most women 
at high risk are not receiving annual MRI (Cohen, 2010). Approximately 10% of sisters 
and daughters in our study population were considered at high risk but had never received 
an MRI nor had one recommended by their primary care provider (Himes et al., in 
preparation). Women with indeterminate negative BRCA1/2 tests may require more 
active psycho-educational interventions about what information to share with family 
members and strategies for sharing it. If family members are not aware of their risk, they 
may not be aware of all screening and prevention options available to them. Evidence-
based genetic counseling interventions are needed to promote effective family 
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communication, and readily provide consultation to family members and their primary 
care providers. 
Research Recommendations 
While current practice guidelines suggest a duty to warn family members when 
counselees refuse or are incapable or sharing information, some clinicians have taken the 
duty to warn a step further (Suthers et al., 2006). It has been suggested that because many 
women have a difficult time understanding familial cancer risk information, interpreting 
it, and communicating this information to relatives, counselors should routinely guide 
their patients in the communication process or even inform relatives directly about test 
results and their risk if possible (Chan-Smutko, Patel, Shannon, & Ryan, 2008; Godard et 
al., 2006; Seymour et al., 2010; Stol et al., 2010; Suthers et al., 2006; Vos, Jansen, et al., 
2011). There is some evidence that family members prefer receiving risk information 
from a health care provider rather than from their family member (Tunin et al., 2009). 
Future research is needed to determine the feasibility, acceptability, and effectiveness of 
these strategies in the presence of indeterminate negative BRCA1/2 results when pedigree 
analysis indicates family members may be at elevated-risk. Genetic counselors might 
consider a letter addressed to family members that can be copied and hand delivered or 
mailed by the counselee or request consent from the counselee for a direct mailing of this 
information to their at-risk relatives.  
Study Limitations 
 Our study population was virtually all non-Hispanic White and well educated, 
limiting the generalizability of our findings to more underserved populations. Whenever 
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family history is used to assess risk, there is the potential for inaccurate or incomplete 
cancer information. However, the women in our study had sufficient time to collect the 
required family history data. Further, many participants conferred with other family 
members to obtain data as accurately as possible, enhancing validity of family history 
information. Studies comparing self-reported family history with verified cases have 
yielded a high sensitivity for breast cancer when compared to validation by chart review 
(83-97%) (Kerber & Slattery, 1997; Parent, Ghadirian, Lacroix, & Perret, 1997). Because 
our study participants had participated in a previous study about breast cancer prevention 
and that we asked them to collect family history information for pedigree analysis, it is 
possible that they may have heightened awareness of breast cancer, yielding higher 
distress scores and inflated risk perceptions. However, this does not appear to be the case 
given that risk perceptions and distress scores were relatively low. 
Conclusion 
 The most common result of BRCA1/2 mutation testing when performed in a 
family without a previously identified mutation is the indeterminate negative test result. 
Women in these families may have an increased risk for breast cancer based on family 
history. We evaluated sisters and daughters of women who received an indeterminate 
negative BRCA1/2 results and found that most of them reported receiving very little 
information about the counseling session from their sister or mother. When more 
information was shared about the genetic counseling session, sisters and daughters had 
more accurate perceptions of their own risks for breast cancer. However, our study 
participants reported that very little information was shared. At-risk female relatives of 
counselees are generally not aware of the existence of a genetic counseling summary 
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letter. It is important for genetic counselors to explore new ways to help their patients 
share information with family members to help family members perceive their risk for 
breast cancer more accurately, which could potentially allow family members to pursue 
risk-appropriate prevention and screening measures. 
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Figure 5.1  
Final moderation model* allowing regression of Perceived Risk on Calculated Risk to vary with information shared. 
 
* Chi-Square Test of Model Fit 22.550, df = 28 (p = 0.755); Difference in chi-square compared with model constraining equal regressions of Perceived Risk on 
Calculated Risk = 4.79, df=1, (p =0.0287) 
 
Note: All analyses and were conducted with respect to the unstandardized solution. Standardized coefficients are presented here for interpretability. All included 
covariates and indicator variables were significant (p <0.05). Beta weights for explanatory covariates and indicator variables have been weighted based on group 
size and combined so that information in the model can be presented with one diagram. Thus, coefficients for all parameters should be considered to reflect the 
whole sample except for the arrow between the latent variables Calculated and Perceived lifetime risk for breast cancer. This arrow represents the accuracy of 
risk perception in women who reported that low or high amounts of information were shared with them by their relative who received genetic counseling and 
testing. As can be seen in the bolded numbers, women reporting high amounts of information shared were found to be more than twice as accurate in their risk 
perceptions based on our measure.  
High amount of information shared (n=17) 
 Standardized estimate = 0.707 (p=0.000) 
Low amount of information shared (n=68) 
 Standardized estimate = 0.326 (p=0.003) 
0.513 -0.229 
0.245 
0.837 0.702 
0.702 1.000 
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135 women contact 
information provided  
by REACH-Pilot study  
135 attempted to call 
13 unreachable 
122 reached, invited to participate  
11 refused 
eligibility 
 screening 
11 ineligible 
initially 100 women agreed to participate, 
mailed survey, scheduled phone 
interview 
2 became ineligible - 
developed breast cancer 
after agreeing to 
participate but before 
survey or interview 
completed 
10 withdrew  
5 contacted PI to 
withdraw 
5 lost to follow-up  
N =85 Final Sample 
3 completed 
interview 
but not 
survey 
111 screened for eligibility 
98 ultimately eligible 
Figure 5.2  
Flow of participants 
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Table 5.1 
Demographics of participants and nonparticipants  
                             
   
Participants 
n = 85 
 
Nonparticipants
 
n = 11 
Category   n (%) M (SD)   n (%) M (SD) 
Age 
    
52.2 (8.9) 
   
55.4 9.8 
Race/ ethnicity 
         
 
Non-Hispanic White 84 (98.8) 
   
11 (100.0) 
  
 
Asian 
 
1 (1.2) 
   
0 (0.0) 
  Education 
      
    
  
 
High school/ GED 13 (15.3) 
   
0 (0.0) 
  
 
Some college/ vocational 32 (37.6) 
   
6 (54.5) 
  
 
4 -year degree 28 (32.9) 
   
2 (1.8) 
  
 
Graduate degree 12 (14.1) 
   
3 (2.7) 
  
a Nonparticipant data were provided by 11 of 23 women who did not participate because they, refused screening, withdrew, were lost 
to follow-up, or became ineligible. Other nonparticipants refused to provide demographic data. Percentages are based on 
nonparticipants who provided data. 
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Table 5.2 
Calculated risk 
  
                
                        
            Lifetime   Lifetime   
            >15%risk   >20%  risk 
Model   [Range %] M (SD)   n (%)   n (%)   
Gail                        
  5-year [0.6-12.0] 3.14 (2.3)               
  Lifetime [8.3-38.8] 20.07 (6.6)   72 (84.5)   29 (34.1)   
Claus                        
  5-year [0.2-5.7] 2.15 (1.2)               
  Lifetime [2.0-38.3] 11.84 (6.7)   14 (16.5)   9 (10.6)   
BRCAPRO                        
  5-year [0.8-2.2] 1.24 (0.5)               
  Lifetime [4.0-14.7] 9.53 (2.0)   0 (0.0)   0 (0.0)   
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Table 5.3 
Descriptive data for responses to psychological and cognitive measures 
                  
Variable 
  
[range]   mean (SD)   
Cronbach's  
Alpha   
Distress (Impact of Events Scale) [1-46]   8.20 (11.1)   0.890 
 Health Literacy (Set of Brief  
Questions) [6-12]   10.91 (1.3)   NA 
 Knowledge about Breast Cancer 
Genetics (BGKQ) [1-24]   10.26 (5.5)   0.854 
 Numeracy (Rausch Based Numeracy 
Scale) [2-8]   4.48 (1.5)   0.530 
 Note: n=85 for Cronbach’s alpha calculations for health literacy and knowledge. One participant refused to 
answer all numeracy questions and was excluded from analysis of that instrument and one participant did 
not answer one question on the Impact of Event Scale; therefore, on these measures, Cronbach’s alpha is 
calculated for n=84.  
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Table 5.4 
Sharing/ understanding of information from family member's genetic counseling session 
                    
Question     Response n (%)   M SD 
Please rate on a scale 
of 0-5 how much 
information your 
sister/ mother shared 
with you about what 
she learned in her 
genetic counseling 
session, with zero 
being she shared 
nothing about the 
session to five being 
she shared a great 
deal. 
  Shared nothing 0 16 (18.8)   2.04 1.53 
   1 20 (23.5)       
   2 17 (20.0)       
   3 15 (17.6)       
   4 11 (12.9)       
 Shared a great deal 5 6 (7.1)       
  Total   85 (99.9) 
      
Please rate how well 
you understand the 
information she 
shared on a scale of 
0-5 with zero being 
that you don't 
understand it at all to 
five being that you 
understand a great 
deal. 
 Don't understand at all 0 0 (0.0)   3.57 1.49 
 
  1 4 (4.7)       
 
  2 5 (5.9)       
 
  3 15 (17.6)       
 
  4 20 (23.5)       
 
Understand a great deal 5 25 (29.4)       
 
Total Valid   69 (81.2)       
 
Nothing was shared   16 (18.8)       
  
Total   85 (100.0) 
      
  
CHAPTER 6  
 
DETAILED RESULTS  
 Chapter 6 includes detailed analysis and results that were beyond the scope of the 
prepared manuscripts. 
IRB Approval 
 IRB approval was received by the University of Utah on September 4, 2013.  
Recruitment 
Contact information was provided by the REACH Pilot research team (PI Anita 
Kinney) for 135 women who had indicated willingness to be contacted again for future 
cancer-related research. Information was transmitted via encrypted email. Initial 
recruitment letters were mailed. Women were recruited from September through 
November 2013. The script for the recruiting telephone call, including eligibility 
questions are found in Appendix A. 
Of the 135 potential participants, we were able to reach 122 by telephone to 
assess for interest in participation and eligibility. Eleven refused screening with 8 stating 
that time was the primary reason they did not want to participate and three cited lack of 
interest – 1 of those specifically noting that she does not believe the cancer in her family 
is hereditary.  
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When asking the screening questions to potential participants, we stopped asking 
questions when we received an answer that would disqualify the participant from 
participation. Participants may have been deemed ineligible based on more than one 
criterion; however, we can only report on the first criterion that disqualified them. Of the 
11 ineligible women at the initial screening, 2 women were outside the range of 40-74, 2 
women had a cancer besides nonmelanoma skin cancer, 2 women were of Ashkenazi 
Jewish descent, 3 women received genetic counseling for breast or ovarian cancer 
themselves (2 of which also mentioned that they had genetic testing for the BRCA1/2 
mutation), and 2 women who had prophylactic oophorectomies. Overall, 100 women 
were initially eligible and consented to participate. These women were mailed survey 
packets including consent cover letters.   
Of the 100 women who were mailed surveys, 2 became ineligible, contacting the 
PI to report that they had been diagnosed with breast cancer before they were able to 
complete the survey and had their scheduled interviews. Ten women withdrew from the 
study. Of those, 5 contacted the PI and 5 became unreachable. Those contacting the PI 
gave cited time constraints as a reason with 2 mentioning that filling out the family 
history portion of the survey would take too much time because of their large families. 
The other 5 were lost to follow-up.  These women became unreachable after the survey 
had been mailed and appointments had been set for telephone interviews. Some 
rescheduled their telephone interviews one or more times because they stated they needed 
more time to collect the family history. After up to five unsuccessful attempts were made 
to reschedule, no further calls were attempted. These women never returned a completed 
survey and were therefore presumed to withdraw. Additionally, 3 women completed 
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telephone interviews but did not return the survey packet. After four voicemail reminders 
and no response back from the participants, we determined that we would not be able to 
include these women in our final analysis. Therefore, the final sample includes 85 women 
belonging to 62 family clusters who completed both the telephone interview and the 
written survey. Of the 122 women contacted, 69.7 were eligible, and agreed to participate 
and completed the study. Of the 98 women who were screened, and determined to be 
eligible, 86.7% completed the study (Figure 5.2). Interviews were completed between 
September and November 2013. 
Data Cleaning 
 Once all data were entered into IBM SPSS software version 21; several iterative 
processes were undertaken for data cleaning. All dates were sorted high to low and 
scanned for outliers. Frequency tables were created for categorical variables and 
histograms were created for continuous variables including instrument sums and means. 
Outliers and missing data were investigated by going back to the data collection 
instruments and comparing them against data that were entered. In several cases, the data 
file was updated to reflect the accurate information.  
Family Member Who Received BRCA1/2 Test 
Contact information was sent to us for women who completed the REACH-Pilot 
study. These women were identified as having a sister or mother who received genetic 
counseling and testing with indeterminate negative BRCA1/2 test results. We did not 
know which relative had received counseling and testing and so we asked women which 
relative had received genetic testing and counseling. Sixty-five women (76.5%) reported 
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that their sister was the member of their family who had genetic testing and counseling, 
18 women reported it was their mother, and 2 women did not know who in their family 
had genetic testing or counseling. 
Measures 
Demographics  
Women’s ages ranged from 40-71 with a mean of 52.2 (SD 8.9). Nearly all 
women (98.8%) reported their race as non-Hispanic White with 1 woman reporting her 
race as Asian. Women in the sample were highly educated. All women had completed 
high school or the equivalent, 43.5% had a 2- or 4-year college degree, and 14.1% had a 
postgraduate degree (see Table 4.2). Age, race, and education were similar between 
nonparticipants who shared demographic information and study participants. Further 
demographic factors were not collected for nonparticipants. Nearly 80% of participating 
women described themselves as married and most described themselves as Latter-day 
Saints (Mormon) when asked about religious affiliation. 
Risk Perception 
Women were asked via written survey to report what they thought their chances 
were of getting breast cancer with comparative verbal and quantitative responses.  
Comparative verbal risk perception was assessed by asking the question, “In your 
opinion, compared to other women your age, what are your chances of getting breast 
cancer?” About a third of women thought their chances were “the same” as other women. 
Over 50% thought their chances were “higher” or “much higher,” and about 13% thought 
their chances were “lower” or “much lower” (see Table 4.4).  
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 Comparative, quantitative risk perception was measured by first presenting 
women with the following information, “On average 12 women out of 100 will get breast 
cancer in their lifetime.” Women were given an illustration of 100 women with 12 out of 
100 women shaded to illustrate the concept. Women were then instructed,  
Picture yourself in a room with 100 women exactly like you (same risk-factors.) 
How many of you will get breast cancer in your lifetime? Please pick a number 
between 0 and 100. You can pick any number between 0 and 100. 
 
 Women gave responses ranging from 1% to 95% perceived lifetime risk with an 
average of 25.62%, SD = 19.94. More women wrote “12” % than any other number (16 
women of 85, or 19.0%). The next most frequently written number written was “20” (13 
women) and “25” was written by 10 women. Most women described their risk as lying 
between 5 and 30%; however, some selected very high numbers. One woman described 
her lifetime risk as being 95%, and 2 women selected 90% (see Figure 6.1). 
Cancer-related Distress 
Cancer-related distress was measured using the Impact of Events Scale (Horowitz 
et al., 1979).  Women were given a list of 15 comments that have been made by people 
after stressful life events. The stressor for this study was defined as a family history of 
cancer. Women were asked to indicate how frequently the comments were true for them 
during the past 7 days. The scale is scored as, not at all = 0, rarely = 1, sometimes = 3, 
and often = 5. Therefore, it is possible to score 0 to 75 points on the 15-item scale with 
higher scores indicating higher levels of distress. Most women in this study reported a 
low amount of distress related to their family history of breast cancer. Scores ranged from 
0 – 46 points with an average of 8.20 (SD = 11.10) (see Table 5.3).  One participant 
skipped one item on this scale. To compensate for this missing data point, the mean of 
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each item was calculated and multiplied by the number of items in the scale. The 
Cronbach’s Alpha was 0.890 for the Impact of Event’s scale in this sample, calculated 
using the 84 participants who completed every item. 
Health Literacy 
Self-assessed health literacy was measured using the Set of Brief Questions 
developed by Chew, Bradley, and Boyko (2004). Three questions asked about 
participants’ abilities to read hospital/medical materials and fill out medical forms. Items 
are scored on a five-point scale (range 0 to 4 points) with higher scores indicating higher 
self-reported levels of health literacy. There were no missing data for these three 
questions. Participants rated themselves highly on self-literacy questions with averages 
above 3.5 on each question (see Table 6.1). Chew, Bradley, and Boyko (2004) do not 
promote using the three items as scale, however we did run a Cronbach’s Alpha on the 
three questions and found it to be 0.511 (see Table 5.3).  
Knowledge about Breast Cancer Genetics 
In this study, breast cancer genetic knowledge was measured using the 27-item 
Breast Cancer Genetic Counseling Knowledge Questionnaire (BGKQ) (Erblich et al., 
2005). Twenty-three items are answered as either “true,” “false,” or “don’t know,” four 
items are multiple choice items with five to six options (see Appendix B). Items were 
scored as correct if the correct answer was chosen. Items were scored as incorrect if an 
incorrect answer or “don’t know” was chosen. The questionnaire has a total possible sore 
of 27. Participants in this study scored between 1 and 24 with a mean of 10.26 
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(SD=5.50). There were no missing data on this scale. The Cronbach’s Alpha was 
calculated at 0.854 (see Table 5.3). 
Numeracy 
Numeracy was measured using the Rausch-based numeracy scale recently 
developed by Weller, Dieckmann, Tusler, Mertz, Burns, and Peters  (2012). The scale 
includes 8 questions that test the ability to understand and use mathematic concepts such 
as probability and percent; it also tests the ability to interpret numbers presented in a table 
(see Appendix B). This measure was completed by 84 of 85 participants. One participant 
wrote that she refused to answer those questions. All other participants attempted to 
answer every question or wrote “don’t know” in the answer field. Scores in this study 
ranged from 2 to 8 with a mean of 4.48 (SD=1.54). The maximum score for this 
instrument is 8, representing a high level of numeracy. Cronbach’s Alpha for this scale 
was 0.537 in this sample (see Table 5.3). In initial testing of this instrument, Weller et al. 
(2012) obtained a Cronbach’s alpha of 0.71 – however, they suggested that for measuring 
a broad, higher-order construct, mean interitem correlation is a better measure of internal 
consistency.   
Information from Family Member’s  
Genetic Counseling Session 
Women in this study had either a sister or a mother diagnosed with breast cancer, 
attended genetic counseling, and received a blood test that did not identify a BRCA1/2 
mutation. Women were asked in the interview to rate how much information their sister 
or mother shared with them. Surprisingly, 18.8% of women said their family member 
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shared nothing about her genetic counseling (see Table 5.4). Given that these women 
were referred into the initial REAH Pilot study (P.I. Anita Kinney) by family members 
who participated in the REACH noninferiority trial, we expected that they would know 
about the genetic counseling visit. When women reported that their family member 
“shared nothing,” it created a challenge in our interview flow. The next question in the 
interview asked women to rate how well they understood the information that was shared. 
Initially, we entered zero as if they gave this response, figuring that our participants had 
zero understanding if zero information was shared. However, as more data came in we 
found that some women reported a very high level of understanding when very little 
information was given. They would say something like, “all she told me is that she 
doesn’t have the gene, so yeah, I understood that very well.” We then changed our 
interview format so that if women reported no information was shared, we skipped the 
item about level of understanding. Thus, we have 16 women who reported that their 
family member shared nothing. For 5 of these women, we rated them as zero 
understanding and for 11 we rated them as “missing” (see Table 5.4).  Generally, as less 
information was shared, women rated their understanding of the information higher (see 
Figure 6.2).  This could be interpreted as smaller amounts of information were easier to 
understand. It seems that it was easier for women to understand small amounts of 
information. On average, women rated the amount of information shared as a 
2.04(SD=1.53) on a 0-5 scale and their understanding as a 3.57(SD=1.49) on the 0-5 
scale.  
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Sharing Information with Primary Care Providers 
Women were asked whether they had shared information with their primary 
health care providers about (1) their family history of cancer, (2) their sister or mother’s 
genetic counseling, or (3) their sister or mother’s test results. Two women indicated that 
they “didn’t know” the answer to one or more of those questions. Nearly 90% of women 
had shared information about their family history of cancer with their primary care 
providers, but very few indicated that they shared information about their family 
member’s genetic counseling or genetic test results (see Table 6.2). 
Summary Letter/ Informational Pamphlet 
Women were asked whether they were aware that their sister or mother received a 
summary letter about their genetic counseling session. Only 12 women (14.1%) reported 
that they were aware of such a letter. Of those who were aware of a letter, 7 women saw 
the letter and 2 were given a copy to keep. Three women report that they shared 
information about the letter with their primary care provider. Two women report that 
their primary care provider received a copy of the letter. Of the 12 women who were 
aware of the letter, 3 (25%) indicated that some of the information in the letter applies 
strongly to them (see Table 6.3). Four women reported that they were aware of an 
informational pamphlet that their sister or mother received as a part of the genetic 
counseling session. Two women reported that they saw the pamphlet and 1 reported that 
she read it. On a zero to five scale, these 3 women rated the pamphlet as applying to them 
at levels three, four, and five, with five representing “some information in the pamphlet 
applies strongly to me. None of the women shared the pamphlet with their primary care 
provider.  
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Mammography 
During the telephone interview, women were asked questions related to their 
understanding and use of mammography. After a definition was read, all women in the 
sample reported that they had previously heard of a mammogram.  Most women reported 
that a doctor or a family member recommended that they receive a mammogram. 
We asked how often mammography was recommended. Response options 
included (1) just one time (2) every year (annually), (3) every 2 years, and (4) other. Most 
women (86.8%) reported received recommendations from their primary care providers 
for annual mammography. In the interview, we allowed for the option of free response 
answers to the question of how often mammography was recommended in addition to the 
options we provided. The intent of this free response option was to allow for clarification 
of the “other” response. However, some women chose to clarify their answers even 
though they selected one of our other options. Free response answers to the question of 
how often mammography was recommended were summarized by the interviewers as 
follows: 
o told to start having them, no specific time fame,  
o starting at an earlier age than normal,  
o every 3 months for a while  
o now and every 6 months 
o every 2-3 years,  
o every 3 years,  
o every 5 years,  
o 1st annual, then every three, now annual again,  
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o one doctor - one time only because of a lump, second doctor “periodic” 
o just heard that it was important in the last 5 years  
Occasionally a woman noted that she “didn’t know” whether a certain type of 
person (e.g., doctor) recommended a mammogram or not. For the purposes of this study, 
we counted these women as not receiving the recommendation because in our perception, 
a recommendation not recalled is as good as a recommendation not received. One woman 
in the sample had a mammogram but states it was never recommended by anyone that 
she have it. This woman didn’t give a response for how often mammography was 
recommended because it did not apply. This particular participant with a lifetime risk of 
16.2 according to the Claus model receives mammograms annually and plans to continue 
to receive them annually despite them not being recommended. She did state that her 
doctor looks at her mammograms each year at her physical exam.  
All but 1 woman in the sample had previously received a mammogram. Of the 85 
participants, 76 (89.4%) received their most recent mammogram as a screening test. Of 
those 76, 68 (89.5%) received their most recent screening mammogram within the past 2 
years (see Table 4.7). The number of months since most recent mammogram ranged from 
zero to 103 with an average of 12.74 (SD=19.31). More than 90% of women received 
their most recent mammogram as part of a routine screening (see Table 6.4). The one 
woman in the sample who had never had a mammogram reported that she had received a 
recommendation for a mammogram from her doctor. 
To assess a pattern of mammography, we also asked about the mammogram 
before the most recent. Nearly 80% of the sample had received a mammogram within 2 
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years of the most recent (see Table 6.5) and the vast majority of those were also part of 
routine screening (see Table 6.6). 
Nearly all women in the sample plan to receive annual mammography in the 
future (see Table 6.7). Women were also given the option of a free response related to the 
frequency of their mammography plans. Free responses were summarized by the research 
team as follows: 
o Annual to 18 months 
o Every 1-2 years 
o Every 3-4 years 
o Every 4-5 years 
o Every 5 years 
o Every 7 years 
o Unless directed otherwise 
Magnetic Resonance Imaging (MRI) 
Women were also asked about their familiarity with and use of MRI. In this 
sample, only 52.9% of participants had ever heard of breast MRI before the test was 
described in the telephone interview. Thirteen women reported receiving a 
recommendation for breast MRI and 7 reported that they had received a breast MRI (see 
Table 6.8). These 7 women estimated that their MRI took place between 5 and 65 months 
ago with a mean of 37.3 months (over 3 years) ago. Two women reported that they had 
their MRI for screening purposes and the other 5 reported that it was because of a 
symptom or a follow up from a previous abnormal test (see Table 6.9). Only 2 women 
reported receiving more than one MRI, with 1 reporting that the MRI prior to the most 
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recent was for screening and the other reporting that it was a follow-up from an earlier 
abnormal test.  
 The question, “do you plan to receive breast MRIs in the future?” did not perform 
as well as we had hoped. Many women reported that they had never heard of an MRI, 
had never been recommended to have an MRI, and had never had an MRI. According to 
our survey, these women were still supposed to be asked whether they planned to receive 
breast MRI in the future or not. Sometimes the question was skipped by the interviewer. 
Often women answered “if it is recommended I will.” One woman said, “It sounds like a 
good idea.” The intent of this question was to determine whether or not women had plans 
to screen in the future with MRI; however, most women did not know and struggled to 
answer this question with a simple “yes,” “no,” or “don’t know.” After several 
interviews, the interviewers began to code responses of “if it is recommended” as a 
“don’t know” since women could not know whether or not it would be recommended in 
the future. Because the answers to this question were coded inconsistently the results are 
not presented here. 
Health Care 
The vast majority of women reported that they had health insurance had a 
physician as their primary care provider. A few women had a Nurse Practitioner or a 
Physician Assistant as their primary care provider (see Table 6.10). 
Subject Burden 
Most women (72.9%) reported that it took 30 minutes or less to complete the 
survey, 22.4% took between 30 and 60 minutes, and 4.7% took more than 1 hour to 
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complete the survey. Most women (74.1%) completed the survey in one sitting. 
Instructions encouraged participants to complete the survey independently. Most women 
(96.5%) reported that they completed the survey independently; however, 3 women 
reported they did have help.  
There was space at the end of the survey for additional comments. One participant 
noted that she had her husband help with the math portion. Another simply claimed, “I 
hate math!” Several participants felt like they did not know many of the answers on the 
knowledge questions. One noted that the study made her feel less worried about 
developing breast cancer. 
We asked participants twice if we could contact them in the future for research, 
on the survey and during the telephone interview. On the survey, 81 women (95.3%) 
marked yes, 2 women marked no, and 2 women did not answer the question. At the 
conclusion of the interview, women were asked verbally if they would allow us to contact 
them again; 78 (91.8%) agreed to future contact while 7 (8.2%) did not.  
The number of telephone interviews conducted by members of the research team 
include Deborah O. Himes 39(45.9%) and two research assistants: Amy Hullinger 
26(30.6%), and Ali Hatch 20 (23.5%). Both research assistants were undergraduate 
students in a baccalaureate nursing program. Both completed privacy (HIPPA) and 
human subjects research training (CITI).  
Specific Aims 1 and 2 
The results related to the first two specific aims are covered thoroughly in the 
proposed manuscripts and so are not repeated here. The first two specific aims were: 
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Specific Aim 1 
Specific aim 1 was to calculate an estimate of women’s lifetime risk for breast 
cancer and compare this estimate to women’s perceived risk about developing future 
breast cancer. This aim included three research questions: 
1. What is the average calculated risk for breast cancer using the Claus model, 
the BRCAPRO model, and the Gail model for women (with sisters or mothers 
who received genetic counseling and indeterminate negative BRCA1/2 
results)? 
2. What percent of women (with sisters or mothers who received genetic 
counseling and indeterminate negative BRCA1/2 results) qualify for annual 
MRI breast screenings based on NCCN guidelines (a lifetime risk for breast 
cancer > 20%) based on the Claus or the BRCAPRO risk calculators?  
3. What percent of women (with sisters, mothers, or daughters who have 
received genetic counseling and had indeterminate negative BRCA1/2 results) 
over-estimate vs. underestimate their risk as compared to their calculated risk 
for breast cancer?  
Specific Aim 2 
Specific aim 2 was to determine whether self-reported screening plans and self-
described screening practices are in alignment with risk-based guidelines in women 
whose first-degree female relatives have received genetic counseling and indeterminate 
negative BRCA1/2 test results.  This aim includes two research questions: 
1. What percent of women whose first-degree female relatives have received 
indeterminate negative test results report that they are screening for breast 
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cancer according to risk-based guidelines, i.e., are women who have >20% 
lifetime risk of developing breast cancer, receiving both annual mammogram 
and MRI (as recommended by the National Comprehensive Cancer Network 
(NCCN) and the American Cancer Society (ACS))? 
2. What percent of women whose first-degree female relatives have received 
indeterminate negative test results report receiving recommendations for 
breast cancer screening from their primary care physicians or from another 
source that are consistent with the National Comprehensive Cancer Network 
(NCCN) and American Cancer Society (ACS) guidelines based on the level of 
risk (i.e., annual mammography if < 20% lifetime risk and > 40 years of age; 
mammography with MRI if > 20% and > 30 years of age)? 
Specific Aim 3 
 The third study aim involved statistical analysis using latent variables. This 
specific aim changed from proposal defense to study implementation because it became 
evident that the variable “understanding of information shared” was not a reliable 
variable and because the third research question became irrelevant after the second 
question was answered in the affirmative. Below is the initial specific aim with 
accompanying research questions followed by an explanation about how the questions 
changed and how they were answered. 
Specific Aim 3  
Specific aim 3 was to determine the contribution of a woman’s self-rated 
understanding of genetic health information, shared by her first-degree female relative 
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about genetic counseling sessions, to her risk perception and to the accuracy of her 
perception of individual lifetime risk for breast cancer while controlling for confounding 
influences of factors known to contribute to risk perception, including age, education, 
health literacy, numeracy, knowledge about breast cancer genetics, and self-reported 
distress related to family history of breast cancer and perceived personal risk for breast 
cancer. This aim includes the following research questions: 
1. What is the magnitude of the relationship between calculated lifetime risk for 
breast cancer and perceived lifetime risk for breast cancer?  
2. Does a woman’s self-rated understanding of genetic health information shared 
by her first-degree relative moderate the accuracy of risk perception?  
3. Does a woman’s self-rated understanding of genetic health information shared 
by her first-degree relative predict risk perception?   
A model with latent variables was developed to test relationships between 
calculated risk and perceived risk, a relationship we are referring to as accuracy of risk 
perception. Additionally, we wanted to assess whether a woman’s self-rated 
understanding of genetic health information shared by her sister or mother might predict 
her risk perception or moderate the accuracy of her risk perception (see Figure 3.2). 
Covariates that may influence risk perception were selected for the initial model based on 
Tilburt’s Model of Risk Perception in High Risk Populations (2011). 
As we began to collect data, we realized that a woman’s self-rated understanding 
of information shared may not be the best indicator to use. Many women reported that 
their sisters or mothers shared very little information. On a 0 to 5 scale, the mean 
response was 2.04 (SD=1.53). Nearly 19% reported that their sister/mother shared 
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nothing about the genetic counseling session. We were unable to assess how well women 
understood information when they reported that “nothing” was shared. Our initial thought 
was to mark these as having zero understanding. However, as the data came in, we 
noticed that quite often, women who said very little was shared reported high levels of 
understanding for that little bit of information (see Figure 6.2). We determined that a 
rating of amount of information shared would be a better variable to include (see redrawn 
Latent Variable Model in Figure 6.3).  
Statistical Analysis with Latent Variables 
Data were assessed for missing items and outliers using descriptive statistics and 
appropriate figures as described in the section on missing data.  
Dependent variables for the latent variable model (quantitative and verbal 
perceived risk and calculated risk by Claus and BRCAPRO) were evaluated for non-
normality as normality is an assumption of SEM.  MPlus has a sophisticated model in 
that the assumption of normality is not required for the observed explanatory covariates 
(distress, numeracy, and knowledge in our model). They can be of arbitrary distribution 
and everything is conditioned on them regardless of their values (Muthén & Muthén, 
1998-2010).   
Multivariate normality is, however, a requirement for the indicators of latent 
variables (verbal and quantitative perceived risk and calculated risk by Claus and 
BRCAPRO). These indicator variables were analyzed for normality by looking at 
histograms and by looking at the absolute value of skewness over the standard error of 
the skewness. Transformations for variables with absolute values greater than 2 were 
attempted to see if greater normality could be achieved.  To achieve greater distribution 
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normality, Clause Lifetime Risk was transformed by taking the log (y+1, to avoid zeros) 
and the quantitative estimate of perceived risk was transformed by adding one and taking 
the log (y+1 to avoid zeros). 
Evaluating the Moderating Effect of Information Shared  
 on Agreement Between Perceived and Calculated Risk 
An attempt was made to estimate the model as originally conceptualized, 
including all covariates to evaluate the moderating effect of the amount of information 
shared on the relationship between calculated risk and perceived lifetime risk. This model 
failed to converge, indicating that the model did not fit the data. Therefore, a simplified 
model consisting of the two latent variables, their dependent (indicator) variables and the 
amount of information shared stratified by two levels, was created. This simplified model 
also failed to converge. An additional transformation was conducted to bring the 
variances between the quantitative and qualitative indicators of perceived risk into similar 
ranges. The quantitative was multiplied by 10. This linear transformation has no effect on 
the statistics but makes the iterative process more stable. 
A model including all covariates also failed to converge, perhaps due to small 
sample size. Covariates were removed and then added back in a stepwise fashion, 
retaining only those that were found to be statistically significant (p<0.05). Ultimately, 
covariates retained in the model included numeracy, knowledge about breast cancer 
genetics, and distress (see Figure 6.3). Age, education, and health literacy were found not 
to be significant and were not included in the final model.  
We had considered including a family grouping variable.  However, the intraclass 
correlation of the average of the four dependent variables was .022, indicating the 
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observations were essentially independent of family grouping. Therefore, we did not 
include the family grouping variable. Most women belonged to a unique family. The final 
sample included 85 women belonging to 62 family clusters. Considering family group as 
a cluster is important in theory, but in this case, the contribution was negligible.   
Moderation 
It was hypothesized that the amount of information shared moderates the 
relationship between risk perception and calculated risk. The effect of moderation was 
evaluated by comparing two models, one with moderation (allowing different slopes and 
intercepts for the regression of perceived risk on calculated risk) and one with no 
moderation (with slopes and intercepts equal in the two strata). 
The variable “information shared” was stratified into high and low groups based 
on the amount of information women reported their family member had shared with them 
about the genetic counseling session. The low group (n=68) included women who 
responded between 0 and 3 and the high group (n=17) included women who responded 4-
5 on the Likert scale. Stratifying on the basis of all six options (0-5) that women could 
have chosen was not feasible due to small sample size. We evaluated splitting the group 
into low and high based on different breaking points (<1, <2, and <3) and all yielded a 
similar pattern. We also attempted a three-group solution with a low group (0,1) a 
medium group (2) and a high group (3-5). This split showed a proper low, medium, high 
“dose” effect with a p-value of (0.15), indicating that with the current sample size, we did 
not achieve significance with a three-level split for the variable amount of information 
shared. Splitting the sample into two groups reflecting high and low amounts of shared 
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information (0-3, 4-5 responses) seemed to be the best split and demonstrated a 
significant moderation effect with our sample size. 
Model Fit 
A chi square test was conducted to assess significance of the difference of 
deviance between the models. A difference in chi-square between the model with 
moderation and the model where the groups were constrained to be equal was 4.79 (df=1) 
(p = 0.287). This indicates significant improvement in model fit when groups are not 
constrained to be equal. Fit indices for the alternative model assessing moderation effect 
of amount of information shared were: Chi-Square Test of Model Fit 22.550 (df=28, 
p=.7552), RMSEA = 0.0000, 90% CI [0.000-0.086].  A nonsignificant chi-square 
indicates that the model–implied covariance matrix is consistent with the population 
covariance matrix and supports the model; in other words, the model and the data are not 
significantly different (Kline, 2010). RMSEA is below 0.05, indicating good model fit .  
Covariates numeracy, knowledge, and distress were all significant (p< 0.05). Of 
the three, distress had the greatest impact on perceived risk (0.513), slightly more than 
double the impact of numeracy (0.245), and knowledge (-0.229). Where higher levels of 
numeracy and distress were associated with higher levels of perceived risk, however, 
higher levels of knowledge about breast cancer genetics were associated with lower 
perceived risk (see Figure 5.1). 
Individual parameter estimates for this model are presented in Table 6.11 (for the 
Low information group) and Table 6.12 (for the high information group). It can be noted 
that regression relationships with observed explanatory covariates were equal across 
strata, but that the regression of perceived risk on calculated risk and intercept for 
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perceived risk differed based on amount of information shared.  Note that the group with 
a low amount of information shared had a lower accuracy of risk perception (0.326) or 
agreement between perceived and calculated risk. The group with a higher amount of 
information shared had over double the level of accuracy of risk perception (0.707) (see 
shaded areas on Table 6.11 and Table 6.12).  
Thus, we have the answer to the first and second research questions of specific 
aim 3: The magnitude of the relationship between calculated and perceived lifetime risk 
for breast cancer is moderated by the amount of information a woman has received by her 
sister or mother who attended genetic counseling. Women who reported higher amounts 
of information shared had over twice the agreement as those with low amounts of 
information shared (0.707 vs. 0.326 – standardized estimates)  
 Because the moderating effect was found, answering the third research question 
of specific aim 3, “Does a woman’s self-rated understanding of genetic health 
information shared by her first-degree relative predict risk perception?” becomes 
irrelevant. This question assumes a single relationship of amount of information shared 
on risk perception. There is not a single relationship between the latent variables for all 
individuals. To ignore the moderating relationship and run a model assessing direct effect 
would be to purposely choose a model that fits the data more poorly and analyze it.     
Discussion 
A woman’s rating of amount of information shared was found to moderate the 
agreement between the latent variables “calculated lifetime risk for breast cancer” and 
“perceived lifetime risk for breast cancer.” Higher levels of information shared resulted 
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in higher parameter estimates (see Table 6.11 and Table 6.12).  See the results and 
discussion in Chapter 5 for further explanation.    
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Figure 6.1  
Perceived risk – comparative quantitative 
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Figure 6.2  
Information from family member’s genetic counseling session 
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Figure 6.3  
Revised latent variable model 
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Table 6.1 
      Self-reported health literacy 
                        
Question   Response n (%)   Points M SD 
How often do you have 
someone help you read 
hospital materials? 
  
     
3.81 0.45 
 
Never 71 (83.5) 
 
4 
  
 
Occasionally 12 (14.1) 
 
3 
  
 
Sometimes 2 (2.4) 
 
2 
  
 
Often 0 (0.0) 
 
1 
  
 
Always 0 (0.0) 
 
0 
  
  
Total 85 (100.0) 
    How confident are you 
filling out medical 
forms by yourself?  
          3.52 0.75 
 
Extremely 54 (63.5) 
 
4 
  
 
Quite a bit 25 (29.4) 
 
3 
  
 
Somewhat 4 (4.7) 
 
2 
  
 
A little bit 1 (1.2) 
 
1 
  
  
Not at all 1 (1.2) 
 
0 
  
  
Total 85 (100.0) 
    How often do you have 
problems learning about 
your medical condition 
because of difficulty 
understanding written 
information?  
            3.56 0.63 
 
Never 52 (61.9) 
 
4 
  
 
Occasionally 28 (33.3) 
 
3 
  
 
Sometimes 3 (3.6) 
 
2 
  
  
Often 1 (1.2) 
 
1 
  
  
Always 0 (0.0) 
 
0 
      Total 85 (100.0)         
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Table 6.2     
 Information shared with PCP 
           
     n (%)   
Family History of Cancer     
   Yes 76 (89.4) 
   No  9 (10.6) 
   Don't Know 0 (0.0) 
   Total 85 (100.0) 
 Sister/ Mother's Genetic Counseling 
   Yes 21 (24.7) 
   No  62 (72.9) 
   Don't Know 2 (2.4) 
   Total 85 (100.0) 
 Sister/ Mother's Test Results     
   Yes 19 (22.4) 
   No  65 (76.5) 
   Don't Know 1 (1.2) 
   Total 85 (100.0)   
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Table 6.3       
Genetic counseling summary letter   
          
    n (%)   
Aware of the letter       
  Yes 12 (14.1)   
  No  70 (82.4)   
  
Don't 
Know 3 (3.5)   
  Total 85 (100.0)   
Sister/ Mother told me about it     
  Yes 8 (9.4)   
  No  4 (4.7)   
  Total 12 (100.0)   
I saw it but didn't keep a copy     
  Yes 5 (41.7)   
  No  7 (58.3)   
  Total 12 (100.0)   
I received a copy to keep       
  Yes 2 (16.7)   
  No  8 (66.6)   
Don't Know 2 (16.7)   
  Total 12 (100.0)   
I read the letter       
  All 2 (28.6)   
  Part 3 (42.8)   
  None 2 (28.6)   
  Total 7 (100.0)   
I understand the letter       
 not at all = 0 0 (0.0)   
  1 0 (0.0)   
  2 1 (8.3)   
  3 5 (41.8)   
  4 4 (33.3)   
very well = 5 1 (8.3)   
  Missing 1 (8.3)   
  Total 12 (100.0)   
Some information in the letter applies to me 
  none =0 0 (0.0)   
  1 0 (0.0)   
  2 2 (16.7)   
  3 2 (16.7)   
  4 4 (33.3)   
some  strongly = 5 3 (25.0)   
  Missing 1 (8.3)   
  Total 12 (100.0)   
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Table 6.4       
Reason for most recent mammogram 
   
          
Reason     n (%) 
Part of routine exam of checkup 76 (89.4) 
Because of a symptom or health problem 3 (3.5) 
Follow-up from earlier abnormal test 5 (5.9) 
Have not had a mammogram 1 (1.2) 
Total:     85 (100.0) 
 
 
 
Table 6.5 
   When was the mammogram before the most recent? 
            
      n (%) 
Most recent was the first (no prior) 5 (5.9) 
A year ago or less before most recent 49 (57.6) 
More than 1 but not more than 2 years before the most recent 19 (22.4) 
More than 2 but not more than 3 years before the most recent 3 (3.5) 
More than 3 but not more than 5 years before the most recent 4 (4.7) 
More than 5 years before the most recent 4 (4.7) 
Has not had a mammogram 1 (1.2) 
Total:     85 (100.0) 
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Table 6.6       
Reason for mammogram before the most recent   
          
Reason     n (%) 
Part of routine exam of checkup 73 (85.9) 
Because of a symptom or health problem 4 (4.7) 
Follow-up from earlier abnormal test 2 (2.4) 
Never had mammogram, or most recent was first 6 (7.1) 
Total:     85 (100.0) 
 
 
Table 6.7       
Mammography future intentions 
 
  
          
Question   n (%) 
Plan to receive future mammography?     
  Yes   83 (97.6) 
  No   1 (1.2) 
  Missing   1 (1.2) 
  Total   85 (100.0) 
How often mammography future?     
  Annually   72 (84.7) 
  Every 2 years 4 (4.7) 
  Less often than every 2 years 1 (1.2) 
  Other    6 (7.1) 
  Missing   2 (2.4) 
  Total   85 (100.1) 
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Table 6.8       
Breast MRI recommendations   
          
Question     n (%) 
Ever heard of breast MRI     
  Yes   45 (52.9) 
  No   40 (47.1) 
Ever had breast MRI       
  Yes   7 (8.2) 
  No   74 (87.1) 
Anyone recommend breast MRI?     
  Yes   13 (15.5) 
  No   72 (84.7) 
    Total 85 (100.0) 
Who recommended a breast MRI? 
  Family member? 2 (2.4) 
  Doctor?   8 (9.5) 
  Nurse Practitioner? 1 (1.2) 
  
Physician's 
Assistant? 0 (0.0) 
  
Other kind of 
person? 4 (4.8) 
How often recommended?     
  Just once   7 (8.3) 
  Annually   2 (2.4) 
  Other    4 (4.8) 
    Total 13 (100.0) 
 
 
Table 6.9 
Reason for most recent breast MRI 
 
  
          
Reason     n (%) 
Part of routine exam of checkup 2 (2.4) 
Because of a symptom or health problem 3 (3.6) 
Follow-up from earlier abnormal test 2 (2.4) 
Total:     7 (100.0) 
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Table 6.10 
Health insurance and type of PCP 
          
Category   n (%) 
     Health Insurance 
  
 
Yes 
 
78 (91.8) 
 
No 
 
1 (1.2) 
PCP Type 
   
 
Doctor 
 
69 (81.2) 
 
Nurse Practitioner 5 (5.9) 
 
Physician Assistant 4 (4.7) 
 
None 
 
7 (8.2) 
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Table 6.11 
Parameter estimates for latent variable model: Low* amount of information shared 
 
                    
    
Parameter 
  Estimate 
Standard 
Error 
Est/SE p value 
Standardized 
Estimate 
Measurement Relationships 
 
    
 
  
Calculated Risk by  
 
    
 
   
 BRCAPRO 
 
2.960 0.326 9.090 0.000 0.702 
   
Claus 
 
1.000 0.000 999.000 999.000 1.000 
  
Perceived Risk by 
 
    
 
   
 Verbal 
 
0.121 0.018 6.842 0.000 0.827 
   
 Quantitative 
 
1.000 0.000 999.000 999.000 0.846 
  
Claus 
 
    
 
   
Intercept 
 
2.433 0.056 43.142 0.000 5.232 
   
Residual Variance 
 
0.000 0.000 999.000 999.000 0.000 
  
BRCAPRO 
 
    
 
   
Intercept 
 
9.506 0.225 42.159 0.000 4.847 
   
Residual Variance 
 
1.952 0.299 6.519 0.000 0.507 
  
Perceived Risk  Verbal 
 
    
 
   
Intercept 
 
2.953 0.244 12.109 0.000 3.550 
   
Residual Variance 
 
0.219 0.069 3.185 0.001 0.316 
  
Perceived Risk  
Quantitative 
 
    
 
   
Intercept 
 
26.442 2.077 12.734 0.000 3.931 
   
Residual Variance 
 
12.857 4.524 2.842 0.004 0.284 
Structural Relationships 
     
 
  
Perceived risk on 
Calculated  (Accuracy)  
3.992 1.354 2.949 0.003 0.326 
  
Perceived risk on Numeracy 
 
7.620 3.106 2.454 0.014 0.258 
  
Perceived risk on 
Knowledge  
-7.187 2.930 -2.453 0.014 -0.225 
  
Perceived risk on Distress 
 
4.328 0.877 4.936 0.000 0.491 
 
 
Perceived risk Intercept 
 
0.000 0.000 999.000 999.000 0.000 
 
*Perceived level of information shared = 0-3 (n=68)  
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Table 6.12 
Parameter estimates for latent variable model: High* amount of information shared 
 
 
    Parameter   Estimate 
Standard 
Error Est/SE P value 
Standardized 
Estimate 
Measurement Relationships 
     
 
 
 
Calculated Risk by  
      
 
  
 BRCAPRO 
 
2.960 0.326 9.090 0.000 0.702 
 
  
Claus 
 
1.000 0.000 999.000 999.000 1.000 
 
 
Perceived Risk by 
      
 
  
 Verbal 
 
0.121 0.018 6.842 0.000 0.877 
 
  
 Quantitative 
 
1.000 0.000 999.000 999.000 0.892 
 
 
Claus 
      
 
  
Intercept 
 
2.433 0.056 43.142 0.000 5.232 
 
  
Residual Variance 
 
0.000 0.000 999.000 999.000 0.000 
 
 
BRCAPRO 
      
 
  
Intercept 
 
9.506 0.225 42.159 0.000 4.847 
 
  
Residual Variance 
 
1.952 0.299 6.519 0.000 0.507 
 
 
Perceived Risk  Verbal 
      
 
  
Intercept 
 
2.953 0.244 12.109 0.000 3.031 
 
  
Residual Variance 
 
0.291 0.069 3.185 0.001 0.230 
 
 
Perceived Risk  
Quantitative 
      
 
  
Intercept 
 
26.442 2.077 12.734 0.000 3.336 
 
  
Residual Variance 
 
12.857 4.524 2.842 0.004 0.205 
Structural Relationships 
      
 
 
Perceived risk on 
Calculated  (Accuracy) 
 
10.744 2.899 3.706 0.000 0.707 
 
 
Perceived risk on 
Numeracy 
 
7.620 3.106 2.454 0.014 
0.195 
 
 
Perceived risk on 
Knowledge 
 
-7.187 2.930 -2.453 0.014 
-0.246 
 
 
Perceived risk on Distress 
 
4.328 0.877 4.936 0.000 0.599 
  
Perceived risk Intercept 
 
0.923 1.558 0.592 0.554 0.131 
 
* Perceived level of information shared = 4 -5 (n=17) 
  
CHAPTER 7 
 
SUMMARY 
 Sisters and daughters of women who have received genetic counseling and testing 
for breast cancer have the potential to receive personal genetic information about their 
own risk for breast cancer. This is important because women often make decisions about 
screening and prevention based in part on their perceptions and women in these families 
may be at higher risk than the average population. The American Cancer Society (ACS) 
and other organizations have recommended annual breast MRI in addition to annual 
mammography for women at elevated-risk for breast cancer, defined as having a lifetime 
risk of  >20% based on estimation models that take extensive family history into account. 
Genetic testing and counseling provides information important to family members 
beyond the person receiving the testing.  
 If the pattern of cancer in a family is suspicious for familial or hereditary cancer, a 
woman who has had cancer may undertake genetic testing for a BRCA1/2 mutation. 
Women and their families go into genetic counseling hopeful that they will walk away 
with some amount of certainty. Women who receive testing want to know, “will I get 
cancer again or not?” and “are my sisters and daughters going to get cancer or not?” 
Unfortunately risk assessment is not a process that ends in certainty (Bylund et al., 2012). 
It is a process that ends in odds ratios and percent chance over a specified number of 
years.  
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 The majority of women who have breast cancer and are the first person in their 
family to receive BRCA1/2 testing receive an indeterminate negative test result, meaning 
that no harmful mutation was identified. However, women in these families may remain 
at risk-based on the familial pattern of cancer in the family. In families with an 
indeterminate negative test result, uncertainty persists (S. C. O'Neill et al., 2006). 
Unaffected sisters, mothers, and daughters of these women do not have the option to be 
tested for a BRCA1/2. It is not standard practice to test unaffected women because (1) if a 
mutation is not found, they are no further along in their understanding of risk than they 
were before because it is not possible for them to get a true negative result and (2) 
chances of finding a mutation in an unaffected woman from a family where the most 
likely candidate for BRCA1/2 testing has already tested indeterminate are extremely 
small.  
 Recommendations for those identified with a dangerous BRCA1/2 mutation are 
clearer. Women with mutations know they are at high risk and have specified prevention 
and surveillance methods open to them. Their family members not diagnosed with cancer 
can be tested if they choose and they will receive either a positive or a true negative test 
result. Then women in the family who test positive will also know they are at high risk. 
Women who test negative are truly negative having no greater risk than the general 
population. Neither women with positive or negative results know for certain that they 
will or will not get breast cancer, but at least they know that they do or do not carry the 
dangerous gene mutation and that is one level of certainty.  
 It is difficult for women with a sister or mother with indeterminate BRCA1/2 test 
results to know what to think or what they should do about their own risk for breast 
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cancer. Women may talk about risk in their family, but information shared by the genetic 
counselor about family risk analysis is often not shared accurately with the other women 
who do not have cancer and did not attend genetic counseling (Vos, Menko, et al., 2011).  
 Primary care providers are responsible to help women navigate muddy waters of 
understanding their risk for breast cancer and screening according to risk-based 
guidelines. Advising women about risk is complex. Cancer in women from families with 
breast cancer predisposing mutations only account for 5% of all breast cancers. A much 
larger portion comes from women in families that are at elevated-risk where no 
autosomal dominant gene mutation has been identified (P. D. P. Pharoah, Antoniou, 
Easton, & Ponder, 2008).  It is important to stratify women based on their risk because 
more intensive screening is advised for women at high risk. In the absence of an 
identified mutation, risk in the family must be assessed based on the family pedigree and 
personal risk factors. Calculating risk can be confusing as there are several different risk 
calculators and each provides different calculations for the same woman. Further 
complicating matters, professional organizations provide conflicting recommendations 
regarding risk-based screening. 
 Women who receive genetic counseling and testing are typically provided with a 
genetic counseling summary letter that among other things identifies other members in 
the family who may be at elevated-risk for breast cancer and encourages women to alert 
these family members that they may be at risk and require additional screening or be a 
candidate for chemoprevention. A typical excerpt from a summary letter might include:  
As we mentioned earlier, your female relatives are still considered at increased 
risk for developing breast cancer. We recommend that they have annual clinical 
breast exams starting by age 25 and begin having annual mammograms at age [10 
years prior to dx OR 35, whichever comes first]. The American Cancer Society 
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currently recommends MRI be added to the screening plan for women with a 20% 
or greater lifetime risk for breast cancer. Your relatives may not meet this 
criterion based on your history alone, but this additional screening may be 
appropriate if they have other risk factors or dense breast tissue. Medications have 
been found to help reduce breast cancer risk. Women who take medications such 
as tamoxifen for 5 years can reduce their risk of breast cancer by as much as 50%. 
(W. Kohlmann, personal communication, July 29, 2011)   
 
 Genetic counselors typically  do not contact relatives of their patients directly 
because of privacy concerns. However, research has shown that even in families where a 
positive BRCA1/2 mutation has been found, all family members do not receive the 
information that was shared in genetic counseling. In families where an indeterminate test 
result was received, the amount of information shared is even lower. Often, information 
that is shared is inaccurate.  
 It should be noted that it is not necessary for information to be shared by the 
woman who received genetic counseling with her sister or daughter for risk-based care to 
be provided. A woman’s risk for breast cancer should be assessed based on the family 
history whether an indeterminate BRCA1/2 test has been received or if no BRCA testing 
has been undertaken in the family. We hypothesized that having a family member go 
through the process of counseling and testing might spark interest in women, prompting 
them to ask questions of their sisters and mothers, and also of their primary care 
providers about their own risk for breast cancer.  
Purpose 
 The purpose of this cross-sectional descriptive study was to assess risk perception 
and calculated risk in sisters and daughters of women who had received indeterminate 
BRCA1/2 test results. Additionally we sought to determine whether women were 
receiving breast cancer screening recommendations and participating in breast cancer 
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screenings that are in accordance with risk-based guidelines. We wanted to understand 
the impact of information shared about genetic counseling sessions by close relatives on 
the accuracy of risk perception for women potentially at increased familial risk of breast 
cancer. 
 The first specific aim of this study related to assessing women’s risk for breast 
cancer. The aim had three parts: (1) to calculate women’s risk for breast cancer, (2) 
determine how many women would be considered to be at increased or high risk (thus 
qualifying for more intensive screening according to certain guidelines), and (3) 
determine how many women over-estimate vs. underestimate their risk. The second 
specific aim for this study involved (1) determining whether women were receiving 
mammography and breast MRI screenings according to risk-based guidelines and (2) 
whether their health care providers were recommending that they do so. The third 
specific aim asked (1) how accurate women were in their risk perceptions and (2) 
whether the amount of information shared by their sisters and mothers who attended 
genetic counseling influenced their accuracy of perceptions about risk for future breast 
cancer.  
Methods 
 Following IRB approval, we sent potential participants an introductory letter 
followed up by a telephone call to screen women for eligibility and invite them to 
participate. These women had previously completed a study titled REACH-pilot. Women 
had been referred to the REACH-pilot study by their sisters or mothers who had received 
genetic counseling and testing with indeterminate negative BRCA1/2 results.  
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 Women who agreed to participate completed a written survey and provided a 
three-generation pedigree as part of a mailed packet. They also participated in a telephone 
interview. Data were collected about risk perception for future breast cancer using verbal 
and quantitative estimates. We assessed factors that are known to influence risk 
perception, including distress, knowledge, health literacy, and numeracy. We calculated 
women’s objective risk for breast cancer using three software-based statistical models 
(Gail, Clause, and BRCAPRO). We asked women how much information their sisters or 
mothers had shared with them related to the sister’s/mother’s genetic counselling session 
and how well they understood that information. Further, we asked about whether they 
were aware if their sister/mother received a genetic counseling summary letter or an 
informational pamphlet about breast cancer genetics. Finally we collected information 
about what recommendations women had received about breast cancer screening and 
about their recent breast cancer screenings. 
Analysis 
 We completed a statistical analysis using latent variables to test the influence of 
amount of information shared by sisters and mothers about genetic counseling on a 
woman’s accuracy of risk perception. The model was based broadly on the Common 
Sense Model of Self-regulation by Leventhal et al. (2003) and informed by Tilburt et al. 
(2011).  We operationalized accuracy of risk perception as the level of agreement 
between perceived and calculated risk. 
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Results 
Specific Aim 1  
 The average lifetime risks for women in this study varied by model used and were 
found to be: Gail 20.07 (SD=6.6), Claus11.84 (SD=6.7) and BRCAPRO 9.53 (SD = 2.0). 
Our results were consistent with previous findings that the Gail model estimates tend to 
be higher than the Claus model for most participants (McTiernan et al., 2001). Nine 
women, 10.7% of the sample, had a lifetime risk as calculated by the Claus model that 
was 20% or higher and are therefore considered to be at elevated-risk for breast cancer. 
 We considered women to “over-estimate” their risk according to a given 
calculator if they estimated more than 3% higher than that calculator. Conversely, if 
women’s estimates were more than 3% below a given model calculation, they were 
considered to have underestimated according to that model. It was rare for all three risk 
calculators to provide lifetime risk estimates within 6% of one another. Therefore, it 
would be nearly impossible for most women to be considered “accurate” by all three risk 
calculators; in fact, some women were counted as overestimating by one model and 
underestimating by another. Women tended to over-estimate their risk compared to 
calculations obtained using the Claus and BRCAPRO models (73.8% and 78.6%, 
respectively). On the other hand, 57.1% of women either underestimated or gave similar 
estimates compared to the Gail model results. 
Specific Aim 2 
 We found that 88.2% of the women in our study had lifetime risk calculations by 
the Claus model that were lower than 20%. According to the American Cancer Society, 
these women should be screening annually with mammograms since all were over 40 
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years old. Most were doing very well, with 68.1% receiving a screening mammogram 
within the past year and 86.9% within the past 2 years. All but 10 women in our sample 
received recommendations for annual mammograms. The American Cancer Society 
recommends that high-risk women receive annual breast MRI screening in addition to 
annual mammography. All of the women in our sample who were at elevated-risk had 
received a mammogram within the past year, but none had received a breast MRI at any 
time; similarly, none had received a recommendation for screening breast MRI. 
Therefore, none of the women in our sample who were at elevated-risk are counted as 
screening by risk-based guidelines or receiving appropriate risk-based screening 
recommendations.    
Specific Aim 3  
 Statistical analysis using latent variables demonstrated that the amount of 
information shared by close relatives about their genetic counseling session moderates 
the accuracy of risk perceptions in their family members who did not receive genetic 
counseling. Difference in chi-square compared with model-constraining equal regressions 
of Perceived Risk on Calculated Risk = 4.79, df=1, (p =0.0287). In the final model, the 
Chi-Square Test of Model Fit 22.550, df = 28 (p = 0.755) indicated that the model fit the 
data well. The correlation between calculated and perceived risk was 0.326 (p=0.003) in 
the low amount of information shared group and 0.707 (p=0.000) in the high amount of 
information shared group (standardized values). This indicates that the amount of 
information shared by sisters and mothers who received genetic counseling significantly 
improves the accuracy of risk perception while controlling for cognitive and emotional 
factors known to influence risk perception. In fact, women who reported that their sisters 
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and mothers shared more with them had nearly twice the accuracy of risk perception as 
those who reported low amounts of information shared. Unfortunately, only about 20% of 
the women reported a high amount of information was shared with them.  
Limitations 
 This study is limited in the fact that our sample only included women 40 and 
older. If we had the resources to include women down to age 30, we would have likely 
found a greater percent of women in the high-risk category. Lifetime risk decreases as 
women age because less of their “lifetime” exists. We would have liked to include 
women between the ages of 30-39 because the ACS recommends MRI screening begin at 
age 30 for women at elevated-risk. Generalizability of this study may also be limited by 
sample size and homogeneity of our population.  
 It should also be noted that the perceived amount of information shared is not an 
objective measure of either the amount of information shared or the accuracy of 
information shared. A variety of other factors could influence the perception of amount of 
information shared. For example, in families that generally communicate a lot, a certain 
amount of information may be perceived as sparse, where the same amount of 
information shared in a family that generally communicates rarely would be seen as a 
great deal of information. It was beyond the scope of this study to evaluate the actual 
amount or content of information shared. 
 Another potential limitation in this study is that we do not have information about 
their relationships between our participants and their PCPs. An important finding was 
that none of the women at elevated-risk received breast MRI screening recommendations. 
Because there were only 9 women in the elevated-risk group, it would have been difficult 
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to draw generalizable conclusions about these relationships had we gathered that data. 
However, if this study were to be repeated in the future with a larger sample, it would be 
helpful to obtain information about the patient/ PCP relationship, including how long the 
woman has been following with her PCP and whether or not she receives regular check-
ups. Annual exams are often the time when family history is updated and screening and 
prevention options are discussed.  
 As noted elsewhere in this dissertation, we do not have enough data to report on 
over-screening. PCPs may recommend screening tests based on factors besides age and 
calculated risk level. Clinical findings such as breast density or heightened anxiety in the 
patient could prompt a PCP to begin mammograms earlier or order them annually rather 
than biennially. Thus, all we were able to report is whether women were meeting 
minimum guideline standards.  
Discussion 
 The discovery that family members have improved accuracy of risk perception 
when counselees share more information about their genetic counseling sessions with 
them is a novel finding. Encouraging counseled women to share information with their 
family members is the most common method used by genetic counselors to disseminate 
information within a family.  
 Unfortunately, most women did not fall in the category of receiving high amounts 
of information. This study supports the idea that counselors may need to play a greater 
role in either helping women share information with family members or sharing 
information directly. Privacy concerns typically prevent counselors from sharing 
information without consent; however, several genetic counseling practices have piloted 
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projects to obtain consent from their counselees and then send postcounseling letters 
directly to family members. This has been piloted in families with known BRCA1/2 
mutations (Suthers et al., 2006), but we have not found evidence that it has been tried in 
families with indeterminate results where the pedigree is concerning.  
 Primary care providers face the challenge of helping women understand their risk 
and recommending risk-based screenings for breast cancer. This task is made difficult by 
the fact that models using extensive family history are needed to determine if women 
meet the 20% lifetime risk threshold for screening breast MRI recommendations.  These 
models take a great deal of time both to collect the required family history and to enter 
the data. There seems to be a need for increased collaboration between genetic counselors 
and primary care providers. Given that 10% of women were at > 20% lifetime risk and 
none had received recommendations for breast MRI screening suggests that these women 
had not been identified as being at high risk by primary care.  These women had sisters or 
mothers who had received genetic counseling and risk assessment, meaning that risk in 
the family had been evaluated by a professional, but the message about more intensive 
breast screenings does not seem to be getting through. To illustrate this point, we share a 
couple details about 2 women at elevated-risk. 
 One woman who was 43 years old was not sure if it was her mother or sister who 
had genetic counseling. She thought it was probably her mother, but neither of them had 
told her that they received counseling. Her mother had breast cancer at age 48 and she 
has two sisters with breast cancer; one at 44 and one at 48. She said that no information 
was shared about her family member’s genetic counseling session. This woman estimated 
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her own lifetime risk to be 12%. The Claus model showed that she had a 29% lifetime 
risk for breast cancer. She had never heard of breast MRI screening before.  
 Another woman was 42 years old. Her sister had breast cancer at age 37 and her 
mom at age 39. She mentioned during the telephone interview that she does not believe 
what she was told, that the cancer in their family is “not genetic,” which is how she 
understood the interpretation of her sister’s BRCA1/2 test. Her physician told her that her 
risk is “about double” for breast cancer because of the family history. She said that she 
has heard of breast MRI, but no one has recommended it for her. She estimated her own 
risk to be 30%. By the Claus model she had a risk of 38%.  
 These stories demonstrate a lack of information being shared and a lack of 
understanding in relatives of women who received genetic counseling and testing. The 
first woman had no idea that genetic counseling had taken place. The second woman 
knew that it had taken place, but did not understand the implications for her – she thought 
the results meant that the cancer in her family was “not genetic.” She was not aware that 
screening with MRI was an option.  The first woman did not have an accurate perception 
of risk; she thought her risk was average at 12% and marked “average” for the verbal 
response – however, her risk was close to 30%. The second woman was fairly accurate in 
her risk perception. However, neither was receiving risk-based screenings.  
Future Research 
 Further research is needed to establish effective ways of disseminating 
information within families that may result in women at risk for breast cancer being 
offered risk-appropriate screenings for breast cancer. Further research is needed to assess 
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methods that will help PCPs identify women at risk and provide recommendations for 
risk-based screenings for breast cancer.  
Practice Implications 
 Our findings have implications for both genetic counselors and primary care 
physicians. Counselors should not assume that women will share messages clearly with 
family members at risk.  Genetic counselors may want to consider writing letters, 
specifically for family members in cases where model estimations indicate close relatives 
may qualify for breast MRI screening. These letters could be given to the counselee to 
hand deliver or mailed directly to family members if the counselee gives permission. 
Once the pedigree has been entered for the patient being counseled, it only takes one 
click in CancerGene software to change the proband and calculate lifetime risk for a 
sister or a daughter. This type of communication may improve risk perception in the 
counselee’s close relatives and is important because perception of risk plays a role in 
decisions people make about how to care for their health (Collins & Street, 2009). Tilburt 
et al. (2011) note, “misperception of risk has been shown to both increase and decrease 
use of preventive health services and therefore can have significant implications for the 
health of those at greater than average-risk of developing cancer” (p. 2). 
 Primary care providers, in addition to genetic counselors, may be trained in 
performing breast cancer risk assessments (Moyer, 2013). Our findings suggest that some 
women at elevated-risk may not have been identified as such by their primary care 
providers. It can be a challenge in a busy practice to find the time to complete such 
assessments. It may be possible to train office staff to collect and input information that is 
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needed for family history intensive models or to have patients enter their own data on a 
web-based instrument. This is another avenue for future research. 
 The US Preventive Services Taskforce recently updated guidelines for primary 
care providers to screen women in order to identify those who would benefit from an in-
depth risk assessment. They identified five brief screening instruments that can be used 
for this purpose (Moyer, 2013). Women identified as potentially at elevated-risk by these 
instruments can then be further assessed, either by the provider (if trained) or be referred 
to genetic counselors for assessment.  
 Based on our findings, primary care providers should not assume that women will 
tell them if a family member has received genetic counseling and testing. Likewise, if a 
woman tells her primary care provider that her sister was tested and found that the cancer 
is “not genetic,” the PCP should not assume that the woman does not have elevated-risk 
based on the family pedigree. Therefore, even in families where genetic counseling has 
been provided to a member, PCPs still need to screen and may need to perform a full risk 
assessment. 
  
APPENDIX A  
 
RECRUITING LETTER AND SCRIPTS 
 This appendix includes materials used in the recruiting process. First is a 
recruiting letter that served as our first contact with potential participants. This letter was 
mailed to 135 women. Next is the script used for our recruiting telephone call. This 
internal document was used to screen participants and invite eligible women to 
participate. This instrument was also use to collect demographic information from 
women who declined participation. 
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Recruiting Letter for Potential Participants 
 
Dear [First Name, Last Name] 
 
We hope this letter finds you and your family well. We are writing to invite you 
to participate in a research study. The purpose of our study is to learn about women who 
have a sister or mother who has received genetic counseling. We are doing this study to 
find out what family members of women who have received genetic counseling know 
about their risk for cancer and what they should do to screen for cancer.  
We were given your name because you participated recently in another study 
called the “Breast Cancer Prevention Pilot Study.” In the questionnaire for that study you 
indicated that you would be willing to be contacted again for cancer-related research 
studies. We hope that you will consider participating in this new important study. 
Participation involves completing a questionnaire and a telephone interview.  
We will telephone you in a few days to ask you if you would like to participate. 
Participation in the study is completely voluntary. You can choose not to take part. You 
can choose not to finish.  
If you chose to participate we will mail you a packet of questions and set up a 
good time for the telephone interview. The packet of questions will takes approximately 
15 minutes to answer. We will ask that you mail it back to us in a postage-paid envelope 
that we will provide. We will also ask you to participate in a telephone interview that will 
take about 40 to 60 minutes to complete. During this phone call we will ask you for 
information about your family history of cancer and about things that you are doing to 
screen for cancer. From the information we collect during this interview we will be able 
to calculate your lifetime risk for breast cancer. If you would like to have that information 
yourself we can send it to you following the interview in a letter that you can share with 
your primary health care provider if you would like.  
As a thank-you for your participation we will mail you a $25.00 Visa gift card 
once we have received the completed packet and completed the interview. 
 The questionnaires and information from the telephone interview will be kept 
confidential. The questionnaires are kept in locked cabinets and entered into a secure 
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database. Only staff that needs to use the information provided in the questionnaires will 
have access to them.  
 The principal investigator for this study is Deborah O. Himes MSN, APRN. If 
you have any questions, complaints, or if you feel you have been harmed as a result of 
participation, you can call her at (801) 422-6066. Contact the Institutional Review Board 
(IRB) if you have questions regarding your rights as a research participant. Also, contact 
the IRB if you have questions, complaints or concerns which you do not feel you can 
discuss with the investigator. The University of Utah IRB may be reached by phone at 
(801) 581-3655 or by e-mail at irb@has.utah.edu .   
Our research assistants will be calling you in a couple of days to see if you would 
be willing to help us with this study. They can answer questions about the study.  If you 
agree to participate, they will mail you the question packet and schedule a time for the 
interview. By completing the questionnaire and answering the telephone interview 
questions you are giving your consent to participate. If you have any questions or 
concerns, if you don’t hear from our research assistants in a couple of days or if you 
would prefer NOT to participate or be contacted please call Deborah Himes at (801) 422-
6066 or by email at deborah-himes@byu.edu.  
 
 
We will be in touch soon, 
 
Thank you, 
 
Deborah O. Himes 
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APPENDIX B 
 
PACKET QUESTIONS AND INSTRUMENTS 
 The following pages include images of documents mailed to potential participants 
who had agreed over the telephone to participate. The first images are of the IRB 
approved consent covered letter followed by images of the survey and the family history 
questionnaire. In the survey instrument, names used by researchers such as “Impact of 
Events Scale” are not presented to the participants. For example, the first question 
includes our two measures of risk perception; 1a is our verbal measure and 1b is our 
quantitative measure.  The question section is titled “Thoughts about Your Risk” for the 
participants. The following list provides the concept being measured and the name of the 
instrument used to measure it (if applicable) by question number: 
1. Risk perception/ Comparative Verbal and Comparative Quantitative 
2. Distress/ Impact of Events Scale 
3. Health Literacy/ Brief Set of Screening Questions 
4. Numeracy/ Rausch-Based Numeracy Scale 
5. Knowledge/ Breast Cancer Genetic Counseling Knowledge Questionnaire 
6. Media Sources of Breast Cancer Information and How Much Women Talk with 
Selected Family Members about the Family History of Breast Cancer 
7. Demographics  
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APPENDIX C  
 
TELEPHONE INTERVIEW QUESTIONS AND INSTRUMENTS 
 The following pages include images of the instrument used to collect data during 
the telephone interview. This instrument was for internal use only and includes the codes 
for data entry and variable labels.  
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APPENDIX D 
THANK YOU LETTERS  
 
[Thank-you letter for participants not wishing risk information] 
 
Dear Ms. [Name] 
 
On behalf of our research team, we thank you for participating in our study titled the 
Family Risk Assessment Project. You have provided us with valuable information that 
will help us better understand what family members of women who have received genetic 
counseling know about their risk for cancer and what they are doing to screen for cancer.  
 
Please accept the enclosed gift card as a thank you for your time and effort.  Feel free to 
call if you have any questions about your participation in the study at (801) 422-6066 or 
email deborah-himes@byu.edu.  
 
We appreciate your participation. 
 
Sincerely, 
 
Deborah O. Himes MSN, APRN 
Principal Investigator 
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[Thank-you letter for participants wishing risk information] 
 
Dear Ms. [Name] 
 
On behalf of our research team, we thank you for participating in our study titled the 
Family Risk Assessment Project. You have provided us with valuable information that 
will help us better understand what family members of women who have received genetic 
counseling know about their risk for cancer and what they are doing to screen for cancer.  
 
As part of our study we used risk calculators to estimate women’s lifetime risk for breast 
cancer based on the family history information they provided. You indicated that you 
would like to receive your estimates. Given the personal and family history you provided 
we have calculated the following breast cancer risk estimates for you using three different 
models. 
 
Claus Model   [XX%] 5 year risk,  [XX%] lifetime risk 
BRCAPRO Model  [XX%] 5 year risk  [XX%] lifetime risk 
Gail Model   [XX%] 5 year risk  [XX%] lifetime risk 
 
We encourage you to discuss any questions you may have about your risk for breast 
cancer, as well as breast cancer screening and prevention measures with your primary 
healthcare provider. The American Cancer Society and other organizations have issued 
breast cancer screening and prevention guidelines that are based on risk level. Your 
primary healthcare provider should be able to help you navigate that information.  If you 
would like to find a genetic counselor in your area, one good resource is the National 
Society of Genetic Counselors website: www.nsgc.org .  
 
Again, we thank you for participating in our study. Please accept the enclosed gift card as 
a thank you for your time and effort.  Feel free to call if you have any questions about 
your participation in the study at (801) 422-6066 or email deborah-himes@byu.edu.  
 
We appreciate your valuable participation. 
 
Sincerely, 
 
Deborah O. Himes MSN, APRN 
Principal Investigator 
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